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 INTRODUCTION  
 
 AIDS the chilling acronym for acquired Immune Deficiency Syndrome 
evokes a response of familiarity to day. Seventeen years ago, this was not so. In the 
summer of 1981 the Centre for Disease Control (CDC) in the united state reported 
five previously healthy homosexual men in Los Angles suffering from an unusual 
type of pneumonia caused by pneumocystis carinii. CDC also reported 26 previously 
healthy homosexual men in New York and Los Angles, who had developed a rare 
form of skin cancer called Kaposis Sarcoma. This reports signaled the arrival of a 
mysterious acquired disorder of the human immune system, which disable the body's 
defenses. This was the beginning of one of the biggest public health problems of this 
century.1 
 HIV seems likely to have originated in central Africa, where serum samples 
from as early as the 1950s have been found to be seropositive.2 Although HIV 
appears to have been present in Africa longer than in the united states; the rapidly 
rising incidence of cases in Africa also suggest a new epidemic. Subsequently the 
syndrome was found in Haitian immigrants on the east coast of the USA. Earlier in 
Europe three Norwegian cases reported. This HIV infection was present several 
years before AIDS was recognized, clinical manifestations present as early as 1966 
and serological confirmation was in 1971. These patients are the first proven case of 
AIDS in Europe. The daughter seems to be the earliest recorded case of paediatric 
AIDS.3 
 AIDS in Africa, sometimes called slim disease, was usually characterized by 
opportunistic outcomes such as disseminated tuberculosis and chronic diarrhoea. 
Because the outcomes of AIDS were often different in different geographical areas 
of different population group.4 In the absence of any identifiable cause, the 
syndrome was labelled as Gay Related Immunodeficiency Disease (GRID)5. 
 The present term, acquired immunodeficiency syndrome (AIDS) came 
couple of year time later, when similar cases were identified among the blood 
transfusion recipients, intravenous drug addicts and heterosexual. The year of 1983 
which saw the emergence of the modern Sherlock Homes Dr. Lue Montagnier, Dr. 
Robert Gallow and other scientists, who solved the mystery by sheer hard work and 
intelligence to describe the act and the actors. The heroes of the story were those 
who died and consented to autopsy. 
 The term AIDS was officially adopted in 1982.6 The causative retrovirus, 
called Lymphodenopathy associated virus (LAV), was identified first in 1983 by 
Montagnier and colleagues in Paris. Simultaneously Gallo and colleagues reported 
isolation from patients of a virus, which they called Human T-cell Lymphotropic 
virus type-III. (HTLV-III) Investigations conformed the identity of LAV and HTLV 
III by international agreement this virus is referred to now as the Human 
Immunodeficiency Virus type-1 (HIV-1). The second AIDS virus HIV-2, was 
isolated in 1985 from West African patients by Montagnier and his collegues7. The 
most characteristic lesion of AIDS is a progressive loss of T lymphocytes. In most 
infected individuals this progresses to pathological levels and disease develops 
within 6 to 8 years. 
 In the mid 80s when the HIV epidemic was making fast inroade in USA, 
Africa and Western Europe we, in India, reacted timely to detect whether this virus 
has reach our country also. In 1985 the Indian Council of Medical Research (ICMR) 
established a tasked force and intuted HIV screening of the presumed risk groups to 
detect the presence of this virus in India. Since that time we have come a long way 
having established an extensive surveillance network in the whole country8. 
 The prevalence of HIV infection in India was first detected in February 1986 
among a small group of prostitutes at Madras. First AIDS case was reported from 
Bombay at May 19869. First HIV-2 reported from Bombay, Vishakapatnam and 
Madras at January. 199110. The infection is transmitted in majority of cases through 
sexual contact, blood and blood product, contaminated needles and from infected 
mother to the newborn. Through the surveillance network we have observed that the 
situation is highly variable in the different states of India, being determined by the 
socio-economic factors as well as the magnitude and pattern of distribution of high 
risk behaviour practices in all state excluding state of Maharashtra and Manipur. The 
highest rate of infection have been observed among injecting drug users in Imphal 
(Manipur). The second highest rate of HIV infection was found in female sex 
workers in Bombay (Maharashtra). Maharashtra has reported highest number of 
cases in the country.  
 Though HIV infection has been reported from all the state and union 
territories 5 states and union territories have not reported a single case of full blown 
AIDS. They are Arunachal Pradesh, Andaman and Nicobar, Island, Dadra and Nagar 
Haveli, Lakshadweep and Tripura11. 
Table - I  
Calendar of events related to HIV / AIDS in India10. 
1985 Oct. HIV Serology testing introduce at CMC Vellore and NIV, Pune. 
1986 Feb. 1st case of HIV ab +ve CSW in Madras. 
1986 March HIV ab +ve CSW detected in interior towns of Tamil Nadu 
(Madurai and Vellore) 
1986 April ICMR Initiates National AIDS surveillance programme with at least 
one testing station in every state. 
1986 May 1st reported case of patients with AIDS in Bombay (Acquired 
through unscreened blood in USA) 
1986 Dec. 1st seropositive man detected at STD clinic in Vellore (TN) 
1987 July 1st seropositive blood donor detected in Vellore. 
1987 Oct. 1st seropositive infant detected in Pune. 
1990 Jan. HIV ab detected among IVD's in Manipur. 
1991 Jan. HIV-2 reported from Bombay, Madras and Vishakapatnam. (It is 
clear that HIV will continue to be a global problem well into the 
twenty first century). 
 UNAIDS and NACO estimate about 5 million people are living with 
HIV/AIDS infection and 62785 cumulative AIDS cases reported in Jan. 2004. 
NACO reported 3596 AIDS cases in Gujarat at Jan. 200412. 
 AIDS has emerged as one of the most grasome and dreadful disease of 
mankind which has evoked wide spread alarm not only in the medical profession but 
also almost the general public. In light of all that we know about this diabolical 
virus, currently there is no vaccine so India needs to act vigorously to dramatically 
enhance awareness.  
 In the mean time we will have to bring out the best in each one of us by way 
of compassion, understanding and love for those of are afflicted and already 
affected. India can do no less. 
 So let us stop AIDS before it is too late !! 
 
 AIMS AND OBJECTIVES 
 
 To dertermine the incidence of HIV infection in patients and healthy blood 
 donors. 
? To dertemine the incidence of HIV infections in symptomatic patients of 
tuberculosis. 
? To determine the incidence of HIV infections in sexually transmitted disease 
patients. 
? To determine the incidence of HIV infection multi transfused thallassaemic 
children. 
? To determine the incidence of HIV infection in pregnant women (antenatal 
mother). 
? To determine the incidence of HIV infection in blood donors. 
 REVIEW OF LITERATURE 
 
HISTORY : 
ORIGIN OF AIDS : 
 Acquired Immune Deficiency Syndrome (AIDS) was first described as a new 
and distinct clinical entity in 198115. The first cases were recognized because of 
unusual clustering of diseases such as Kaposis Sarcoma and Pneumocystis 
Pneumonia in young homosexual men. Although such syndromes were occasionally 
observed in different well defined subgroup of the population, such as older men of 
Mediterranean origin in the case of Kaposi's Sarcoma and severity impaired cancer 
patients in the case of pneumocystis pneumonia, the occurrence of these diseases in 
previously healthy young people was unprecedented.  
 Within a brief period of time AIDS cases were also reported in other 
populations, such as intravenous drug abusers and hemophiliacs14. In the case of 
hemophiliacs, this would be associated with clotting factor preparations, which were 
prepared from the pooled blood of a huge number of donors. In the case of 
intravenous drug abusers, increased exposure to foreign tissue antigens might occur 
when recipients used dirty needles contaminated with small amounts of blood from 
previous users. Even independent of clinical AIDS, asymptomatic hemophiliacs and 
intravenous drug abusers were often found to have inverted T-lymphocyte helper to 
suppressor ratios, as did AIDS patients and a proportion of asymptomatic 
promiscuous homosexual men.  
 Soon after the first cases of blood transfusion associated AIDS were 
suspected. These were suspected because some individuals with clinical AIDS were 
found to lack any of the characteristics of the previously defined risk group 
homosexuality, hemophilia or intravenous drug abuse but were found to have a 
history of receiving blood transfusion within the preceding 3 to 5 years. 
 Although still dismissed by many, it seemed increasingly logical that an 
infectious etiology for AIDS had to be considered. Subsequently, several studies 
were initiated to determine seroprevalence rates for exposure to numerous 
microorganisms, especially viruses, and to compare exposure to given agents in 
AIDS patients and controls. High on the list of candidate viruses was 
cytomegalovirus, because it was already associated with less severe 
immunosuppression in kidney transplant patients; Epstein Bar virus, presumably 
because it was a lymphotropic virus, and hepatitis B, because it was already known 
to occur at elevated rates in both homosexual men and recipients of blood or blood 
products. Yet, since AIDS was a new disease, it was difficult to imagine how it 
might be caused by a viral agent that was not itself new. If a virus such as hepatitis 
B, Epstein Barr, or cytomegalovirus were to be etiologically involved, it would 
presumably have to be a newly mutated or recombined genetic variant. 
 At that time, Gallo and his colleagues and Montagnier and his colleagues, 
postulated that a variant T-lymphotropic retrovirus (HTLV) might be etiologic agent 
of AIDS. Among the most compelling reasons for considering such a retrovirus was 
that the human T lymphotropic retrovirus discovered as a cause of adult T-cell 
leukemia by Gallo and colleagues was the only human virus known to infect T-
helper lymphocytes, the cells that became impaired or eliminated in individuals with 
AIDS. Along with this cell tropism, HTLV was known to be transmitted by all the 
appropriate routes; sexual contact, with transmission apparently more efficient from 
males, transmission by blood; and transmission from mothers to newborn children15. 
 Several approaches were taken to determine if a virus related to HTLV might 
be associated with AIDS, and enticing but inconclusive results were initially 
obtained. Soon after, proof that the disease was linked to a T-lymphotropic 
retrovirus was obtained by Gallo and his colleagues. Further characterization of the 
agent, now termed human immunodeficiency virus type-1 (HIV-1) revealed that it 
was only distantly related to HTLV but was the same as the isolate detect earlier by 
Montagnier and his colleagues. 
ORIGINS OF HUMAN RETROVIRUSES : 
 HTLV-1, the first human retrovirus identified, was known to be present at 
elevated rates in regions such as southwestern Japan, the Caribbean Basin, Northern 
South Africa and Europe. The theory that this virus originated in Africa was initially 
suggested by Gallo, who cited early reports of Africans in Southwestern Japan16 
Miyoshi and his colleagues then identified a virus related to HTLV-1 in Asian 
monkeys.  This virus, designated simian T-cell leukemia virus (STLV), was later 
found in African monkeys and apes and was associated with lymphoproliferative 
diseases in captive macaques. 
 Seroepidemiologic studies in Old World primates from both Asia and Africa 
revealed that more 30 species of monkeys and apes had widespread infection with an 
STLV. However, on further molecular characterization, it was recognized that the 
STLV viruses from Japanese macaques and related Asian species of monkeys were 
not as closely related to HTLV-1 as were STLVs isolated from African primates 
such as chimpanzees and African green monkeys. All isolates of HTLV-1, whether 
from Japanese, Caribbean, or African people, were highly related to African strains 
of STLV but not as highly related to Asian strains of STLV. This suggested that 
HTLV-1 evolved from a subgroup of STLVs present in Africa but not in Asia. It 
also suggested that the STLV/HTLV-1 family of retroviruses was present in 
numerous species of Old World monkeys for some time before it was introduced to 
humans from an African species of monkey or ape. 
 HTLV-II, the second human retrovirus detected, was only about 40% to 50% 
related to HTLV-1 at the genomic level, HTLV-II was also found at high prevalence 
in selected human populations of New World origin. The closest HTLV-II related 
virus of subhuman primates was in a New World species, the South African spider 
monkey. 
 Whereas substantial genetic variation is seen among different isolates of 
HIV-1, particularly in the envelope gene, the same degree of variation is not seen for 
HTLV-1. Presumably, the rate of genetic drift seen in retroviruses is related to their 
rate of replication. Although HIV-1 can replicate to high titers and be detected as 
free virus in serum or plasma, HTLV-1 cannot. Because HTLV-1 is apparently 
transmitted only in a cell-associated manner. 
ORIGIN OF HIV-1 : 
 After HIV-1 was recognized as the probable cause of AIDS, it soon became 
apparent that this virus was new to populations in the Western hemisphere. This 
raised the question of whether HIV-1 was also new in Old World human populations 
or whether it had recently been introduced from another species. If HIV-1 had been 
present in some human populations in Africa to the point of evolutionary 
equilibration (as had HTLV-1), it probably would have been limited to isolated 
tribes of people, and selection for host immunity as well as selection of an virulent 
virus would have occurred. Such isolation seemed essential for evolutionary 
equilibration to have occurred, because, in both the United States and Haiti, blacks 
were just as likely as whites to develop clinical AIDS after exposure to HIV-1. 
 The possibility that HIV-1 or a related virus was present in human 
populations in central Africa at the same time or even before AIDS was diagnosed in 
the United States seemed even more probable after what was apparently the same 
syndrome was reported in Africans who sought treatment in Europe. Subsequently, 
it was recognized that HIV-1 infection and clinical AIDS were rapidly spreading in 
Central Africa. 
 Serum samples collected from Africans at earlier periods were also examined 
for the presence of antibodies reactive with HIV-1. In some cases, the examination 
of stored samples suggested elevated rates of infection in Africa during the period 
1965 to 1975. Subsequently, it was revealed that most of those surveys were 
conducted with first stage tests that were imperfect, and the reactors were mostly 
false positive cases, caused either by contamination of the HIV antigen or by "Sticky 
sera" containing antibodies that reacted non specifically because of repeated freezing 
and thawing and maintenance under poor conditions. 
 While examining sera taken from African patients in the period 1955 to 
1965, one antibody positive sample was found that was clearly specific17. When 
tested by radioimmunoprecipitation, this sample was found to contain high titers of 
antibodies that were reactive with virtually all the major antigens of HIV-1 
detectable by this technique; gp160, gp120, gp55, gp41, p27, p24, and p17. However this 
sample represented only a rare positive reactor in a high risk group of individuals 
exposed to general infections and AIDS like illness in a region that subsequently had 
high rates of infection with HIV-1. Positive results were obtained from fever than 
1% of sick individuals tested from Kinshasa, Zaire, which is now classified as a 
region of moderate to high prevalence. This suggests that the virus was only rarely 
present at that time in places that would now be considered within the AIDS belt of 
Africa. It was speculated that HIV-1 or a virus very similar to it had moved to the 
cities of this region of Africa before the mid 1950s, either by introduction from 
subhuman primates or by migration of a few resistant carriers from a previously 
isolated tribe or tribes. Population redistribution was occurring at that time, with 
movement of previously isolated people into the newly expanding cities. Still it 
seems unlikely that HIV-1 would have been present, as such, for many generations 
in isolated tribal regions. If this were so, we would expect to find Africans who 
show greater resistance to infection and disease development, owing to genetic 
evolution of the human species. However, it prospective studies conducted to date, 
exposed Africans appear to develop clinical AIDS and other signs and symptoms of 
HIV disease as rapidly as individuals in the United State of Europe. Furthermore, as 
has been mentioned, the degree of genomic variation seen in African isolates of 
HIV-1 is greater than that seen in isolates from Europe or the United States. 
 A virus that could be a progenitor of HIV-1 has been isolated from a 
chimpanzee in central Africa. This finding, combined with the knowledge that all 
HIV-1 viruses tested appear to be a virulent when inoculated into chimpanzees, is 
also compatible with a subhuman primate origin for HIV-1. Some African isolates of 
HIV-1 appear to be as close to the chimpanzee isolate as to other prototype strains of 
HIV-1. 
ORIGIN OF HIV-2 
 Because a relative of HIV-1 (SIV) had been found in wild African monkeys 
but was only about 50% related to HIV-1 at the genomic level, it seemed logical that 
viruses more highly related to SIV may also be present in human populations.  
Serum samples from West African prostitutes were examined to determine whether 
they had antibodies that were more highly cross-reactive with SIV than with HIV-1. 
West Africa was chosen because, at that time, it was largely free of HIV-1 and 
clinical AIDS, and female prostitutes were selected because they represent a group 
at high risk for amplification of prevalence rates for infection with sexually 
transmitted viruses.  
 Through Western blot techniques, it became clear that a significant 
proportion of Senegalese prostitutes had antibodies that were highly reactive with all 
the major antigens of SIV detected by this technique.  These included the gag-
encoded p24, the pol-encoded p64/53 and p34, and the env-encoded transmembrane 
protein p34.  Yet, when the same SIV antigens were reacted by Western blotting 
with sera from HIV-1 infected individuals of either European or central African 
origin with classic disease manifestations little or no reaction was seen with the 
envelope antigens. Because the transmembrane protein of SIV is usually smaller 
than the comparable protein of HIV-1, this is manifested as the loss of reactivity 
where it might be expected at gp41 and the acquisition of reactivity with gp32, the 
carboxy1-terminus peptide of the env gene of SIV. The class of reactivity seen with 
serum samples from West African prostitutes was virtually indistinguishable from 
that seen with serum samples from African monkeys or captive rhesus.  Similar 
results were also obtained by radioimmunoprecipitation, except that this procedure 
readily detects the gp120 amino-terminus env glycoprotein that is often missed by 
Western blotting. In this case, serum samples from the West African prostitutes 
reacted very well with the gp120 and gp160 of SIV but reacted only infrequently and 
weakly with the gp120 and gp160 of HIV-1. 
 With evidence that a virus more closely related to SIV than to HIV-1 was 
present in Senegalese prostitutes, more extensive studies were undertaken to 
determine whether the SIV-related virus was more widely distributed in Africa in 
general, particularly in West Africa.  The screening of more than 2000 high-risk 
individuals from central Africa, including many persons with AIDS and other 
sexually transmitted diseases, revealed no evidence that the virus, termed HIV-2, 
was present in the same regions in which HIV-1 was rampant.  However, pockets of 
infection with HIV-2 were detected in Mozambique and in Angola; although distant 
from West Africa, these regions are often on the same trade routes as Guinea Bissau 
and Cape Verde, West African countries whose rates of infection are among the 
highest. Within Senegal, prevalence rates for HIV-2  were substantially higher in the 
southern region of Casamance , which borders Guinea Bissau, than in the northern 
region. 
 Infection with HIV-2 was also substantially higher in female commercial sex 
workers than in other population groups, indicating that this virus is also sexually 
transmitted. However, HIV-2 is transmitted less efficiently than HIV-1, both 
perinatally and sexually.  Analysis of circulating lymphocytes by polymerase chain 
reaction techniques reveals that most HIV-2-infected carriers or fewer copies of 
proviral genomes per infected cell, or both.  As with the infrequently pathogenic 
HTLV-I, but not with the highly virulent HIV-1, the age-specific prevalence for 
HIV-2 increase with increasing age.  This presumably happens because relatively 
few HIV-2 - infected people are lost from the population because of death. 
 The observations that HIV-2-infecteed carriers have lower loads of virus and 
slower rates of sexual transmission between people are compatible with the 
observations that HIV-2s appear to evolve and deviate less rapidly than HIV-1s.  
This does not appear to be caused by any reduction in the error rate of the HIV-2 
reverse transcriptase. The slower rates of HIV-2 replication and spread also help 
explain why the HIV-2 epidemic is largely restricted to West Africa.  Further, ven 
within West Africa some HIV-2s are essentially indistinguishable from the SIVs that 
occur naturally in a particular monkey species living in the same area. 
 The lower rates of replication for HIV-2 may also help explain why this virus 
appears less virulent than HIV-1 within individual hosts. Case reports and cross-
sectional studies reveal that some HIV-2 infected people develop clinical AIDS18.  
However, even early studies in HIV-2 endemic areas suggested that disease rates 
were much lower than expected, based on HIV-1 associated disease with 
proportional prevalence rates.  One possible explanation for this dichotomy was that 
HIV-2 entered the human population more recently that HIV-1.  This possibility was 
largely dismissed after it was recognized that HIV-2 rates had stabilized in West 
Africa.  It seems clear that HIV-2 had stabilized in some regions of West Africa 
before HIV-1 had even moved in. Also, analyses of West African sera stored from 
earlier time periods have shown that HIV-1 has been present in the region for an 
extended period. 
 Recently, a natural history study was completed that followed disease 
development for seroconverting commercial sex workers infected with either HIV-2 
or HIV-1 in the same cohort. HIV-2 infected individuals resisted clinical AIDS 
development much better than did HIV-1 infected women.  HIV-2 infected 
individuals also had stable T4 helper cell numbers for prolonged periods and did not 
experience the high rates of skin test energy seen with HIV-1infected patients.  It is 
too soon to say whether the slower pace of disease development with HIV-2 is 
associated with complete long-standing resistance to AIDS or whether most HIV-2 
infected people eventually succumb to disease.  A small fraction of HIV-1 infected 
persons, perhaps 2% to 5%, remain healthy with stable T4 cell numbers for 10 to 15 
years. This small fraction appear to have a natural history that is similar to that of 
most HIV-2 infected individuals.  However, for both HIV-2 and HIV-1 it is also too 
soon to conclude that all strains and clades in different geographic regions show the 
same patterns of virulence characterized by HIV-1 in the West and HIV-2 in 
Senegal. 
MOLECULAR BIOLOGY : 
 The causative agent of acquired immunodeficiency syndrome (AIDS), 
human immunodeficiency virus type-1 (HIV-1), is a retrovirus of the lentivirus 
subfamily. Although a lentivirus was one of the first known viral agents19, the study 
of lentiviruses intensified after the discovery of HIV-1 and its similarity to other 
lentiviruses.  
 The lentiviruses are exogenous, nononcogenic retroviruses causing persistent 
(i.e. chronic / active) infections; the diseases have long incubation periods. These 
viruses usually infected cells of the immune system, such as macrophages and T-
cells, and have cytopathic effects in permissive cells; such as syncytia and cell death. 
Lentiviral infections are not cleared by the immune system, and their damage 
accumulates over many years. This important characteristic is reflected in the name 
of the subfamily; lenti means slow. Lentiviruses have a larger RNA genome 
(approximately 10 kilobases (kb), which encodes additional proteins. They produce 
a large and heavily glycosylated envelope protein (Env) and, in the case of HIVs, a 
magnesium ion (Mg2+) dependent reverse transcriptase. They encode essential 
regulatory and accessory genes that allow regulation of their own expression in the 
infected cell. Unlike other retroviruses, lentiviruses can infected non-dividing cells. 
 Many lentiviruses affect the immune system, causing acquired 
immunodeficiency. The ovine and caprine lentiviruses  primarily infect monocytes, 
and the viral DNA is integrated into the cellular DNA. The provirus remains silent 
unit the monocyte matures into a macrophage. Equine infectious anaemia virus also 
infects macrophages, but the feline simian, and human immunodeficiency viruses 
primarily infect T lymphocytes. Replication of the lentiviruses usually is toxic to the 
cell and leads to cell dysfunction and death. The structure and replication properties 
of the lentiviruses may be the reason that the immune system is unable to eliminate 
the infection. 
GENOME AND VIRION STRUCTURE : 
 Retroviruses are enveloped, positive strand RNA viruses that rely on a 
unique enzyme reverse transcriptae, to convert their RNA genome into a DNA 
"Provirus" which is integrated into the cellular genome. The viral envelope is a lipid 
bilayer that is produced by the cellular plasma membrane and contains the 
protruding viral Env. glycoprotein. The core viral partical is composed of the P24 
capsid (CA) protein and contains the viral RNA and enzymes. 
 The genomic organization of HIV-1 is shown in HIV is 120 nm icosahedral, 
enveloped RNA virus. HIV comprises of an outer envelope consisting of a lipid 
bilayer with uniformly arranged 72 spikes or knobs of gp120 and gp41. Glycoprotein 
gp120 protrudes out on the surface of the virus and gp41 is embedded in the lipid 
matrix. Inside is the protein core surrounding two copies of RNA. Core also contains 
viral enzymes reverse transcriptase, integrase and protease, all essential for viral 
replication and maturation. Proteins p7 and p9 are bound to the RNA and are 
believed to be involved in regulation of gene expression20 (Fig. 1) 
 All retroviruses have in common the three coding regions gag pol and env, 
which encode the capsid proteins (Gag), the viral enzymes necessary for replication 
(Pol), and the external glycoprotein (Env) that protrudes out of the lipid viral 
envelope and is responsible for the infectivity of the viral particle by means of 
attachment to specific cellular respectors. The viral enzymes encoded by pol are 
reverse transcriptase, integrase, and protease. 
 Retroviruses have one promoter and one polyadenylation site within the long 
terminal repeats (LTRs) and express one primary transcript.  
 The additional proteins expressed by HIV-1 are part of the viral particle (i.e. 
Vif. Vpr, Vpx) regulate directly viral gene expression (i.e. Tat, Rev), or interact with 
the cellular machinery to promote virus propagation (i.e. Vpu, Nef). The additional 
proteins increase the complexity of the organization and expression of HIV and the 
other lentivitruses. 
Table - II 
Human immunodeficiency virus and simian immunodeficiency virus proteins 
Name Size Function Localization 
Gag MA P17 Membrane anchoring, Env 
interaction, nuclear transport of 
viral core (myristylated protein)  
Virion 
Gag CA P24 Core capsid Virion 
Gag NC P7  Nucleocapsid, binds RNA Virion 
 P6 Binds Vpr Virion 
Protease P15 Gag-Pol cleavage and maturation Virion 
Reverse  
transcriptase, 
RNase H 
P66 
P51  
(heterodimeter) 
Reverse transcription, RNase 
Hactivity 
Virion 
Integrase  DNA provirus integratior Viron 
Env gp120/gp41  External viral glycoproteins bind 
to CD4 receptor 
Plasma membrane,  
virion envelope 
Tat P16/P14 External viral glycoproteins bind 
to CD4 receptor 
Primarily in nucleolus /  
nucleus  
Rev P19 RNA transport, stability and factor 
(phosphoprotein) 
Primarily in 
nucleolus/nucleus use 
shutting between 
nucleolus and cytoplasm  
Vif P23 Promotes virion maturation and 
infectivity 
Cytoplasm (cytosol,  
membranes) virion 
Vpr P10-15 Promotes nuclear localization of 
preintegration complex, inhibits 
cell division, arrests infected cells 
at G2/M 
Virion, nucleus  
(nuclear membrane?) 
Vpu P16 Promotes extracellular release of 
viral particles, degrades CD4 in 
the endoplasmic reticulum 
(phosphoprotein); only in HIV-1 
and SIV cpz 
Integral membrane 
protein 
Nef P27/P25 CD4 downregulation (myristylated 
protein) 
Plasma membrane,  
cytoplasm (virion?) 
Vpx P12-16 Virion protein, vpr homologue (not 
in HIV-1, only in HIV-2 and SIV) 
Virion (nucleus?) 
Tev P28 Tripartite Tat-Env-Rev protein 
(also named Tnv) 
Primarily in nucleous /  
nucleus 
 
STRUCTURAL PROTEINS :  
Gag Proteins : 
 The Gag precursor Pr 55 forms the core viral particle and interacts with other 
viral and cellular components, including RNA. Pol and Env proteins, and the plasma 
membrane, to facilitate their incorporation into the budding viral particle. Pr 55 is a 
self associating protein capable of assembling into virion like particles without the 
requirement of any other viral factors. In addition to Gag precursor, a Gag Pol fusion 
protein (Pr 160gap-pol) is produced by ribosomal frameshifting. The self associating 
properties of the Gag portion also direct the incorporation of some molecules of the 
Gag Pol fusion protein into the forming particle.  
 During or shortly after assembly, the protease is activated, and the Gag 
precursor is cleaved into four proteins (i.e. matrix (P 17 mA), Capsid (P. 24cA), 
nucleocapsid (P7 NC) and (p6 gag) and two small peptides (i.e. P1 gag and P2 gag.) 
The proteolytic cleavage products form the core of the mature virus. Pr 160gag-pol 
polyprotein is also cleaved by protease into the Gag components and several active 
enzymes; protease, reverse transcriptase and integrase. 
 Proteolytic cleavage by cellular and viral enzymes, myristylation, and 
phosphorylation of the Gag Precursor are essential step in the viral life cycle. After 
translation of the Gag precursor, the initiator Met residue is removed and a myristoyl 
group is attached to the amino group of Gyl 2 by cellular enzymes. The P17MA & 
P24CA proteins are posphorylated by cellular kinases. The P7NC protein binds two zinc 
ions to form the two zinc fingers of the NC domain, which are necessary protein 
RNA interactions. 
 Gag interacts with additional cellular factors, which are essential for 
formation of infectious virions. A region between residues 178 and 300 in the CA 
domain of the Gag precursor has been shown to bind cyclophilin A, a peptidyl prolyl 
cis-trans isomerase thought to play a role in immune regulation. This protein has 
been found in purified HIV-1 virions. Viral particles formed by Pr55 gag, in contrast 
to particles formed by the Gag polyproteins of other retroviruses, contain significant 
amount of cyclophilin A. Mutation of the cyclophilin A binding domain results in 
noninfectious viral particles. Cyclosporine and cyclosporine analogs disrupt the 
binding of cyclopuilin A to Gag and inhibit HIV-1 replication. In contrast, a 
cyclosporine analog was shown to be inactive against SIV mac, which does not 
incorporate cyclopuilin A. Moreover a cyclosporine analog (SDZ NIM 811) that is 
completely devoid of immunosuppressive capacity was found to have potent and 
selective anti HIV-1 activity. SDZ NIM 811 may interfere with Gag cyclophiln A 
interaction and affect the infectivity of the virions and early events of viral nuclear 
transport and integration21. 
 The arrangement of the Gag-pol transcription and translation unit is essential 
for packaging the viral enzymes encoded by Pol. The pol encoded products are 
expressed as a Gag Pol fusion protein after a 1 ribosomal frame shifting, which 
happens at a frequency of approximately 5%. A stemloop structure 3' of the HIV-1 
shift site is important for wild type levels of fromshifting in Vivo. In vitro studies 
did not show the importance of the 3 stemloop structure for frameshifting. The 
resulting fusion protein, the Gag Pol precursor (Pr160gag-pol), contains the Gag 
proteins required for incorporation into the virion.  
The Capsid : 
 The structure of the nucleocapsid of retroviruses is not well understood. 
When virions are carefully treated with mild detergent, two rather fragile structures 
are formed, depending on virus and conditions. The nucleoprotein contains the virus 
RNA, the NC protein, and a fraction of the RT activity, The core contains, in 
addition, the CA protein. Electron microscopy of whole or fractionated virions has 
not been particularly revealing of the fine structure; the particles are somewhat 
pleomorphic and do not reveal obvious overall symmetries, although local 
icosahedrally symetric regions can be seen. Immature virions containing 
unprocessed Gag proteins seem to have a much better defined structure22. Most of 
the structural features observed are atributable to gag proteins. Indeed, almost 
normal looking virions can be formed in the absence of pol and env proteins as well 
as of genome RNA. The major gag proteins are most readily studied as the cleavage 
product found in virions; and they act in two different forms at different times. 
 During virion assembly, they are unified as a precursor protein; it is 
however, the cleavage product that enter the cell to initiate the infection cycle. Thus, 
domains filling important roles in assembly may not be neatly distributed among the 
cleavage products. As a consequence of the mode of assembly, it can be expected 
thatall gag proteins will be present in equal numbers in the virion. This expectation 
seems to be borne out, and it has been estimated that there are about 2000 to 4000 
copies of each cleavage product per virion. 
Matrix Domain (MA Protein) :  
 Are necessary for targeting the Gag precursor to the cell membrane resulting 
in the anchoring of Env. to the viral particle. The mature MA protein remains 
associated with the inner side of the lipid envelope. 
 Several domains of the MA protein in which single amino acid substitutions 
dramatically reduce the efficiency of virion particle production were identified by 
mutagenesis. Mutagenesis results also suggest the existence of a specific functional 
integration between the MA protein and the gp41cytoplasmic tail; virion 
incorporation of envelope glycoproteins with long, but not short, cytoplasmic tails 
was blocked by specific, single amino acid substitutions in the MA protein23. 
Capsid Domain (CA protein)   
 In the CA domain of HIV-1, amino acids 240 through 430 are essential for 
self associaton24. The CA domain of all retroviruses contains a major homology 
region (MHR) that is required for efficient viral replication and particle production. 
Deletions within the MHR or deletions C-terminal to this region blocked viral 
replication and significantly reduced the ability to form viral particles.  
Nucleocapsid Domain (NC Protein)  
 The Gag precursor binds to and is responsible for the packaging of the viral 
genomic RNA. The NC domain of the Gag precursor is directly involved in this 
nucleic acid binding. Rich in basic residues (i.e. Lys and Arg). the NC domain 
contains two copies of a zinc-binding sequence [Cys (x)2) cys(x)4 His (x)4 Cys] 
referred to as a retroviral CCHC zink finger. The basic residues confer a nucleic acid 
binding property to the domain and the CHC zink fingers contribute to the 
specificity for the viral RNA.  During viral assembly, the NC domain of the Gag 
precursor bind to the encapsidation site (ie Psi site) near the 5' end of the genomic 
RNA.  
 Disruption of either of the two zink fingers in the NC domain resulted in 
noninfectious particles with reduced levels packaged viral genome25.  Deletion the 
zink fingers also eliminated virus particle formation.  Gag sequences up to and 
including the first zink finger domain are necessary and sufficient for virion 
formation. Mutants of the NC protein that still packaged RNA but had alterations 
coition the zink finger structures, reduced infectivity. 
 The NC protein also catalyzes the formation of the genomic RNA dimer 
found in virion particles. HIV-1 encoding a defective protease incorporated RNA 
with a different dimer structure. This indicates that dimer formation is probably 
catulyzed by the mature NC protein and not by the Gag precursor. 
P6gag protein: 
 The only established function of P6 gag is the interaction with Vpr, resulting in 
virion incorporation of this accessory protein. The P6 gag protein is necessary and 
sufficient for this incorporation. The role of Vpr is not known exactly, but it appears 
to block cells in the G2 or S phase of the cell cycle26. 
P1 and P2 Peptides : 
 The role of the P1 peptide is unknown. The P2 sequences were shown to 
modulate the rates of Gag processing. The proteolytic processing sites of the Gag 
precursor are cleaved in a sequential manner by viral protease. The exact hierarchy 
of protedytic processing may be important for capsid formation and viral infectivity. 
The presence of a C-terminal P2 tail on processing intermediates slows cleavage at 
the upstream CA/P2 site. Deletion of the P2 domain of Gag resulted in released 
virions that were less infectious despite the presence of the processed final product 
of Gag27. 
The Envelope : 
 As with most enveloped viruses, the retroviral envelope is derived by 
budding from the cell membrane and compries preexisting lipids and other 
membrane components modified by the insertion of viral proteins in place of normal 
cellular components. All retroviruses have a similar complement of envelope 
proteins. The three dimensional structure of a retroviral env protein has yet to be 
determined. 
Env. Protein : 
 The HIV-1 Env. precursor gp160 is cleaved intracellularly into gp120 and gp41 
by a cellular protease. The surface glycoprotein gp120 binds CD4 in the initial step of 
virus-cell interaction. This binding leads to conformational changes and membrane 
fusion assisted by the N terminus of gp41. The part of Env. interacting with CD4 has 
been identified within four noncontiguous regions of gp120. The overall structure of 
gp120 is important for virus receptor interaction and virus entry. Env. is a heavily 
glycosylated protein. N linked glycans are necessary for the creation, but not the 
maintenance of a bioactive conformation, and drug induced alteration of the 
glycosylation pattern can impair virus infectivity28.  
 Different isolates of HIV-1 very in their cell tropism, that is the range of cell 
types in which they are able to establish a productive infection. The env. 
glycoprotein gp120 is responsible for the difference in cell tropism in many cases. 
The region of Env. involved in the determination  of cell tropism includes sequences 
that encode the V3 loop of gp120. Control of cell tropsim by a part of Env. including 
the V3 loop may be general phenomenon that applies to many different HIV-1 
isolates. 
 Interactions between gp120 and CD4 are responsible for the entry of HIV-1 
into host cells in most cases.  HIV-1 into host cells in most cases. HIV-1 replication 
is commonly followed by the disappearance or down modulation of cell - surface 
CD4. This process potentially reders cell nonsus ceptible to subsequent infection by 
HIV-1 and other viruses that use CD4 as a receptor. Disappearance of CD4 from the 
cell surface is mediated by several different viral proteins that act at various stages 
throguh the course of the viral life cycle.  
Virion Enzymes :  
 The product of the pro and Pol regions constitute the enzymatic activities 
found in retrovirus virion. Their mode of synthesis, as occasional extension products 
of gag, results in their presence in much smaller numbers, less than 100 compared 
with thousands of copies per virion. 
Protease (PR) : 
 HIV-1 protease in an aspartic protease containing the characteristic active 
centre of such enzymes (i.e. Asp Thr Gly). Protease is only active as a dimer, which 
is formed after Gag and Gag Pol multimerization, and contains two identical 
subunits of approximately 10 Kb In contrast cellular aspartic proteases (eg. 
Pepsinogen) are monomers containing two Asp Thr Gly domains that form the 
active centre. Premature activation of protease does not occur before capsid 
formation at the plasma membrane, because the amount of Pr160 gag pol is limited. 
Several mutations prevented protease activation in the context of a Gag protease 
polyprotein, perhaps by preventing polyprotein dimerization. The appropriate 
activation of protease is essential for virus maturation, but excess protease activity is 
deterimental to the virus29. 
 Inhabitation of HIV protease results in noninfectious particles and is an 
attractive target for therapy designed to block the progression of HIV infection. 
Elucidation of the tertiary structure of HIV-1 protease has aided the rational design 
and development of protease inhibitors. Inhibitors of HIV protease from a variety of 
chemical classes have been synthesized and antiviral activity has been demonstrated 
in lymphocytes and cell of the monocytemacrophage lineage. Several of these 
inhibitors have shown promise in clinical trials. Saquinavir (Invirase, Hoffman La 
Roche) was the first protease inhibitor in clinical trials, and other protease inhibitors 
are under clinical evaluation, including MK-639 (Merck), ABT-538 (Abbot 
Laboratories), KNI-272 (Kyoto/national cancer institute), U 96988 and U 103107 
(Upjohn) and AG 1343 (Agouron). 
Reverse Transcriptase / Rebonuclease (RT) : 
 Active reverse transcriptase (RT) is a heterodimer produced by protecolytic 
processing of Pr160gag-pol by the viral protease. The gag pol precursor first produces 
P66, which presumably dimerizes. The P66 subunits in the homodimer are loosely 
associated, and the dimer has low enzymatic activity. During viral infection, the P66 
homodimer is further cleared at the C-terminal part of one P66 subunit to give a 
tightly associated P66-P51 heterodimer, which has full enzymatic activity. 
Enzymatic Activities : 
 Reverse transcriptase possesses three enzymatic activities : RNA dependent 
DNA polymarase, DNA dependent DNA polymurase and ribonuclease H (RNase 
H). The polymerase activity of reverse transcriptase lise within the N terminal 
portion P66 and the RNase H activity lies within the C terminal portion of P66. A 
'tether' region lies between the two domains. Rt also binds specifically to t RNA lys, 
which is preferentially encapsidated and subsequantly hybridized to the PBS. When 
isolated from HIV virions, the t RNA is annealed to the RNA at the PBS. 
 The three dimensional structure of HIV reverse transcriptase reveals an 
unprecedented degree of asymmetry within the heterodimer30. The P66. submit has a 
large cleft similar to that of other polymarases, while the P51 subunit has a very 
different structure.  
 Rt uses RNA primers with 3' OH ends to initiate DNA synthesis. The RNase 
H activity is responsible for the cleavage of the RNA strand in the RNA-DNA 
hybrid. The synthesis of the minus strand starts at the PBS by the tRNA primer, 
while the synthesis of the plus strand starts at the PPT, next to the U3 region. 
 The fidelity of the DNA polymerases is largely attributable to a two step 
nucleotide binding michanism. In the first step binding contacts are initially made 
between the template and the incoming nucleotide triphosphates. In the second step, 
a change in protein conformation occurs, which leads to rapid incorporation of the 
nucleotide triphosphates into the growing polymer. The fidelity of polymerization 
due to these mechanisms approaches one errors in 105 or 106 nt. The proofreading 
function of the DNA polymerases increases the fidelity by another 103 to 104, 
resulting in the extraordinary overall fidelity approaching one error in 1010 nt. Right 
does not have a 3' exonuclease proofreading activity, which results in high error 
rates. During one replication cycle, the viral genetic information is copied twice, 
first by the reverse transcriptase to proviral DNA and second by the RNA 
polymerase II to RNA. The combined error results in about one error in 104 nt. 
which means that every genomic RNA molecule of approximately 104 nucleotides 
contains one misincorporation.  
Inhibitors of RT : 
 RT has been the first and most successful target for anti HIV-1 
intervention31. Nucleoside analogs were found to be present inhibitors of rt, resulting 
in widespread clinical utility. The nucleoside analogs that have been approved for 
clinical use or are at various stages of clinical development include AZT 
(Zidovudine, Retrovir) ddi (didanosine, Videx), ddC (zalcitabine, Hirid), d4T 
(Stavudine, Zerit), and 3TC (lamivudine). These nucleoside analogs act after 
phosphorylation to nucleotide triphosphates to inhibit elopngation at the active site 
of rt. 
 The major problems with these drugs are their toxicity, caused in part by 
inhibition of cellular polymerases, and the rapid development of resistance to the 
drugs by HIV-1. Resistant viruses can be detected soon after treatment. Multiple 
reverse transcriptase mutations have been shown to confer resistance to AZT, 
including mutations at amino acids 41, 67, 70, 215 and 219. Accumulation of more 
than one mutation leads to higher resistance. Treatment with different nucleoside 
analogs may result in different mutations conferring resistance. Many, mutations 
have been observed in vitro and in vivo. Ongoing clinical trails are testing 
combinations, with the hope that different inhibitors may prevent or delay the 
development of resistance. 
 Nonnucleoside analogs, such as nevirapine, TIBO, and L 697661, that inhibit 
reverse transcriptas also have been developed, these inhibitors are specific for HIV1.  
Integrase (IN) : 
 Integrase is the viral protein responsible for the integration of the proviral 
DNA into the host nuclear DNA. Integrase is a 31 Kd protein produced from the C-
tgerminal part of Pol after processing of Pr 160 gag pol Integrase possesses the 3' 
processing and DNA strand transfer activities that are required to integrate HIV-1 
DNA into a host chromosome. It cleaves the ends of the liner viral RNA, leaving 3' 
recessed termini that may slow self ligation and favour integratgion of the linear two 
LTR DNA. Integrase also cleaves the cellular DNA randomly and joins the viral 
DNA to the host's chromosome. These activities have been reconstituted and studied 
extensively in vitro. 
 Biochemical analysis of HIV-1 integrase with purified protein and synthetic 
DNA substrates has revealed extensive information regarding the mechanisms of 
action of the enzyme and identified critical residues and functional domains. In 
vitro, a stable complex containing only purified HIV integrase and a model viral 
DNA substrate processively executes the 3' trimming and DNA joining step in the 
integratgion reaction. Purified integrse was also shown to promote the same action 
in reverse, a process called disintegration. Integrase is an important component of 
the preintegration complex. Association of integrase, but not reverse transcriptase or 
MA proteins, with viral DNA was stable in the presence of detergents. The domains 
involved in the integration of integrase with the viral DNA substrate have also been 
studied32. 
 Integration is an obligate step in productive HIV-1 infection of activated 
peripheral blood mononucler cells (PBMCs) and primary human macrophages. 
Mutations introduced into infectious DNA clones of HIV-1 affect virus replication at 
a variety of steps. Mutations that altered virion morphology, levels of particle 
associated integrase and reverse transcriptase, and viral DNA synthesis have been 
identified. Although none of the replication defective mutants were able to intgrate 
into the host genome, a subset of them with alterations in the catalytic triad were 
capable of Tat-mediated transactivation of an indicator gene linked to the viral LTR 
promoter. Although unintegrated viral DNA can serve as a template for Tat 
expression in infected indicator cells, this level of expression is insufficient to 
support a spreading viral infection in CD4 positive lymphocytes. Integration of the 
HIV-1 provirus is essential not only for productive infection of T cells, but also for 
virus passage in cultured peripheral blood lymphocytes and macrophages. 
REGULATORY PROTEINS : 
 The two essential regulatory proteins of HIV-1 are Tat and Rev. These are 
the two gene products for which there is direct proof of involvement in different 
steps of gene expressions transcription for Tat and posttranscriptional regulation for 
Rev. Because the other nonstructural gene products do not appear to be directly 
involved in gene expression control, they were named accessory to differentiate 
them from Tat and Rev. which act on gene expression. Tat and Rev appear to 
recognize specifically a limited number of functional group in the major groove of 
an RNA double helix distored by virtue of unpaired or non watson crick paired 
nucleotides. 
Tat : 
 Tat is an essential regulatory protein for HIV-1 replication33. The 16 kd, two 
exon Tat protein is encoded from two separate exons of multiply spliced mRNAs. 
Whereas a one exon, 14 kd form of Tat (Tat-1) is produced by singly spliced 
mRNAs. Tat varies in size among the different isolates (86 to 101 amino acids); 
turncated (58 to 72 amino acid) forms encoded by the first exon are also functional. 
Tat accumulates in the nucleolus and is responsible for the transcriptional activation 
of HIV expression. It is the first charactrized eukaryotic transcription factor that 
binds to a nascent leader RNA and affect the HIV enhancer promoter. 
 All HIV-1 mRNAs contain a region at the 5' end named TAR, which has 
been mapped to nt + 1 through 44. This sequence is necessary for transactivation of 
viral gene expression by Tat. TAR is predicted to form a stable stem loop structure, 
with a bulge in the stem. Result of mutational analysis indicate that the bulge and the 
stem are necessary for transactivation Tat binds directly to the bulge region. of the 
TAR element. The nucleotide sequence of the bulge, UCU, is critical for Tat 
binding. Specific sequences are also required for Tat binding in the double stranded 
region that flanks the bulge. These interactions are necessary but not sufficient for 
Tat function; cellular factors have also been shown to bind to TAR or to Tat and 
some cooperate with Tat in promotor activation. Factors produced by the human 
chromosome 12 contribute to the binding of Tat to TAR. The HIV promoter is 
significantly less activated in the presence of Tat. 
 All RNA binding Tat proteins contain an 'activation domain' and an arginine 
rich basic domain which are necessary for activation of transcription, specific 
binding to TAR RNA, and nuclear localization. 
 Viruses defective for Tat do not replicate, except in some in vitro cell lines 
after cytokine stimulation. 41 irradiation can also activate expression of tat-
integrated proviruses. Tat defective proviruses could easily be detected in patient 
tissues. Transitions from tat + to tat - and back may be a mechanism for tetancy in 
human tissues. Tat has been found in the medium of infected cells, suggesting that it 
may have an extracellular role. Tat has also been implicated as one of the cofactors 
in Kaposis sarcoma induction. 
 Tat is a potent and essential transactivation element acting through RNA 
binding. Its role in the virus life cycle is complex and has the potential to interact 
with multiple cellular components. It has been used as a reliable marker for HIV-1 
infection, and as a target for development of antiviral strategies. 
Rev : 
 Rev is an essential regulatory viral protein that accumulates in the 
nucleolus34 and shuttles between the nucleolus and the cytoplasm. Rev is a small, 
positively charged protein of approximately 116 amino acids. The abnormal 
mobility of Rev on denaturing gels (19 Kd) probably results from the structure of the 
protein. Rev. is phosphorylated on ser residues. Mutagenesis studies indicated that 
phosphorylation is not essential for Rev. function in vitro. 
 In the absence of Rv. most of the viral mRNAs are multiply spliced, the 
production of the structural protein is very low, and no virions are formed.  
ACCESSORY PROTEINS : 
 The accessory genes (i.e. Vif, VPr, Vpu and nef) and proteins of HIV-1 were 
so named because they were dispensable for virus replication in many cultured cells 
in Vitro, although their conservation in all virus isolates demonstrates that they are 
essential during the virus life cycle in the host. Most of the accessory proteins 
appears to enter the virion, and they interact with viral and cellular components to 
increase viral replication in the host. Two of the accessory genes, vif and Vpr, have 
recognizable homologs in nonprimate lentiviruses. 
Vif : 
 The viral infectivity factor Vif (previously named sor or Q) has been shown 
to influence the infectivity but not the production of virus particles. The vif ORF is 
located after the Pol ORF and overlaps with the 3' part of pol. Homologs of vif exist 
in all lentiviruses except equine infectious anaemia virus. The vif gene encodes a 23 
Kd protein, which is immunogenic in infected individuals. Vif is expressed from 
partialy spliced mRNAs; its expression is activated by Rev35. Vif is a cytoplasmic 
protein, existing in a soluble cytosolic form and a membrane associated form. The 
latter form of Vif is a peripheral membrane protein that is tighty associated with the 
cytoplasmic side of cellular membranes. This localization and other observations 
suggest that vif is incorporated in the virion. 
 Vif is required for HIV-1 replication in the CD4 positive T cell lines CME 
and H9 and in peripheral blood T lymphocytes. 
 The mechanism of function of Vif is not clear several studies agree with the 
conclusion that Vif affects late events in the viral life cycle, which result in lower 
infectivity. Vif may affect virus particle maturation. It was shown that 
nonhomogeneous packing of the core takes place in most vif virions production in 
CME and Jurkat cells. In the absence of Vif, the cone shaped virus core contained 
dense material in its broad end, but in contrast to Vif+ virions, the material inside its 
narrow end appeared transparent. Notably, vif virions recovered from restrictive 
cells, but not from permissive cells, were abnormal in terms of morphology and viral 
protein content.  
 Vif is required for proper assembly of the virion and for efficient Env. 
mediated infection of target cells. Failure to infect target cells results from a defect 
in the formation of the viral particle in PBMCs or nonpermissive cell lines. In a 
single round of infection vif virus is approximately 25 (from CEM x 174 cells) to 
100 (from H9 cells) times less infectious than wild type virus. 
 The observation that vif virions do not produce cDNA after infection led to 
an alternative proposal, suggesting that vif stimulates efficient nucleocapsid. 
internalization or activation of reverse transcription after infection. The levels of 
viral DNA were examined by RNA PCR during infection by Vif + and vif - viruses 
of MT2 and H9 cells, in which Vif is required for HIV-1 replication. Inefficient viral 
DNA synthesis correlated with restricted replication of the vif virus. Instead, vif 
virions were severely impaired in their ability to complete the synthesis of viral 
DNA after they were internalized in the target cell. The impaired reverse 
transcription may be the result of defects in virus maturation in the nonpermissive 
producer cell. 
 The C terminus of Vif is required for the stable association of Vif with 
membranes and is essential for Vif function, suggesting that this association is likely 
to be important for its biologic activity.  
Vpr : 
 Vpr (Viral Protein R) is a 96 amino acid, 14 Kd protein that is incorporated 
into the virion. It interacts with the P6 part of the Pr55 precursor36. Vpr detected in 
the cell is localized to the nucleus. Proposed functions for Vpr include the nuclear 
import of preintegration complexes, cell growth arrest, transactivation of cellular 
genes and induction of cellular differentiation. 
 Most retroviral integration requires cell division. In contrast, HIV-1 and the 
other lenmtiviruses can inegrate their genomes in nondividing cells by transporting 
the preintegration complex into the nucleus. Vpr is one of the two identified 
nucleophilic componants that promote nuclear localization of viral nucleic acids in 
nondividing cells. 
 Serval observations raise the possibility that some aspects of HIV-1 induced 
pathologies are caused by a disturbance of cells by Vpr. Although Vpr has no effect 
on the initial cytopathic effect of HIV-1, viruses that contain an intact Vpr gene are 
unable to establish a chronic infection of T cells, whereas viruses with a mutated 
Vpr gene can readily establish such longterm cultures. Expression of Vpr alone 
affects the progression of cells in the cell cycle, arresting the cells in Gz / M phase. 
These results suggest hat HIV-1 uses Vpr to modulate chronic infection of T cells. 
Vpr can directly inhibit cell proliferation and induce cells differentiation of the 
human rehabdomyosarcoma cell line TE671 These results may be related to the 
ability of Vpr to block cell division, and link this proein with cellular proliferation 
pathways possibly relevant to the control of HIV-1 replication.  
 The C terminal third of the Vpr protein caused cell growth arrest and 
structural defects in yeast cells, indicated by osmotic sensitivity and gross cell 
enlargment. The Vpr molecular clones were viable and did not have any obvious 
defects when growth in T cells, but their growth was severely delayed in 
macrophages. Loss of Vpr reduced viral antigen production in macrophages by up to 
1000 fold but only marginally affected replication in lymphocytes. The block to 
infection in monocytes was identified at a step in the viral life cycle after entry and 
reverse transcription, but before or at the time of proviral transcription. Infection of 
mononuclear phagocytes with virions that had been loaded with Vpr molecules in 
the producer cells by transcomplementation still showed a Vpr phenotype, 
suggesting a role for Vpr produced in newly infected cells in addition to its 
presumed function in the virion. In support of this theory, Vpr was found to be 
produced by multiply spliced (Rev. independent) and by singly spliced (Rev. 
dependent) mRNAs, suggesting that Vpr is present early after infection. 
 Vpr contains an amphipathic alpha helical domain in the N terminus 
(residues 17 through 34) that is highly conserved among Vpr sequences of different 
isolates. Acidic and hydrophobic residues and the helial structure in this region are 
critical for the stability of Vpr and its efficient incorporation into virions. Mutation 
of the highly conserved acidic residues in the N terminal domain (residues 17 
through 34) disrupted the alpha helical structure and eliminated virion incorporation.  
Vpu : 
 Vpu (Viral Protein U) is unique to HIV-1 and SIV, a close relative of HIV-1. 
Vpu is a 16 kd, has two different biologic functions. degradation of CD4 in the 
endoplasmic reticulum and enhancement of virion release from the plasma 
membrane of HIV-1 infected cells.  
CD4 Degradation : 
 Intracellular complexing between Env. and CD4 results in trapping of both 
molecules in the endoplasmic reticulum. The presences of Vpu releases Env. from 
these complexes. In several systems, Vpu was shown to act on CD4 in the absence 
of Env. or any other viral protein. Degradation of CD4 by Vpu requires the two 
proteins to be present in the same membrane compartment. Immunoprecipitation 
experiments showed that Vpu specifically binds to he cytoplasmic tail of CD437. The 
ability of CD8 / CD4 chimeric molecules and various CD4 mutunts to form 
complexes with Vpu correlates with their sensitivity to degradation, and amino acid 
residues in the CD4 cytoplasmic tail that are important for degradation are also 
necessary for Vpu binding. 
Virus Release : 
 In addition to CD4 degradation, Vpu appears to have another function, it 
enhances the release of virions from the infected cells. This function of Vpu may be 
related to the multimerization of Vpu and potential ion channel forming capacity. A 
structural homology of Vpu with the influenza M2 membrane protein has been 
observed. M2 forms ion channels and may modulate the pH of intracellular 
compartments. This activity of Vpu is not restricted to HIV-1. It was reported that 
Vpu enhances the release of capasids produced by the Gag genes of widly divergent 
retroviruses in CD4 negative cells. 
Nef : 
 Nef (previously named 3' ORF) is an approximately 27 kd myristylated 
protein produced by an ORF located at the 3' and of the primate lentiviruses. Other 
forms of Nef are knonw, including nonmyristylated variants. Nef is predominantly 
cytoplasmic and associated with the plasma membrane through the myristly residue 
linked to the conserved second amino acid (Gly.) Nef has also been identified in the 
nucleus and found associated with the cytoskeleton in some experiments. Its 
association with the virion is suspected but not proven. Nef is not preferentially 
accumulated in the virion, but its membrane localization may result in virion 
incorporation. 
 Initially thought to be a negative factor, nef was found to be important for 
viral replication in vivo. A nef + HIV-1 molecular clone induced severe depletion of 
human thymocytes in immunodeficient (Scid) mice containing human lymphoid 
tissues (scid-hu) within 6 weeks of infection, but a nef-HIV-1 did not38. Thus HIV-1 
nef is required for efficient viral replication and pathogenicity in vivo. 
Down regulation of surface CD4 : 
 A well established function of Nef is the downregulation of CD4, the 
primary viral receptor. Nef acts by inducing CD4 downregulation is strongly 
enhanced by the association of Nef with cell membranes through myristylation.  
 This function of Nef appears to be redundant with the function of Vpu, 
which degrades CD4 in the endoplasmic reticulum. For both proteins, membrane 
association is essential for CD4 degradation involves binding to CD4. Binding has 
been demonstrated for Vpu; however, no direct evidence exists for an association 
between Nef and CD4 and attempts to demonstrate CD4-Nef complexes have failed. 
Whatever the mechanism, this function of Nef results in rapid CD4 downregulation 
and possible prevention of superinfection. In concert with the function of Vpu, these 
effects may result in higher levels of intact Env. protein in the capsid and increased 
virus production. 
 CD4 down regulation is a property of nef alleles found in many primary 
HIV-1 isolates. It was proposed that CD4 down regulation is a conserved function of 
Nef, selected in vivo during human HIV-1 infection. 
VIROLOGIC AND BIOLOGIC FEATURES OF HIV-2 :  
 Both HIV-1 and HIV-2 are human lentiviruses with a number of similar 
virologic properties. Both viruses have a target cell tropism for CD4 + T 
lymphocytes and a propensity for establishing latent infections. Like other 
retroviruses, the HIVs are single positive strand RNA viruses with particles 
approximately 100 nm in diameter. Virions have a characteristic dense, cylindrical, 
protein core that encases the genomic RNA molecules and viral enzymes (reverse 
transcriptase, integrase, and protease). This ultrastructurl morphology of HIV-2 can 
be distinguished from HIV-1 and other animal lentiviruses; it is also distinct from 
type C retroviruses. Distinct for HIV-2 is the prominant protruding envelope 
projections and the electron lucent paranucleoid space, which is an open ring around 
the triangular core, compared to HIV-1 where the lucent space extends from the core 
to the envelope binding of the envelope of HIV to the CD4 molecule is only a first 
step in viral entry, with subsequent fusion events that appear to require both viral 
envelope and other cellular factors39. HIV-2 isolates have demonstrated tropsim for 
cells bearing the CD4 marker, similar to both HIV-1 and SIV. Blocking studies with 
recombinant soluble CD4 have verified that SIV and HIV-2, like HIV-1, bind via 
their external envelope glycoprotein, gp120, to a common cellular receptor, the 
differentiation antigen CD4. It is of interest that HIV-2 has a lower binding affinity 
for the CD4 receptor than does HIV-1. 
 Once inside the cells, the processes of reverse transcription and integration 
occur. The HIV replication cycle is unique, with a complex array of various viral 
encoded factors that regulate both positively and negatively on the level of virus 
expression. This culminates in the final steps of virus assembly, maturation, and 
release, similar to other retroviruses. HIV replication is closely linked to the death of 
the CD4 + cell. This cytopathicity is a hallmark of HIV infection and has been 
studied extensively both in vitro and in vivo. In vitro studies of HIV-2 isolates by a 
number of laboratories have described differences in cytopathicity of HIV-2 as 
compared with HIV-1. In comparison with HIV-1, HIV-2 isolates demonstrate 
decreased cell killing, less syncytial cell formation, reduced virus replication, and 
difference in interaction with CD4 in some cases related to the clinical stage of the 
HIV-2 infected individual. 
 The antigenic relatedness of both SIV and HIV-2 to the prototype HIV-1 
virus prompted both the discovery and further classification of these related viruses. 
Subsequent genetic analysis confirmed the relationship indicated by antigenic 
studies, demonstrating that HIV-2 was more closely related to SIV than to HIV-1 
(approximately 40% nucleotide homology). Similar to HIV-1, restriction site 
polymorphism and sequence data indicate variability among HIV-2 strains. As more 
sequence data have become available from various HIV-2 and SIV strains, it has 
also become apparent that no branching order of divergence can be specified and 
that these virus types may in fact share a common ancestor. Sequence variability of 
structural genes such as env and gag has been similar between HIV-2 and HIV-1, 
with greater variability in the env gene. Interestingly, regulatory gene sequences are 
more variable among HIV-2 isolates, compared with HIV-1. 
 Like all retroviruses, HIV-2 encodes gag, pol and env structural gene 
products, flanked by two long terminal repeat sequences (LTRs). The overall 
genomic organizations of HIV-1 and HIV-2/SIV are similar except for the presence 
of the unique gene termed VPx found in both HIV-2 and SIV and the Vpu gene 
unique to HIV-1. The gag precursor polyprotein of HIV-1is translated from the full 
length genomic RNA to a 57 KD protein that is myristylated and cleaved at five 
cleavage sites to yield six products, P17-P27-P2-P1-P6. The major core protein P27 is 
slightly larger in HIV-2 than in HIV-1, whereas the myristylated matrix protein P17 
is of similar size. After a gag-pol polyproptein precursor is formed, the complete Pol 
precursor is cleaved and forms a protein of approximately 180KD. This product is in 
turn cleaved to form the P64 (reverse transcriptase / RNase H), P36 (endonuclease / 
integrae), and P11 (Protease) of HIV-2. The major viral structural proteins are 
readily distinguished on immunoblats and regularly recognized by HIV-2 serum 
samples. The gag and pol genes are well conserved among both HIVs and SIVs, the 
high degree of conservation in the structural genes accounts for the cross reactivity 
of HIV-2 sera on HIV-1 gag and pol antigens, as seen in some serologic assays. 
 In HIV-2 the envelope polyprotein precursor is a heavily glycosylated 
protein which is elevated to form the mature (group 105-120) and the 
transmembrane (group 32-40) envelope proteins. Like HIV-1, genetic variation 
between HIV-2 isolates has been demonstrated, with the most marked variation in 
the envelope gene. The envelope gene demonstrates genetic variation from isolate to 
isolate with some plymorphism exhibited at a protein level. Sequence analysis of 
several HIV-2 strains has demonstrated a stop codon in the middle of the open 
reading frame encoding the transmembrane protein; this finding explains the smaller 
transmembrane protein size that is seen with certain HIV-2 isolates. 
 Functionally important sites on the external glycoprotein appear conserved 
between HIV-1 and HIV-2. This includes the CD4 binding domain, precursor 
processing, fusion, principal neutralizing domain of V3 and at least some cytotoxic 
T-cell epitopes, unlike HIV-1, antibody binding activity appears to concentrate in 
the middle protein of the Group 105 envelope molecule, as opposed to the HIV-1 
antibody response, which is directed more broadly across the group120 molecule. 
Another important immunogenic domain of the envelope of HIV-2 is found in the 
amino terminus of the transmembrane protein, which has been used to advantage for 
a variety of peptide and recombinant based type specific diagnostic assays. 
 Like other complex retroviruses, HIV-2 possesses a number of accessory 
genes with variable homology to HIV-1 genes, including tat, rev, nef, vif and vpr. 
Both SIV and HIV-2 possess a Vpx gene which is absent in HIV-1 and they both 
lack the Vpu gene, the unique accessory gene of HIV-1. Matational studies have 
shown that Vpx is not required for virus replication, yet may fucilitate infection in 
fresh lymphocytes and monocytes. Thus, the Vpx gene product apears to be 
necessary for efficient viral replication under certain circumstances. Although the 
general genomic structure of HIV-2 and HIV-1 are similar, the reading frames 
differ. The reading frames for HIV-2 gag, pol and vif are similar to HIV-1, but the 
reminder of the open reading frames are different from that of HIV-1. This frame 
shift occurs at the site of Vpx, the unique gene of HIV-2. 
 HIV-2 encodes the vif gene which, by analogy to HIV-1, is likely to be 
involved in the infectivity in certain cell types. The nef gene, originally considered 
on the basis of tissue culture experiments to encode a negative regulatory element, is 
now known to encode a protein which actually increase SIV and presumbly HIV-2 
replication in Vivo. The product of the Vpr gene appears to be a virion associated 
structural protein which has been shown to cause a modest increase in HIV-1 
replication to be critical for macrophage infectin. Recent data suggest that Vpr may 
function as a regulatgor of cellular permissiveness to HIV-1 replication. Serum Vpr 
from HIV-1 infected patients activated virus expression in latently infected cell lines 
and in resting peripheral blood mononuclear cells, thus indicating that the Vpr gene 
product may control HIV latency in vivo. The distant genetic relatedness of Vpr to 
Vpx has suggested that Vpx in HIV-2 results from an ancient duplication of the Vpr 
gene. The relevance of this observation to the function of these genes in HIV-2 is 
still not known. 
 The tat protein of HIV-2, like that of HIV-1, transactivates to stimulate viral 
production and is assumed to be essential for viral replication. The tat proteins are 
unsual viral transactivators in that their action is mediated through a site or sites 
downstream of the RNA initiation site. It is generally believed that the primary role 
of tat is to permit elongatgion of properly initiated viral transcripts. Whereas the 
RNA target for HIV-1 tat has only one stem loop structure, the HIV-2 tat target 
sequence has two. It appears that the distal site may be employed only when the 
proximal site can not be used. Functional evidence of tat activity has been shown for 
HIV-2 and SIV similar and cross reactive with HIV-1 tat. 
 Another regulatory gene of HIV is the rev gene, which exhibits a complex 
machanism of action and is required for viral replication. Rev. acts through its RNA 
target in the env gene. The rev responsive element (RRE), to fucilitate the transport 
of HIV structural gene transcripts to the cytoplasm. This is accomplished by 
decreasing the transport of unspliced (structural gene) viral RNA from the nucleus 
and by regulating RNA splicing. Interaction of Rev. with the RRE RNA, either 
alone or with additional cellular factors, presumably mediates the export of these 
RNAs from the nucleus to the cytoplasm. In the absence of Rev, the viral proteins 
encoded by these mRNAs are not expressed because their respective mRNAs are 
trapped in the nucleus. While less well, studied, HIV-2 rev appears to function 
similarly to HIV-1 rev, the HIV-2 rev is phosphorylated, albeit toamuch lesser 
extent, and is localized to the nucleus with marked accumulatation in the nucleolus. 
While HIV-1 rev can function with both the HIV-1 and HIV-2 RREs, HIV-2 rev 
function only with its own RRE. 
 In general, regulation of viral gene expression in HIV-2 seems to resemble 
that observed in HIV-1. However,  several differences have been described thatmay 
play a role in the differential pathogenicity of these virus for example; sequence of 
HIV-1 and HIV-2 have demonstrated differences in the LTR structure. Whereas 
HIV-1 has two NFkB enhancer binding sites, only one can be identified for HIV2. 
Regulation and response to T-cell activation via the viral. LTR also appear to be 
distinct in HIV-2. Specific and unique lements in the HIV2 LTR may regulate HIV-
2 gene expression independently of the T-cell activation signals. Mutational studies 
of the unique sites in the HIV-2 LTR responsible for inducible enhancer function 
demonstrate that this function is more readily disrupted in HIV-2 compared with 
HIV-1. 
 The invitro behaviour of HIV-1 viruses have been used as an indicator of 
pathogenicity. In contrast to most HIV-1s, HIV-2 isolates demonstrate decreased 
cell killing less syncitial cell formation, reduced virus replication and difference in 
interaction with CD4, frequently related to the clinical stage of the HIV-2 is more 
difficult to isolate from asymptomatic people than is HIV-1, but when isolated, it 
appears to show the "slow low" pattern. Similarly, the "rapid high" isolates were 
more likely to be from HIV-2 infected people with advanced stage disease. 
Evaluation of intrapatient variation in the V3 region of HIV-2 in asymptomatic and 
symptomatic individuals followed over time has shown less variation appears to be a 
distinct feature of HIV-2 infection that may result from decreased viral burden and 
also may contribute to lower rate of transmission and disease development. 
LIFE CYCLE : 
 The human immianodeficiency virus (HIV) shares features common to all 
retroviruses. First, retroviruses are so named because of their ability to route genetic 
information from RNA to DNA. This is accomplished by a unique enzyme, reverse 
transcriptase (RT), which is encoded by a gene within the retroviral genome. This 
gene (Pol) and two others, gag and env, are the major coding regions for the 
structural proteins needed for retroviruses to maintain and complete a life cycle. 
Although the seven major genera of ritroviridae are usually differentiated by the 
pathogenic processes they initiate in their host, all use the products of their gag, pol 
and env genes (Table III) to proceed through a single cycle of replication.  
 
 
Table - III 
HIV-1 structural and regulatory proteins 
Gene Protein (kd) and structure of function 
gag Group-specific antigen. Encodes structural core matrix (17-kd), capsid 
(24-kd) and nucleocapsid (7-kd) proteins.  
pol Polymerase enzyme activity. Encodes the protease (10-kd), reverse 
transcriptase/RNase H (66-kd/51-kd dimmer, and integrase (32-kd) 
enzymes. 
env Envelope glycoproteins. Encodes transmembrane (41-kd) and external 
(120-kd) glycoproteins. 
tat Transactivator of transcription. Encodes a one-exon (14-kd) or two-
exon (16-kd) protein that increases the overall level of steady-state 
HIV-1 RNA. 
rev Transactivator of structural gene expression. Encodes a 19-kd protein 
required for expression of HIV-1 unspliced and single spliced mRNAs 
in the cytoplasm. 
 The binding of an extracellular infectious virion to a susceptible cell begins 
the afferent protein of the HIV retroviral life cycle. (Fig.2) Binding occurs between 
the surface gp120 Env. protein of the virus and the cellular CD4 molecule. This 
reaction permits the transmembrane gp41 Env. molecule to fase the viral lipid 
envelope with the cell membrane. Cytoplasmic penetration by virus core results, 
liberating the viral genomic RNA as a nucleoprotein complex. The RNA is than 
rapidly converted by RT into a copy of double stranded DNA and transported to the 
nucleus. Here, in association with viral integrase, the viral DNA is integrated by 
cleavage steps into the host chromosomal DNA. This begins the efferent portion of 
the life cycle. The proviral DNA now functions as a mammalian gene and can 
replicate synchronously with host chromosomal genes. Expression of the viral genes 
begins when the proviral DNA serves as a template for DNA dependent RNA 
polymerase activity. Such activity results in production of viral messenger RNA 
(mRNA), a procedure that can be divided into early and later steps. Early steps 
involve production of viral regulatory factors that enhance and stabilize the late 
stage mRNAs responsible for structural function. These structural proteins assemble 
around viral genomic RNA at the plasma membrane. The final step consists of 
proteolytic cleavage of Gag precursor molecules, which occurs as the particle buds 
free from the cell, incorporating the Env. protein and portion of the plasma 
membrane into its outer envelope coat. 
Binding and Entry : 
 One of the most fortuitous findings in AIDS research was that the molecule 
used to identify the cell type (CD4), which had been observed to be depleted during 
disease progression, was also the major receptor for HIV-140. CD4 is part of the 
immunoglobulin /G super family; it is expressed on the surface of helper T 
lymphocytes and participates in normal class II major histocompatibility complex 
(MHC) recognition in association with T cell responsiveness to foreign antigens. 
The mature virion of HIV-1 makes primary contact with CD4 through a 
constellation of surface gp120 envelope glycoprotein spikes consisting of variable 
(V1 through V5) and conserved (C1 through C5) domains. This glycoproteins are 
noncovalently linked to a transmembrane gp41 glycoprotein. Critical binding may 
occur between the C3 and C4 domains of gp120 and the N terminal extracellular 
domain of the CD4 molecule during primary attachment. Although the V3 loop of 
gp120 does not bind to CD4, its role in overall virus binding and entry may be 
important. Certainly, syncytium induction, neutralization, and T-cell versus 
macrophage tropsim are dependent on the integrity of this region of gp120 Other cell 
surface molecules, such as MHC class-II HLA-DR, β2- microglobulin, and CD4, 
which are 'trapped' in the virion coat during budding, have also been considered as 
possible accessory ligands in virus binding. 
 After gp120 CD4 binding, a number of events take place that position the 
virion for entry. Conformational changes may occur after binding that uncover 
domains of the gp41 transmembrane molecule. It is theorized that exposure of the N - 
terminus of gp41, which contains a stretch of hydrophobic amino acids, allows the 
host cellular membrane to fuse with the lipid envelope coat of the virion. Cleavage 
of the gp120 V3 region by proteases (possibly as a second receptor) has been 
postulated and may facilitate exposure of the fusogenic gp41 domain. 
 In general, enveloped viruses enter a cell by either receptor mediated, PH 
dependent endocytosis or PH independent membrane fusion. Most data support a 
membrane fusion mechanism for HIV-1, and this process has been observed directly 
by electron microscopy. After insertion of the hydrophobic gp41 N-terminal domain 
into the lipid bilayer of the cell membrane, the viral membrane fuses with the 
cellular membrane. At this point, accessory cellular factors (receptors) may facilitate 
entry. 
 After fusion of viral and cellular membranes, the internal virion core is 
released into the cytoplasm as a ribonucleoprotein complex, allowing for reverse 
transcription of the genomic RNA. Not only are the Gag proteins important for 
assembly and release of HIV, but their association with the two plus strands of the 
HIV genome are critical for reverse transcription and nuclear import of the 
preintegration complexes. The P17 matrix protein has been shown to contain nuclear 
localization signals that are responsible for transport of the nucleoprotein complex to 
the nucleus. The Vpr and Nef accessory proteins may facilitate this process. In 
addition, the matrix protein may be responsible for transport of the preintegration 
complex in the absence cell proliferation. 
Reverse transcription, Nuclear import and Integration of viral DNA : 
 Subsequent to internalization and uncoating of the viral core, the HIV-1 
nucleoprotein complex in the infected cell cytoplasm consists of Gag and Pol. 
proteins and genomic viral RNA. The pol protein containing the RT and 
ribonuclease H enzymatic activities (RT/RNase H), is a 66- and 51-kd heterodimer 
that use the single stranded genomic viral RNA to synthesize a double stranded 
linear proviral DNA. The reverse transcription process also generates the long 
terminal repeat (LTR) region on both the 5' and 3' ends of the proviral DNA that are 
characteristic of retroviruses and necessary for integration of the proviral DNA into 
the cellular chromosomal DNA. 
Reverse Transcription : 
 The infecting HIV-1 virion carries the RT / RNase H enzyme and a cellular 
tRNA bound to the genomic RNA at the primer binding site for negative strand 
DNA synthesis, the PBS (-). HIV-1 and other lentiviruses use tRNAlys as a primer 
for the initiation of RNA based, DNA synthesis. The 18 nucleotides of the 3' and of 
tRNAlys bind to a perfect complementary region of the BPS(-) that is located 
immediately 3' to the U5 region in the genomic viral RNA. The RT enzyme initiates 
synthesis of the negative strand proviral DNA at the PBS (-) by copying the R U5 
region at the 5' and of the genomic RNA. The RNase H activity degrades the R 
region tRNA in the newly synthesized RNA-DNA hybrid. The RNase H degradation  
of the 5' R region induces the newly synthesized negative strand DNA (R-V5) + 
tRNAlys  to  rehybridize to the intact 3' R region of the same genomic RNA or to the 
other copy of genomic RNA (intermolecular jump). Negatgive strand DNA 
synthesis is then continued through the env. pol and gag regions, including the 
PBS(-). RNase H degrades the RNA in the DNA-RNA hybrid except for a 16 base, 
polypurine tract immediately 5' to the U3 region. This polypurine tract, termed PBS 
(+), is used as the primer for initiation of positive strand DNA synthesis. Positive 
strand DNA synthesis begins by replication of the 3' LTR and stops in the adjacent 
tRNAlys primer. After RNase H removes the RNA primers in the PBS(+) and PBS         
(-), a final intramolecular jump occurs wherein the PBS(-) region in the newly 
synthesized positive strand DNA hybridizes with the complementary PBS(-) in the 
negative strand DNA. The RT enzyme completes the synthesis of both strands of 
DNA; the negative strand is completed with synthesis of 5' LTR, and the positive 
strand is completed with the synthesis of all the protein coding regions and the 3' 
LTR. 
 The reverse transcription process is the point in the replication cycle that 
generates the rapid genomic variability characteristic of HIV-1. Some of the genetic 
heterogencity may result from possible intermolecular strand switching of the RT / 
RNase H enzyme during synthesis of the negative strand proviral DNA. Moreover, 
the RT enzyme is highly, error prone, in part because of the absence of 3'-5' 
exonuclease activity, which is required for the replacement of misincorporated 
bases. In vitro assays have reported an error rate of 1 per 6000 nucleotides and an in 
vivo mutation rate of 1 base per HIV-1 genome41. This high error rate in replication 
has afforded the virus an intrinsic capacity to avoid immune surveillance, to quickly 
develop resistance to antiviral therapy, and to generate the diverse strtain of HIV-1 
world wide that have impeded vaccine development. 
Nuclear transport of the preintegration complex : 
 The product of reverse transcription, the double stranded linear viral DNA, 
remains associated with the nucleoprotein complex, aptly termed the prientegration 
complex at this point in the virus life cycle. In addition to the double stranded viral 
DNA, the preintegration complex contains the viral Gag matrix, Pol integrase, and 
Pol RT proteins that were present in the infecting virions. The Gag matrix protein 
contains at least two nuclear localization signals that may be pivotal in targeting the 
nucleoprotein complex to the nucleus. Recent data has indicated that the HIV 
accessory protein, Vpr, may be important for nuclear import of the preintegration 
complex.  
 HIV-1 can infect non dividing monocytes and macrophages in addition to 
activated CD4 + lymphocytes, the preintegration complex has to traverse an intact 
nuclear envelope for access to the host chromosomal DNA. Nuclear import of the 
preintegration complex is a two phase process consisting of the initial prenuclear 
pore transport, which is independent of high energy cofactors, and transport across 
the nuclear pore, which is dependent on high energy cofactor because of their 
relatively low metabolic state, and they are presumbly unable to transport the 
preintegration complex across the nuclear pore. 
Proviral DNA Integration : 
 Once inside the nucleus, the linear double stranded viral DNA associated 
with the preintegration complex is capable of integrating into the chromosomal 
DNA. Chrgomosomal integration of the viral DNA requires the pol gene encoded 32 
Kd integrase enzyme contained in the preintegration complex. HIV-1 integrase 
removes the two nugcleotides from the 3' and of both viral DNA strands, producing 
receassed 3' termini. Integrase also generates the integration site by cutting the 
chromosomal DNA in a way that produces a 5' five nucleotide overhang on each of 
the newly formed chromosomal ends. Cellular DNA repair enzymes complete the 
integration process by ligating the recessed 3' ends of viral DNA with the protuding 
5' ends of genomic DNA and filling the resulting five nucleotide gap in the genomic 
DNA. The completed integration process results in a provirus minus two base pairs 
at the ends of both LTRs and an identical five base pair sequence immediately 
upstream and downstream of the provirus. There is conflicting evidence on the 
necessity of an integrated provirus for viral replication. Infectious HIV-1 proviral 
DNA clones with integrase mutation support viral gene expression in transient DNA 
transfection assays, but these same integrase defective DNA clones do not allow the 
spread of an HIV-1 infection through out a cell culture. 
Regulation of viral transcription :  
 HIV-1 RNA transcription initiates in the 5' LTR at the begining of the R 
region and terminates in the 3' LTR at the end of the R region. The combind effects 
of extracellular signals and cellular and viral factors control the amount and type of 
viral RNA transcripts produced in infected cells. The cellular HIV-1 steady state 
RNA levels range widely, from essentially a latent state (undetecteble viral 
transcription) to a highly activated state of traqnscription that produces enormous, 
levels of HIV RNA. 
Tat Transactivation : 
 In addition to the upstream cis-acting elements just described, a major 
control element of HIV transcription is the trans acting response element (TAR), 
which is located downstream of the transcription initiation site. The TAR region (+1 
to +80) is the target for the viral transactivation of transactivation protein, Tat. Tat 
transactivation induces a dramatic overall increase in steady state HIV RNA and is 
required for the high level of virus production observed in human T cell lines and 
activated human peripheral blood lymphocytes in culture. Although interest has been 
generated as the unique features of the HIV-1 tat TAR activation mechanism are 
discovered, three other lentiviruses, HIV-2, S1V and equine infectious anaemia 
virus, also encode a Tat protein TAR mechanism that is very similar to the HIV-1 
transactivation system. 
Post transcriptional control of HIV RNA expression : 
 The Tat induced increase in HIV transcription results in an abundant pool of 
nascent viral RNA in the nucleus that must be processed and transported to the 
cytoplasm for viral protein synthesis to occur. In the eukaryotic nucleus, the RNA 
splicing mechanism for splice competent cellular transcripts is usualy rapid and 
complete42. In an HIV infected cell, both unspliced and spliced mRNAs must be co 
ordinately produced from the same HIV proviral DNA. The discovery of the HIV-1 
rev protein coding sequence has led to the identification of a second HIV-1 encoded 
transactivation mechanism that is required for the cytoplasmic expression of 
introncontaining, unspliced and single spliced viral mRNAs. Rev activity has also 
been confirmed in at least eight other retroviruses, including HIV-2. 
 The HIV-1 Rev protein is a 19 kd phosphoprotein encoded by two exons. In 
contrast to the situation with tat, both rev exons are required for function; one of two 
oligomerization domains spans the exon 1 and exon 2 splice junction, and the 
nuclear localization and activation domains are located in exon 2. The 
oligomerization domains induce Rev protein multimers that are proposed to be the 
active form of the protein. The nuclear localization domain of Rev includes an 
arginine rich RNA binding domain, similar to Tat, that binds to a cis-acting Rev 
response elements (RRE) in viral RNA. The RRE RNA is a 234 nucleotide region 
located in the env gene that is predicted to form a stem loop secondry structure. The 
RRE is contained in all viral mRNAS that encode the unspliced gag pol and single 
spliced vif, vpr and vpu env genes. Transcripts that encode tat, rev. and nef are 
multispliced mRNAs that do not contain the RRE RNA. The activation domain is a 
leucine rich region that appears to mediate protein protein interactions and is not 
involved with RRE bindng. Rev protein that contains mutations in the activation 
domain binds RRE RNA but is functionally incative. 
 The exact mechanism of Rev. function is not determined, the final result of 
Rev. activity is the cytoplasmic (Transport of viral mRNA) containing the structural 
gag pol for the production of infectious virions. Moreover the absence of Rev. 
activity has been proposed to play a role in HIV latency. 
Translational control of HIV protein synthesis : 
 Most cellular mRNA are monocistronic they encode only one protein that 
can be translated in a relatively uninterupted process. Many of the HIV mRNAs are 
multicistronic, with open reading frames that either partially overlap or are arranged 
in tandem. Ribosomal frame shifting and initiation site scan through are two control 
mechanisms during viral protein synthesis that allow the translation of more than 
one protein species from a multicistronic mRNA. In addition to production of 
different viral proteins from one species of mRNA, appropriate stoichiometric 
amounts of these proteins must be maintained to ensure efficient virion assembly. 
 Expression of Gag and Pol proteins from the same unspliced mRNA occurs 
by ribosomal frameshifting, Gag and Pol genes are located in different reading 
frames, which overlap in their 3’ and 5’ regions, respectively. 
 In most translations of the Gag Pol mRNA, the Gag protein is synthesized to 
completion and released from the ribosome. However, as the ribosome traverses the 
3’ and of the gag open reading frame, a – 1 frame shift can occur that puts the 
ribosome in the pol open reding frame. This results in a Gag Pol fusion protein that 
is subsequently cleaved, by the viral encoded protease, into the mature Gag and Pol 
proteins. Pol translation is totally dependent on the – 1 frame shift because the pol 
gene does not have a functional AUG start site. The 1 – frame shift is dependent on 
a specific heptamer sequence at the actual frame shift side and a predicted RNA 
stem loop structure directly downstream of the heptamer*6. The presence of the 
RNA stem loop is predicted to cause a pause of the ribosome at the heptamer 
sequence and thereby allow the 1 – frame shift in a limited number of translations. 
 Many of the spliced mRNAs of HIV-1 are multicistronic and are therefore 
capable of translating more than one protein. The flanking sequences surrounding 
AUG start codons determine how efficient a particular start site is in initiating 
translation. If the most 5' start site in a multicistronic mRNA is suboptimal, the 
ribosome may continue past this site and begin translation at a more efficient start 
site further downstream. This suboptimal initiation site scan through mechanism 
occurs readily in the translation of HIV-1 Env. protein. All of the Env. encoding 
mRNAs contain the Vpu start site upstream of the start site, however, allows a 
majority of the ribosomes to scan through and find the strong Env. start site Because 
all HIV-1 regulatory genes (-) and accessory genes are encoded in multicistronic 
HIV-1 mRNAs, the relative differences in the strengths of their respective 
translation start sites suggest that translational control of these protein is important 
in the virus life cycle. 
Virion Assembly : 
 Before the virion can be released from the cell, the structural viral proteins 
must coordinately assemble. HIV has been observed by electron microscopy to 
assemble both at the plasma membrane and within intracytoplasmic vacuoles. The 
actual mechanism responsible for this bidirection trafficking is unknown. 
Nonetheless, as the major structural precursor proteins (55kd Gag, 180 kd Gag Pol 
and gp160 Env) begin to accumulate, a number of steps are required for completion 
of the life cycle. first, the Gag (P65) polyprotein oligomerizes, at which point the 
matrix (MA) domain of P55 (P17 processed matrix protein) is responsible for 
transport of the entire gag protein to the plasma membrane. As the polyprotein Gag 
complex aproaches the cellular membrane and begin forming the inner framework of 
the virion the nucleocapsid (NC) domain of p55 permits two copies of HIV genomic 
RNA to assemble around the "cys His" box, which is an array of cysteines similar to 
a zinc finger motif. Discrimination among multiple viral and nonviral mRNAs and 
the full length genomic RNA for Gag encapsidation lies in a cis derected sequence, 
designated psi. This site is located at the 5’ region of the HIV genom and is not 
present in spliced viral mRNA transcripts. To complete the encapsidation process, it 
is thought that the specific tRNA lys primer (necessary for priming negative strand 
synthesis by RT) associates with the Pol domain in the larger Gag Pol 180 kd 
polyprotein and is included in the infectious virion. The capsid protein (CA) domain 
of Gag is essential for the morphogenesis of the mature, cone shaped core. 
Virus Budding and Release : 
 As a final step in the HIV life cycle, the infectious virus matures after if has 
been released from the plasma membrane. This  occurs as a coordinated process by 
which the viral protease (located between the Gag and Pol domains) cleaves the Gag 
Pol protein in an ordered fashion. The conserved P2 domain of Gag is required to 
regulate this sequential proteolytic processing. The protease begins its processing by 
cleaving the P55 Gag protein at the N-terminus of the P15  NC protein and than at the 
P2443 CA. P7 and P6 are the last proteins processed. The Pol polyprotein (RT and 
IN) remains inactive. 
 As the Gag and Gag Pol proteins begin to encapsidate the HIV genomic 
RNA, the plasma membrane also begins to form a lipid bilayer around the viral core. 
Precursor gp160 Env. undergoes glycosylation and oligomerization in the 
endoplasmic reticulum. From this point, it is transported to the Golgi complex, 
where cellular enzymes process the glycoprotein to surface gp120 (Su) and 
transmembrane gp41 (TM). Here, they associate noncovalently and are transported to 
the cell surface. Critical to the final budding step is myristolation of the N terminal 
glycine of the P17 MA protein, This event culminates as the final process in 
condensing the inner core shell and linking it with the glycoprotein incorporated 
lipid membrane. 
Cell Activation : 
 The early events (afferent protein) of the viral life cycle are known to occur 
in the absence of activation. Howeve, for efferent functions (integration, 
transcription, and translation) to efficiently take place exogenous T cell stimulation 
is required. Several activation mechanisms are possible and, influence the viral life 
cycle. Probably the one that has the greatest positive effect on viral expression is 
activation through the T3-T1 specific antigen receptor on CD4 + lymphocytes. 
Similar activation can be achieved through mitogens and superantigens. Other 
exogenous factors (eg. cytokines, physiological stimuli) also have been shown to 
have dramatic effects on HIV expression process. Some investigators have predicted 
that repid progression in HIV disease. 
 T cell lines have been developed to better understand these activation process 
and have been extremely useful in synchronizing stages of the viral life cycle so that 
coordinate expression of the life cycle can be analyzed. Second messenger signalling 
by Ca2+ and protein kinases is required for linking the exogenous stimulation to the 
viral life cycle dependent events. Viral transcription is one of the best studied 
mechanisms that is dependent on cellular activation. Intracellular second messenger 
pathways leading to NF-kB activation and other factors interacting with the viral 
LTR appear to be only a small segment of the control over the life cycle that T cell 
activation can impart. Many believe that control of the viral life cycle through its 
dependence on cellular functions offers some of the greatest hope for therapeutic 
intervention44. 
Role of Latency in the life cycle : 
 Much attention has been focused on the afferent and efferent portions of the 
life cycle, primarily because of findings that throughout the course of HIV infection 
there is no microbiological latent period associated with the clinical latent perioid. 
However, there are microbiologically latent infected cells. HIV is replicating with 
virion turnover from the time of infection until the time of death of the patient. 
Nevertheless, high ratios of viral DNA to viral RNA and latent expressing cell lines 
teach us that not every infected cell is programmed to immediately produce virus. It 
is probably premature to discard latency as not contributing to the pathogenic 
process, as some have indicated. In vitro studies have recently implicated Vpr and 
possibly Nef in the control of transcriptional expression of HIV through cellular 
activation pathways. Many factors could be responsible for controlling expression 
and inhibiting the efferent phase of virus replication. 
Cell Death : 
 Because HIV buds from the plasma membrane there appears to be no 
selective advantage for, the death of the virus producing cell. However, direct 
cytotoxicity by replicating virus has been demonstrated most of the direct killing 
effects have been attributed to the env gene products (gp120, gp160) and their affinity 
for CD4 positive cells. Recently the C terminus of gp41 has been demonstrated to 
have a potent toxic effect on cells independent CD445. Syncytium or multinucleated 
giant cell form resulting from fusion of HIV infected and uninfected cells, has been 
shown to contribute to cell loss in culture. However, this process is not usually 
found in tissue of infected patients and may only be an artifact of in vitro virus 
propagation. Apoptosis or programmed cell death has been suggested to explain the 
loss of CD4+ cells seen in HIV infection. Apoptosis differs from necrosis because 
the latter takes place faster, causing loss of plasma membrane integrity but no 
chromatin condensation. However, indirect effects of HIV infection resulting in the 
apoptotic process are thought to account for the majority of CD4 loss in vivo. Such 
indirect effects include gp120. CD4 crosslinking followed by cell activation, 
autoantibodies, and cellular immune destruction. Recently, the HIV regulatory 
protein, Tat, has been implicated with the APO-1/Fas receptor (cD95) as a strong 
inducer of apoptosis. This area of investigation continues to be intensely pursued to 
better understand CD4 depletion in AIDS and the role that products from the viral 
life cycle play in host pathogenesis. 
IMMUNOPATHOGENESIS OF HIV INFECTION :  
 The immunopathogenesis of HIV infection is extremely complex. A variety 
of virologic and immunologic mechanisms contribute to the progressive 
deterioration of immune function and to progression of HIV disease to the acquired 
immunodeficiency syndrome (AIDS). Becaue of the multifactorial and multiphasic 
nature of HIV infection, these mechanisms may vary according to the different 
phases of infection. Among the multiple patghogenic mechanisms that have been 
proposed, four are critical for the establishment and propagation of HIV infection 
over time and for the progration of HIV disease : (1) Lack of elimination of HIV 
after primary infection (2) persistant virus replication in lymphoid organs throughout 
the course of HIV infection. (3) Chronic stimulation of the immune system, which 
may cause inappropriate immune activation and progressive exhaustion of the 
immune response; and (4) destruction of lymphoid tissue, which results in severe 
impairment of the ability to maintain over time an effective HIV specific immune 
response and to generate immune respones against new pathogenes. Identification of 
these pathogenic mechanisms has resulted from recent advance in the delineation of 
the virologic and immunologic events associated with primary infection, and of the 
anatomic compartments that serve as reservoirs for HIV and the sites at which virus 
replication primarily occurs. These observations represent a fundamental advance in 
our understanding of the pathogenesis ofHIV infection. Recent studies on the 
kinetics of virus turnover have supported previous findings that virus replication is 
continuous in all stages of HIV infection and have provided a precise determination 
of the number of virions produced every day. In the same studies, a mathematic 
model has been used to calculate the potential numberof CD4+ T lymphocytes that 
are depleted and replenished every day, and it has been proposed that there is a very 
high tournover of CD4 + T cell (a mean of 1.8 x 109 cells per day). 
 The clinical course of HIV infection has been well studied. Although 
progression to AIDS occurs in most HIV infected individuals, in a small percentage, 
HIV disease does not progress for an extended period of time. This latter finding, 
together with the observations that HIV specific immune responses may be detected 
in individuals who are multiple exposed to HIV despite the fact that they are 
seronegative, supports the concept that HIV infection can be effectively controlled 
or even prevented by the immune response. 
The course of HIV infection : 
 On the basis of the duration of HIV infection and the kinetics of virologic 
and immunologic events observed throughout HIV disease, three dominant patterns 
of evolution of HIV disease have been described :(1) 80% to 90% of HIV infected 
persons are "typical progressors" and experience a course of HIV disease with a 
median survival time of aproximately 10 years (2) 5% to 10% of HIV infected 
persons are "rapid progressor" and experience an unusually rapid (3 to 4 years) 
course of HIV disease. (3) About 5% of HIV infected person do not experience 
disease progression for an extended period of time (at least 7 years) and are termed 
"long term nonprogressors" (LTNP)46. 
Typical Progressors : 
 The typical course of HIV infection includes three phases : primary 
infection, clinical latency and clinically apparent disease. The diagnosis of primary 
HIV infection is made in only a minor percentage of cases : Difficulties reside in the 
variable severity and nonspecificity of the clinical syndrome which is characterized 
by mononucleosis or flue like symptoms such as fever, lethargy sore throat, malaise, 
macupapular rash, lymphadenopathy arthralgias, myalgias, headaches, retroorbital 
pain, photophobia and rarely meningitis. Hospitalization is required in only a 
minority (10% to 15%) of individuals, and this phase therefore usually goes 
unnoticed. Furthermore, during the initial period of primary infection the laboratory 
blood test that is widely used for the diagnosis of HIV infection (i.e. detection of 
HIV antibody specific for various viral proteins) may be negative. On the basis of 
the clinical history, however, it is thought that an acute clinical syndrome of variable 
severity may occuring a relatively large proportiong (50% to 70%) of HIV infected 
individuals, and although HIV specific antibodies may not be detected, the initial 
period of primary infection is characterized by high levels of virus in the circulation 
(i.e. viremia). Determination of plasma viremia or p24 antigenemia represents the 
only valid laboratory approach for the diagnosis of primary infection. Appearance of 
symptoms during acute primaryg infection usually occurs within 3 to 6 weeks of 
infection, together with the high levels of viremia. In most patients, both resolution 
of symptoms and downregulation of viremia occur within 9 to 12 weeks after the 
onset of symptims : both of these events are associated witgh the appearance of HIV 
specific immune responses.  
 The phase of primary infection is followed by the long, clinically latent 
period of HIVg infection. In typical proressors, this phase of infection may last for 
year (median, 8 to 10 years) The observations that active replication of HIV is 
continuous and occurs primarily in the lymphoid organs throughout the entire course 
of infection, together with the development of highly sensitive and quantitative 
polymerase chain reaction techniques for the determination of viremia have clearly 
demonstrated that HIV disease is active and progressive even during this prolonged 
asymptomatic phase. These findings have helped to explain the discrepancy between 
the absence of clinical signs of active disease and the proressive decline of CD4+ T 
lymphocytes that invariably accompanies the clinically latent period. 
 Progression to AIDS and clinically apparent disease occurs within 8 to 10 
years in typical progressors. The progression to AIDS results from the continuous 
replication of virus in the lymphoid tissue, which is associated with progressive 
destruction of this tissue and severe impairment of immune function. This advanced 
phase of infection is characterized by severe and persistent constitutional signs and 
symptoms or by opportunistic infections or neoplasms, or both. In those persons 
who develop generalized lymphadenopathy or the AIDS defining conditions of 
Kaposi's sarcma or neurologic disease clinical disease may be apparent before the 
progression to advanced stage disease. 
Rapid Progressors : 
 In a minor percentage (5% to 10%) of HIV infected persons, rapid 
progression to AIDS occurs wthin 2 to 3 years after seroconversion. Immune 
responses are usually defective in these rapid progressors. Levels of antibodies 
against HIV proteins and neutralizing antibody are low to absent. Although it is 
unclear whether HIV specific cytotoxicity is defective in rapid progressors, it has 
been shown that the CD8+ T cell mediated suppression of HIV replication (i.e. 
mediated by a soluble factor) is severely impaired. A series of immunologic 
abnormalities typical of HIV infected individuals in late stage disease are usually 
observed in rapid progressors, including high percentages of activated CD8+ T cells 
expressing CD38 and HLA-DR and elevated serum levels of β2 microglobulin, 
neopterin, soluble CD8, and soluble interleukin 2 (IL-2) receptors. The levels of 
viral load are usually very high in rapid progressors. In particular, it has been 
reported that rapid progressors have elevated levels of unspliced HIV mRNA 
compared with typical progressors and that HIV isolates from rapid progressors are 
more homogeneous that those from typical progressors and LTNP2. 
Long Term Nonprogressors : 
 Now that considerable experience has accumulated in prospective studies of 
HIV infected individuals, it has become clear that a small percentage of infected 
persons (5%) do not experience clinical progressoion of HIV infection and have 
stable CD4+ T cell counts for many years (7 or more years) despite lack of therapy. 
The criteria we have used for nonprogression include documented HIV infection for 
more than 7 years, stable CD4+ T cell counts higher than 600 cell/µL, absence of 
symptoms, and no antiretroviral therapy. From an immunologic standpoint, immune 
functions are conserved in LTNP2, and both HIV specific humoral and cell mediated 
immune responses are very strong. In addition to normal and stable CD4+ T cell 
counts, the absolute number of CD8+ T lymphocytes is significantly and 
consistently higher in most LTNPs. In addition, quantitative differences in the 
distribution of certain surface markers on CD8+ T cells, which have been associated 
with either a favourable or a severe prognosis in HIV infection have been observed 
in LTNPs. Other immunologic parameters such as serum levels of β microglobulin, 
elevated levels of which have been associated with an unfavourable progresis in 
HIV infection are within the normal range in LTNPs furthermore in contrast to 
typical progressors. LTNPs exhibit preserved proliferative responses to mitogens 
(eg. phytohemagglutinin, pokeweed mitogen), alloantigens, and soluble antigens (eg. 
tetanus toxoid). 
 HIV specific cytotoxic T lymphocytes (CTLs) against various HIV proteins, 
including Env and Gag, can readily be detected in LTNPs, either in freshly isolated 
peripheral blood mononuclear cells or after in vitro stimulation. In contrast to typical 
progressors who experience a decline over time of HIV specific activity, this activity 
remains stable in LTNPs. Although these differences are clearly observed if LTNPs 
are compared with typical progressors who have been infected for a comparable 
period of time, no differences in HIV specific cytotoxicity may be observed between 
LTNPs and HIV infected individuals in early stage disease   
Analysis of virologic and immunologic events associated with HIV 
infection in peripheral blood and lymphnodes : 
Primary HIV infection : 
 The sequelae of virologic and immunologic events associated with primary 
HIV infection in peripheral blood and lymph nodes have only recently been 
delineated. The SIV model of acute infection has been an ideal experimental system 
to determine the initial anatomic site of virus localization and spread. For this 
purpose, sequential lymphnode biopsies were performed in monkeys, and analysis of 
virus distribution demonstrated that virus may be detected in lymph nodes as early 
as 1 week after inoculation47. Significant changes in virus distribution occurred after 
primary infection and during the transition from the acute to the chronic phase of 
HIV infection. Virus that is detected in lymph nodes early after inoculation (i.e. day 
7) is exclusively cell associated, and a peak in numbers of indiviudal virus 
expressing cells is detected at this time. Rapid changes in virus distribution occur 
during the 2 to 3 weeks after inoculation. The number of virus expressing cells is 
dramatically reducedby day 14; this event is probably the result of the emergence of 
virus specific immune responses. By 3 to 4 weeks after inoculation, virus particules 
traped in the follicular dendritic cell (FDC) network in the germinal centers 
represent the predominant form of virus detected in the lymph nodes. Definitive 
evidence that the initial replication and spread of virus in lymph node may account 
for systemic virus dissemination was obtained by comparing the kinetics of virus 
replication in lymphnodes with that in the circulation (i.e. p26 antigenemia). This 
analysis revealed that the peak in numbers of virus expressing cells in lymph nodes 
precedes the peak in p26 antigenemia. These phenomena are usually observed 
during the first 2 weeks of primary infection, and this early period during which 
intense virus spreading occurs, has been designated the stage of virus dissemination. 
 Subsequent to the stage of virus dissemination, the course of primary 
infection is characterized by a dramatic downregulation of viremia. During this latter 
period, levels of virus replication are significantly reduced in both peripheral blood 
and lymph nodes; in addition, in lymph nodes there is a switch in predominance 
from cell associated virus (i.e. virus expressing cells) to extracellulat virus trapped in 
the FDC network. In addition to the elimination of virus expressing cells by HIV 
specific CTLs the trapping of virus particles in the FDC network represents an 
important mechanism for the decrease of virus in the circulation.  
 The major decrease in virologic parameters observed during the first weeks 
of infections are predominantly limited to those that reflect active replication such as 
number of virus expressing cells. viremia p26 in SIV and p24 in HIV, and titers of 
infectious virus changes in the number of HIV proviral DNA copies have not 
consistently been observed. During the acute phase of SIV or HIV infection in 
addition to the systemic dissemination of the virus. other crucial pathogenic events 
may significantly influence the propagation of the infection over time; these include 
the generation of a large pool of HIV latently infected cells (i.e. cells containig 
proviral DNA) and the large number of trapped virus particles that may represent a 
source of virus for de novo infection of target cells that reside in or migrate through 
the lymphoid organs. 
 With regard to HIV specific immune responses, robust cell mediated and 
humoral responses are redily detected during primary infection Usualy, virus 
specific CTLs can be detected within 2 to 4 weeks from the onset of symptoms, and 
their appearrance coincides with the dramatic decrease in viremia in both humans 
and monkeys. HIV specific CTLs play a major role in the initial downregulation of 
viremia by killing virus expressing cells that are responsible for the high level of 
virion production. In the SIV model of acute infection, it has been shown that the 
appearance of virus specific CTLs coincides with a dramatic decrease in the number 
of virus expressing cells in lymph nodes, HIV specific CTLs have been detected 
against both structural (e.g. Env, Gag Pol) and regulatory (e.g. Nef, Tat) viral 
proteins. Variable frequencies and specificities of HIV specific CTLs have been 
observed among different individuals. However, it is unclear whether these 
quantitative and qualitative differences in HIV specific cytotoxicity significantly 
influence the initial down regulation of viremia and the ability to control virus 
replication and spread over time. In addition to typical HIV specific cytotoxicity, 
CD8+ T cells may also potentially mediate suppression of virus replication by 
release of a soluble factor; this CD8+ T cell mediated suppressor activity has been 
detected during primary infection. Taken together these observations strongly 
support an important role for CD9+ T cells in the primary immune response to HIV 
infection. 
 With regard to the virus specific hummoral immune response neutralizing 
antibodies, which represent the protective component of this response, are usually 
detected after the phase of downregulation of viremia, when the transition from the 
acute to the chronic phase of infection has already occurred. Although these findings 
suggest that neutralizing antibodies may have little effect in the control of the initial 
spread of HIV, they do not rule out the involvement of nonneutralizing antibodies in 
the initial downregulation of viremia. 
The Clinically Latent Period : 
 Transition from the acute to the chronic phase of HIV infection is marked by 
the downregulation of viremia and resolution of symptoms. All virologic 
parameters, including viremia, virus expression and titers of infectious virus in 
peripheral blood mononuclear cells as well as frequency of cells containing HIV 
DNA are usually very low in peripheral blood during this clinically latent period48. 
However, determinations of viral load in lymphoid tissue have demonstrated that the 
frequency of cells containing HIV DNA and the levels of virus expression in 
mononuclear cells are 1 to 3 logs higher in lymph nodes that in peripheral blood. 
These observations indicate that virus replication is continuous throughout the entire 
course of infection, including the asymptomatic period. This concept has been 
further supported by the detection of viremia during the clinically latent period with 
the use of a highly sensitive polymerase chain reaction assay and by recent studies 
that have shown that not only is viral replication continuous but the turnover of virus 
is very high (up to 109 virus particles every 1.5 to 2 days). 
 Another important pathogenic event associated with the early stage of 
infection is the trapping of virus particles in the FDC network of the lymph node 
germinal centers. The trapping of virus is related to the histopathologic changes 
associated with the early stage of HIV disease, when CD4+ T cell counts are higher 
than 500 cells/µL. The typical histopathologic abnormality of this stage of HIV 
infection is follicular hyperplasia which is a reflection of the state of immune 
activation of the lymphoid tissue and of the ongoing immune response to HIV or 
other pathogenis. These histopathologic abnormalities, together with increasd 
cellular activation, which is critical for effective virus replication  may contribute to 
the dichotomy of viral load between peripheral blood and lymph nodes by 
promoting trapping of virus particles in the FDC network and by creating 
environmental conditions (i.e. close cellular contact, high concentration of HIV, and 
abnormal retrafficking of lymphocytes) that favor the sequenstration of HIV in the 
tissue. 
 With the progression of HIV disease from the early to the intermediate stage 
(i.e. CD4+ T cell counts between 200 and 500 cells/µL), levels of viral load in 
peripheral blood reflects in part a progressive deterioration of the immune system, 
which in turn results in defective control of virus replication. However, this increase 
is also the result of important histopathologic changes that occur in lymphoid tissue 
as disease progresses. Increasing proportions of lymphoid tissue show signs of 
disruption of tissue architecture, including abnormal location of germinal centers in 
the medulla, greater numbers of germinal centers undergoing follicular involution, 
and increased vascularity and fibrosis. The disruption of lymph node architecture 
leads to a progressive loss of the ability of lymphoid tissue to trap virus; this, 
together with the accelerated replication of virus as disease progresses, probably 
contributes to the increase in viremia observed in patients in the intermediate stage 
of disease. 
Advanced Stages of HIV Infection : 
 From a virologic standpoint, the advanced stage of HIV infection (i.e. CD4+ 
T cell count <200 cells/µL) is characterized by a substantial increae in all virologic 
parameters in both peripheral blood and lymph nodes. In advanced stagedisease, the 
levels of viral load equilibrate between peripheral blood and lymphnodes. Lymphoid 
tissue has for the most part been destroyed and replaced by fibrotic tissue most of 
the virus is cell associated, and virus trapping is minimal or absent. The obvious 
consequence of the destruction of lymphoid tissue is the severe impairment of 
immune function and profound immune suppression. 
Induction of HIV expression : 
 Several factors have been proposed as being involved in the regulation of 
HIV expression and the potentiation and modulation of virus replication. These 
include endogenous viral regulatory proteins such Tat and Rev. cellular transcription 
factors acting at the level of the proviral long terminal repeat (LTR), the state of 
immune activation other pathogens and cytokines. 
 Both Tat and Rev are crucial for efficient virus replication49. Tat protein acts 
at both the transcriptional and postranscriptional levels; Rev protein plays an 
important role in the export of unspliced and incompletely spliced viral messages 
from the nucleus to the cytoplasm of the infected cell. Because these messages 
encode for structural proteins, optimal Rev function is essential for production of 
infectious virions. 
 A general state of immune activation is associated with all stages of HIV 
infection. The inability to eliminate HIV after primary infection and the continuous 
replication of virus thrughout the entire course of HIV disease represent the primary 
mechanisms responsible for the chronic state of immuneactivation. Both individual 
virus expressing cells and trapped virus in lymphoid tissue represent the source of 
antigen responsible for maintaining chronic stimulation of the immune system over 
time. Although a state of immune activation is necessary in order to maintain HIV 
specific immune responses, at the same time it may indirectly enhance virus 
replication, either by leading to the secretion of HIV inducing cytokines or by 
generating a large pool of activated target cells that efficiently support virus 
replication. HIV in vitro can infect both resting and activated CD4+ TG 
lymphocytes with equal efficiency; however it replicates only in activated T cells50. 
As in CD4+ T cells efficient virus replication in monocytes or macrophages depends 
on the state of cellular activation and differentiation. 
 Several pathogens, including cytomegalovirus, herpes simplex virus, 
hepatitis B virus, human herpesvirus 6, human T cell lymphotropic virus type I, and 
microbes such as Mycoplasma, have been shown to enhance HIV expression in 
several experimental in vitro systems. It is not certain whether these pathogenes 
mediate a similar effect in vivo. 
 Since the initial observation that certain cytokines induce HIV expression 
from a state of latent or chronic infection to that of active virus expression, the 
effects of several cytokines on virus expression and replication have been 
extensively investigated. Most cytokines induce HIV expression by mechanisms 
acting at both the transcriptional and postranscriptional levels : TNF-α, TNF-β and 
IL-1 induce HIV expression by activation of the transcription factor NF-kB. 
Although the regulatory effect of cytokines on HIV replication is limited to in vitro 
observations, the fact that several of these cytokines may be found at increased 
levels in plasma cerebrospinal fluid, and lymphoid tissue of HIV infected 
individuals suggests that they probably mediate similar effects in vivo. It is possible 
that cytokines play an important role in maintaining the constant levels of virus 
expression and replication particularly in lymphoid tissue. 
Mechanisms of CD4+ T cell depletion and dysfunction : 
 CD4+ T lymphocytes are the primay targets of HIV infection51. The 
progressive depletion of cD4+ T lymphocyes is characteristic of every stage of HIV 
infection, and CD4+  T cell counts represent a valid surrogatge marker to monitor 
the progression of HIV disease. For these reasons, the potential mechanisms 
responsible for the depletion of CD4+ T lymphocytes have been studied extensively, 
and several mechanisms have been proposed. These can be divided into two groups : 
direct virologic mechanisms that result from an HIV mediated cytopathic effect, and 
indirect, nonvirologic mechanisms that include predominantly immunologic 
phenomena triggered during the course of HIV infection. 
 With regard to direct virologic mechanisms, HIV medited cytopathic effects 
may occur through either single cell killing or HIV induced syncytia formation. 
However, that the evidence that HIV mediates direct killing of CD4+ T cells rests on 
the in vitro observation that cell death can be detected in cultures of cells that are 
acutely inoculated with virus even in absence of syncytia formation. It has been 
proposed that HIV may mediate single cell killing by both accumulation of 
unintegrated viral DNA and inhibition of cellular protein synthesis. The other 
primary mechanism of cell depletion observed after acute inoculation of virus in 
vitro in both peripheral blood and various CD4+ T cell lines is syncytia formation. 
This process involved multiple steps of cell membrane fusion between HIV 
expressing cells and uninfected CD4+ T cells : in the fusion process, one infected 
cell could potentially be responsible for the elimination of up several hundred 
unifected cells. Although the interaction of gp120 with the CD4 molecule represents a 
necessary step in this process, it has been demonstrated antigen (LFA-1) plays a 
fundamental role in the regulation of syncytia formation of peripheral blood CD4+ T 
lymphocytes. Experiments performed with a panel of antibodies directed againstg 
the α and β chains of LFA-1 molecules and the intracellular adhesion molecules-1, 2 
and -3 (the natural ligands for the LFA-1 molecule) have provided evidence that the 
process of HIV mediated syncytia formation is regulated by the LFA-1/ICAM-1/-2/-
3 pathway of cell to cell adhesion. 
 With regard to the induction of anergy in HIV infection, it has been shown 
that after binding of gp120 antibody complexes to the CD4 molecule. CD4+ T cells 
become refractory to further in vitro stimulation. Anti gp120 antibodies have been 
detected on CD4+ T lymphocytes in patients with AIDS suggesting that gp120 is 
bound to the surface of these cells by the CD4 molecule. In this context, it has been 
proposed that gp120 bound to CD4+ T cells may mediate a pathogenic role by being 
presented to other CD4+ T cells. This abnormal presentation of gp120 by other CD4+ 
T cells could induce energy in already activated CD4+ T cells and could generate 
CD4+ cytotoxic T cells from the pool of resting T cells. 
 Finally, HIV specific immune responses, including humoral and cell 
mediated immunity, play an important role in the control of HIV replication and 
spread in vivo. These phenomena may contribute significantly to the elimination of 
HIV infected cells, including CD4+ T cells, macrophages, and FDCs, either by HIV 
specific CTLs or by antibody dependent cellular cytotoxicity. It has been 
hypothesized that HIV may cause immunosuppression and disease progression by 
virus specific cytotoxic T cell mediated immunopathologyg, Therefore, although in 
the initial phase of infection effective immune responses may be critical for the 
containment of virus. It is possible that during the chronic phase of infection these 
virus specific immune responses may have a pathogenic role. 
IMMUNE RESPONSES TO HIV INFECTION : 
 The immune response to the human immunodeficiency virus (HIV) is 
determined by many complex factors. First, the extraordinary host virus interactions 
that lead to the pathogenesis of acquired immunodeficiency syndrome (AIDS) 
induce profound functional host immune defects, beginning soon after infection with 
HIV. Prominent forms of HIV induced immune dysfunction include defects in T and 
B cell responses to specific antigens, polyclonal hypergammaglobulinemia, 
enhanced autoantibody and immune complex formation, dysregulated cytokine 
production, decreased natural killer cell activity, and defective monocyte and 
dendritic cell function. At the time when the host immune system begins to mount 
an anti HIV immune response designed to neutralize free HIV and eliminate HIV 
infected cells, many of the cellular components of the immune responses are being 
adversely affected by HIV. Second, evidence suggests that the route of HIV 
infection, the amount of HIV in the inoculum, the pathogenic potential of a given 
HIV strain, and host genetic factors may modify the host response of HIV. Third, 
evidence suggest that some components of an immune response to HIV may 
enhance HIV infectivity or may be directly responsible for clinical manifestations of 
the disease. Fourth, the remarkable ability of HIV to mutate genome sequences and 
change the primary amino acid sequence of HIV proteins effectively allows HIV to 
evade otherwise effective antiviral immune responses. 
 In individuals with advanced HIV disease, as many as 109 new HIV virions 
are produced each day and as many as 2 x 109 CD4 positive (CD4+) T cells turn 
over per day, with a half life of HIV and CD4+ T cells of approximately 2 days. 
Studies suggest that CD4+ T cell depletion in HIV infection result from the high 
replicative capacity of HIV and direct viral cell killing, although CD4+ cell loss 
could in part be caused by immune mediated cell killing or to T cell apoptosis, or 
both. The complexities of HIV host interactions create myriad obstacles to an 
effective immune response to HIV. 
Antibody responses to HIV : 
 Studies have documented the immunologic and virologic events that occur 
during acute HIV infection52. Acute HIV infection frequently presents as an 
influenza or mononucleosis like syndrome, with fever, adenopaty, pharyngitis, rash, 
myalgias, and arthralgias as common symptoms. Abnormal liver function test 
results, hepatosplenomegaly, encephalopathy, and neuropathy occur less commonly. 
Between 5 and 10 days after HIV infection, serum p24 protein levels rise rapidly, 
serum infectious HIV levels rise, the numbers of circulating HIV infected CD4+ T 
cells rise, and the total number of circulating CD4+ T cells transiently decrease. 
Circulating infectious virus levels peak from 10 to 20 days after HIV infection and 
precipitously fall coincident with an increase in anti HIV cytotoxic T cell (CTL) 
activity and usually, resolution of initial clinical symptoms. However, the initial fall 
in plasma viremia may also reflect trapping of HIV in the spleen and lymph nodes. 
HIV Neutralizing Antibodies : 
 Neutralizign (Anti HIV) antibodies inhibit the infectivity of free HIV or HIV 
infected cells and have been prosposed to be one component of a salutary or 
protective anti HIV immune response Human serum anti HIV antibodies are isolate 
type specific or group specific. The epitopes to which most anti HIV antibodies bind 
have been located on envelope glycoproteins gp120 or gp41. 
 Regions of HIV proteins to which relatively group specific HIV neutralizing 
antibodies bind are conformational epitopes around the CD4- binding site on gp120 
or are carbohydrate in nature. After HIV infection, type specific neutralizing 
antibodies appear in serum, followed by broader reactive group specific anti HIV 
antibodies. 
 Serum levels of neutralizing antibody being to rise 2 to 4 weeks after primary 
HIV infection and peak during the asymptomatic phase of HIV infection. Most 
studies have demonstrated that anti HIV antibodies are present in the symptomatic 
stages of AIDS related complex and AIDS, although frequently at lower levels than 
in the asymptomatic stages of HIV infection. 
Antibodies that promote antibody dependent cellular cytotoxicity of HIV 
infected cells : 
 Anti gp160 antibodies in the serum and cerebrospinal fluid of HIV infected 
persons bind to IgG Fc receptor (R) bearing natural killer (NK) cells by means of the 
antibody Fc region and sensitize IgG FcR positive cells to kill HIV gp160 expressing, 
or gp120 coated, target cells. Peripheral blood monocytes from AIDs patients can also 
mediate antibody dependent cellular cytotoxicity (ADCC) of HIV infected cells. 
 Although ADCC antibodies against p24 Gag proteins have been described, 
most studies have found serum anti HIV ADCC antibodies to react with HIV gp120 
or gp41 envelope proteins. Anti HIV antibodies that mediate ADCC of group120 or 
gp41 expressing target cells arise soon after infection with HIV, are predominantly of 
the IgG1 sub class, and are detected throughout all stages of HIV infection, although 
ADCC antibody levels decrease somewhat with the onset of AIDS. 
Anti Gag Antibodies : 
 Anti p24 antibodies appear within the first 2 weeks of acute HIV infection. 
Rises in p24 antibody levels correlate well with the precipitous fall in infectious HIV 
antigenemia that occurs as the symptoms of acute HIV infection sub side. 
Antibodies to HIV p24 Gag proteins rise to their highest levels during the 
asymptomatic seropositive stage and then fall to usually undetectable levels with the 
onset of AIDs. Antibodies against the p17 Gag protein of HIV have been reported to 
neutralize HIV and to cross react with the thymic hormone thymosin. α1. 
Antibodies to Other HIV Proteins : 
 Antibodies to HIV Rev, Nef, Tat, Vpu, Vpr and HIV protease proteins have 
been reported in various percentages of HIV patients. Antibodies to Nef proteins 
have been found in HIV infected persons who were otherwise HIV seronegative. In 
general, antibody levels to all of these HIV proteins decrease as HIV infection 
progresses to AIDS. 
HIV Enhancing Antibodies : 
 HIV enchancing antibodies bind to epitopes of Env gp41. The presence of 
HIV enahcning antibodies has been correlated with progression of HIV infection to 
AIDS. As new HIV variants emerge over time, new HIV variants are not neutralized 
by autologous sera, and in some cases, antibodies against newly emerged HIV 
variants may enhance HIV replication in vitro, although the significance in vivo of 
enhancing antibodies is controversial. 
T-lymphocyte responses to HIV : 
 Cellular T lymphocyte responses are essential for the control of numerous 
viral infections. CD4+ helper T cell responses are required for induction of B cell 
antibody production and for induction of other T cell responses. In patients with 
HIV infection, anti HIV helper T cell responses, major histocompatibility complex 
(MHC) class I and MHC class II anti HIV CTLs, and non MHC restricted CD8 
positive (CD8+) T cell and HIV activities have been identified. 
Anti HIV major histocompatibility complex restricted cytotoxic T 
lymphocytes : 
 MHC class I restricted CTLs have been demonstrated against Gag, Env, Nef, 
and Pol HIV proteins. Remakably, anti HIV class I restricted CTLs in asymptomatic 
HIV seropositive persons circulate in extraordinary frequency, on the order of 10 to 
20 CTL precursors per 104 peripheral blood mononuclear cells. 
 In primary HIV infection, the initial fall in viremia correlates best with the 
appearance in peripheral blood of anti HIV MHC class I restricted CD8+ CTLs. 
CD8+ CTLs are also thought to be important in the immune response to HIV during 
the chronic phase of HIV infection for the elimination of productively infected cells 
and for control of the viral load. HIV specific CD8+ CTLs may also play a role in 
the immunopathogenesis of HIV infection by contributing to depletion of HIV 
infected antigen presenting cells or through tissue damage after the release from 
CTLs of certain cytokines (eg. tumor necrosis factor α, interferon β) during the 
process of cytolysis. 
Cytotoxic T cells That Suppress HIV Replication by Secretion of Soluble 
Factors : 
 CD8+ T lymphocytes from HIV infected individuals have inhibited HIV 
replication in naturally infected CD4+ cells in vitro. This antiviral activity is not 
mediated by NK cells, is not HLA restricted, and depends on the number of CD8+ 
cells present. This type of anti HIV activity is not mediated though target cell killing 
but is mediated through CD8+_ cell secretion of undelineated soluble anti HIV 
factors. 
Non-T-cell-mediated anti HIV cellular immune responses  
 Non T cell mediated immunity, as is mediated by NK and other FcR positive 
cells that directly kill virally infected cells or that mediate ADCC, is potentially 
important as an anti HIV immune response, because these forms of immunity can 
eliminate virally infected cells in a non MHC restricted fashion and do not require a 
memory T cell response for effector cell induction. Devising ways of augmenting or 
inducing NK responses against HIV infected allogeneic cells or against malignant 
cells that arise in the context of AIDS are important areas of research. 
 Although monocytes in AIDS patients have a chemotatic defect, monocytes 
from asymptomatic seropositive persons mediate ADCC against HIV coated target 
cells and mediate monocyte tumoricidal activity in vitro a potential mechanism of 
immune response against Kaposi's sarcoma and other tumors that occur in AIDS. 
Immune responses to HIV in children : 
 Most HIV infections in children occurs perinatally. Most infants born to HIV 
positive mothers passively acquire maternal anti HIV antibody in utero, which may 
persist for 15 to 18 months postnatally. In this situation, the polymerase chain 
reaction (PCR) assay for HIV proviral DNA sequences has been used to detect HIV 
infection infant with passively acquired Hiv antibody. In children younger than 12 
months of age, AIDS frequently occurs in the presence of higher T cell levels (500 
to 1000 cells / mm3) than are seen in adults with AIDS. However, in older infants 
and children, anti HIV immune responses and progressive immune defects that 
develop over the course of HIV infection are similar to those seen in adults. The 
types of immune responses that may be protective in children born to mothers with 
HIV infection are unknown, but data sugest CTLs may be important53. 
Pathogenic versus salutary anti HIV immune responses : 
 Because of the observations that CD4+ T cells, human monocytes, 
macrophages, dendritic cells, and Langerhans' cells are all capable of infection by 
HIV in vivo, numerous investigators have suggested that one component of the 
pathogenesis of immune dysfunction in HIV might be immune mediated damage to 
HIV infected T cells and antigen presenting cells. Moreover, gp120 bound to the cell 
surface. The presence of enhancing antibody against HIV Eng gp41 has been 
associated with progressive HIV infection. 
 It is difficult to determine if anti HIV immune responses are salutary, 
destructive, or both. There is reason to speculate that, at least in the case of anti HIV 
CTLs, salutary and destructive anti HIV immune responses occur. That HIV specific 
antibody responses and anti HIV CTL responses decrease in the wake of progression 
to AIDS suggests that these immune responses promote the asymptomatic HIV 
seropositive state. However, there is increasing evidence for the involvement of HIV 
specific CTLs in HIV induced pulmonary inflammatory disease, central nervous 
system disease, and lymphadenitis. For example, high numbers of anti HIV CTLs 
have been isolated from the lung of HIV infected patients with lymphocytic 
alveolitis that are capable of killing HIV infected macrophages54. More over, the 
presence of antiHIV CTLs capable of killing a variety of typesof HIV infected 
antigen presenting cells in lymph nodes, bone marrow, and thymus support to the 
notion that, over time, anti HIV CTLs that originally keep HIV infection in check by 
killing virally infected cells, by continued killing of antigen presenting cells and 
other immune types could gradually promote progressive immune system 
dysfunction. 
Anti HIV Immune Responses in Rapid Progressors and Non progressors 
to Acquired Immunodeficiency Syndrome. 
 Rapid progressors to AIDS have a profound decline in CD4+ T cell levels, 
usually within 2 to 3 years after primary HIV infection. Rapid progressors have 
lower levels of anti HIV antibodies and low or absent HIV neutralizing antibodies 
that neutralize autoloous HIV primary isolates grown in peripheral blood 
mononuclear cells. High levels of HIV enhancing antibodies have been reported in 
rapid progressors. Levy and associates found CD8+ noncyutolytic T cell responses 
that suppress HIV replication are decreased or absent in rapid progressors. Rinaldo 
and colleagues found low levels of memory CD8+ CTLs by precursor frequency 
analysis in rapid progressors compared with nonprogressors, although anti HIV CTL 
effector cell activity was present in fresh peripheral blood cells from rapid 
progressors that compared with CTL activity in nonprogressors Rapid progressors to 
AIDS have elevated number of CD8+, CD38+ and DR+  T cells, elevated levels of 
serum neopterin, and β2 microglobulin levels that signify chronci immune system 
activation. 
 Nonprogressors to AIDS have strong peripheral blood CD8+ class I 
restricted anti HIV CTL level that do not fall over time, strong CD8+ non MHC 
restricted HIV supressor activity, and high levels of anti HIV antibodies. Increased 
HIV neutralizing antibodies have been reported in nonprogressors to AIDS. 
Neutralizing antibodies may contribute along with cellular anti HIV responses to 
control of HIV in nonprogressors, although the specificity of such antibodies is 
unknown. 
 There appear to be quantitative and qualitative differences in anti HIV 
immune responses among nonprogressors and rapid progressors. It is unknown if 
nonprogressors only have higher levels of neutralizing antibodies and CD8+ CTL 
responses than rapid prgoressors or if nonprogressors have only salutary anti HIV 
immune responses while rapid progressors have a preponderance of pathologic 
immune responses to HIV that damage lymphoid tissue cells. 
Immunologic Characteristics of HIV Exposed, Seronegative Individuals : 
 Studies of exposed and persons have suggested that rare individuals may be 
resistant to HIV or may have cleared the infection without making anti HIV 
antibodies. CD8+ CTLs have been found in seronegative sexual contacts of HIV 
infected patients and found in seronegative infants born to HIV infected mothers. 
 Bryson and coworkers reported an HIV infected neonate who initially had 
serum anti HIV cultures, but the infant eventually became HIV antibody and viral 
culture negative, having appearently cleared HIV infection. Clerici and colleagues to 
HIV envelope peptides in seronegative homosexual persons with multiple exposures 
to HIV through sexual contacts. Multiply exposed prostitutes in Africa have been 
reported who are HIV negative by serology and PCR for viral DNA and who have 
HIV specific CTLs. 
ROUTES OF TRANSMISSION : 
 The appearance of AIDS in diverse populations implicated several routes of 
transmission : contaminated needles or injection equipment; clotting factor 
concentrates, blood, and selected other blood products; transplacental and 
intrapartum and breast-feeding; anal and vaginal sex.55 (Fig. 3) 
SEXUAL TRANSMISSION : 
 Worldwide, more than 90% of HIV infections are associated with 
heterosexual transmission. In the United States, cumulative 1981 through 1994 
AIDS surveillance reports received through April 14, 1995 to the Centers for 
Disease Control and Prevention (CDC) indicate that 60% of adult cases of AIDS are 
linked to either male-to-male sexual (53%) or heterosexual (7.3%) exposure 
categories, with an additional 6.6% reporting both male-to-male sexual and IDU 
activity56. 
Infectiousness : 
 The risk factors and cofactors associated with HIV transmission through 
sexual contact are often amenable to intervention. Virus load may be the key 
unifying feature of transmission risk. Because the dominant HIV binding affinity is 
for immunologic cells expressing the CD4 molecule, any physical or physiologic 
facilitator of this contact may be expected to increase transmission risk. The 
complex associations that may exist between sexual risk factors and the difficulties 
in measuring these factors make it challenging to identify consistently the same 
significant factors in all populations at all times.  
 A second, more prolonged period of higher infectiousness occurs when the 
HIV infected person becomes increasingly immunosuppressed. This is likely to be a 
consequence of high viremia and increased free and cell-associated virus load in 
cervicovaginal secretions, rectal fluids, and ejaculate, consequent to the deterioration 
of the immunologic gauntlet and the structural disruptions of the lymph node 
architecture that traps circulating virus for presentation to lymph node-based 
humoral and cellular defenses. 
 Although it has been apparent that higher transmission rates have been 
associated with depleted CD4+ cells among HIV-infected sexual partners, causality 
is hard to establish because higher transmission rates in late stage disease may also 
reflect longer duration of exposure to an infected partner. 
 Further contributions to infectiousness are those that recruit more CD4+ cells 
into the genital tract of the infected individual. Sexually transmitted infections that 
result in frank genital ulcers may include chancroid, herpes, syphilis, and other 
diseases.  Infections and conditions resulting in inflammation and exudation include 
chlamydial infection, gonorrhea, trichomoniasis, bacterial vaginosis, and 
candidiasis. Recruitment of infectious lymphocytes, macrophages, or other cells into 
seminal or vaginal secretions may increase transmissibility, as occurs with sexually 
transmitted infections and their inflammatory urethral, prostatic, cervical, vaginal, 
and anal responses. Mucosal ulceration, inflammation, exudation, or trauma to 
protective epithelial surfaces, as occurs with infection of "dry sex," is likely to 
increase the efficiency of viral release and viral entry.  STD patients commonly 
report other high-risk activities and high-risk partners. 
 Although hypothesized, it is unknown whether systemic coinfections in the 
HIV-infected person increase infectiousness. Coinfections such as cytomegalovirus, 
Estein-Barrvirus, human T-cell lymphotropic virus types Ior II, human herpesviruses 
type 6 or 7, Mycoplasma fermentans, and other may increase viral expression in 
vitro and could increase in vivo viremia and infectiousness.  
Table - IV 
Factors of interest in the sexual transmission of HIV 
• Number of sexual partners 
• Number of sexual exposures 
• Likelihood sexual partner is infected 
• Probability of transmission during sexual activity 
• Nature of sexual contact; insertive most infectious versus receptive most susceptible. 
• Noninjecting drug use (cocaine, alcohol, nitrites) through facilitation of high-risk sexual 
contact. 
• Vaginal docuhes, astringents, abrasives, or trauma Anal doches or trauma. 
 The uncircumcised male may have a higher intraurethral and subprepucal 
load of potentially infectious cells than the uncircumcised man, explaining the data 
suggesting this as a risk factor for transmission to a sexual partner. It is plausible, 
but unknown, that a woman who has been circumcised with an infundibuletomy 
would be more infectious if infected because of the trauma to the unnatural 
postsurgical genital anatomy. 
 Host genetics may influence natural history and viral load. Some persons 
may be more infectious as a consequence of their greater genetic susceptibility to 
rapid progression. 
Susceptibility : 
 Factors that probably facilitate transmission include those that increase 
contact with blood  and infectious genital secretions during sexual acts and increase 
virus-cells contact with vulnerable cells in the mucosal epithelia of the rectum, 
cervix, vagina, or oral cavity. Increased contact time with infectious secretions that 
are kept warm and moist is likely to increase transmissibility, suggesting why male 
to female transmission rates are more efficient than female to male and why 
uncircumcised men may be at increased risk for heterosexual transmission from 
vaginal sex. Rates of female to male transmission in Thailand are much higher than 
noted in United State and European studies, suggesting at least one reason for the 
rapid expansion of the heterosexual epidemic in developing countries.  
 Nutritional status, particularly vitamin A deficiency, has emerged as a likely 
cofactor for perinatal transmission57. It will be important to assess whether sexual 
transmission occurs more easily in vitamin A deficient adults, because this 
introduces a potential intervention method for developing countries.  
Sexually transmitted infections : 
 Although it is widely appreciated that STDs are associated with HIV risk, 
only recently has it been documented that a reduction in STDs can reduce HIV 
transmission. Ulcerative STDs disrupt the integrity of the epithelial mucosa and 
facilitate HIV contact with the lymphatic and circulatory systems, as well as 
recruting CD4+ lymphocytes and macrophages to the site of injury or infection. 
Genital ulcers have had the higher relative risk estimates, with a 5 fold to 10 fold 
excess risk demonstrated in cross sectional studies. Inflammatory and exudative 
STDs are less disruptive of the epithelial tissues, but the exudate may recruit large 
volumes of cervical or urethral discharge filled with susceptible cells, and 
inflammation may result in microulcerations and superficialization of capillaries, 
facilitating contact with HIV with more easily infectable cells. Relative risk 
estimates for excess risk for HIV with nonulcerogenic STDs may be in the 2-fold to 
5-fold range. 
 This may suggest that ulcerogenic STDs should be the target of intervention. 
However, inflammatory and exudative STDs such as chlamydial infection, 
gonorrhea, and trichomoniasis are far more common than ulcerogenic STDs such as 
herpes, syphilis, and chancroid. The risk within a such as herpes, syphilis, and 
chancroid. The risk within a given population attributable to STDs is greater, 
therefore, for inflammatory and exudative STDs than for ulcerogenic STDs, 
suggesting the strong need to target all STDs. 
Risk and Age, Race of Ethnicity, and Gender : 
 Sociologic and behavioral characteristics, such as higher prevalence of IDU 
and poorer educational back grounds, are the roots of drug abuse frequencies and 
high sexual risk behaviors in some minority populations. 
 Creak house sex for drugs exchanges, most prevalent in eastern U.S. inner 
city and southeastern U.S. rural minority communities, is a powerful multiplier for 
HIV transmission, analogous to the bathhouse environments prevalent in San 
Francisco, New York City, Los Angeles, and elsewhere from 1977 to 1984. The 
bathhouse catering to homosexual and bisexual men, "swinging singles" clubs for 
heterosexuals, and crack house environments for drug addicts and their sexual 
partners are perfect for HIV transmission when a highly infectious individual is 
introduced into the arena of multiple, unprotected sexual encounters. The efficient 
multiplier is a classic feature of STDs with a "core" transmitter group, but rarely is 
there a more rapid spread than when the core transmitters combine expanded social 
networks with high frequency of infectious contacts.  
 Black women in Alabama have HIV and AIDS rates approximately 20 times 
that of white women, a frequency that may be related to higher rates of HIV in 
African American heterosexual men in Alabama and to higher efficiency of 
transmission because of the relative rarity of condom use and frequency of STDs.  
 Young and postmenopausal women may be at comparatively higher risk of 
HIV infection for a given number of exposures. Immature vaginal mucosa in 
adolescents, with large cervical ectopy zones may be more susceptible to trauma 
during sex and may be especially prone to infection with STDs because of the large 
transformation zone and exposed columnar epithelia. HIV transmission may be 
facilitated by sexual activity at times in which there is expected to be blood 
exposure, as during menses, rape, or first coital experience. Improved understanding 
of mucosa immunity is needed to appreciate the relative importance of physical and 
immunochemical barriers to transmission. 
 Anal sex may facilitate HIV transmission better than vaginal sex, as 
suggested by its independent risk association among heterosexuals. This would be 
biologically plausible because of the abundance of infectable cells in the distal large 
intestine. Similarly, oral sex is probably less infectious, although epidemiologic 
studies are weak in divining causal associations because of the congruence of oral 
sexual risk with anal or vaginal sexual activity.  Animal studies may prove useful in 
assessing human risk through vaginal and viral challenges, microbicide screening, 
and the role of trauma as a facilitator of transmission. 
 Older persons are less likely to practice high risk behaviors, but those who 
do have high risk sexual behavior are less likely to take precautions. Hence, 
attention to risk beyond the adolescent and young adult populations is needed.  
PARENTERAL TRANSMISSION: 
INJECTION DRUG USERS : 
 Even before the first report associating AIDS and use of injectable drug in 
198358, the epidemic among IDUs had spread worldwide. 
 IDU associated AIDS cases constitute the second largest risk exposure 
category in CDC surveillance statistics. In newly reported cases, IDU and 
heterosexual cases exceed male to male sex as the reported risk in many parts of the 
United States.  
 Thousands of infected women and men whose heterosexual partners were 
IDUs, children whose mothers were IDUs and children whose mothers were sex 
partners of IDUs may attribute their infections indirectly to the use of injectable 
drugs.  
 Secondary spread of HIV infection through heterosexual activity from the 
ever increasing reservoir of IDUs continues to rise. This is in dramatic contrast to 
the situation within the male homosexual and bisexual community, in which incident 
HIV infection has fallen since 1983 among older men, largely because of rapid and 
dramatic alterations in sexual behavior. Rates among young men and gay or bisexual 
men of minority background have not declined as notably.  
Infectiousness : 
 Viral load, as with sexual exposure, may be the major factor predicting the 
infectiousness of an HIV infected IDU. Viral load is highest shortly after infection, 
before the host immune system has time to marshal its defenses, and late in the 
course of disease at the time of systemic immune collapse.  Low CD4+ cell counts 
are though to be associated with increased infectiousness, although this is much 
harder to ascertain in needle sharing partners than among sexual couples. Behaviors 
related to drug use that increase cross contamination activities in the window period 
and late in disease would be expected to increase risk. However, given the parenteral 
nature of the inoculation, it is known that HIV can be transmitted at just about any 
time in the course of infection. An infected IDU in open member sharing groups for 
drug use, as is common in "shooting galleries", are expected to be an especially 
dangerous vector for wide spread transmission. Similarly, the non-IDU who is 
exchanging crack cocaine for sex can be in a highly efficient transmission 
environment in which IDUs are among the sexual clients and STD prevalence is 
substantial.  
 
Susceptibility : 
 Needle sharing networks and the "human bridges" that connect them are 
critical in predicting the efficiency of transmission. Drug users tend to share in 
groups. Most dangerous is promiscuous sharing in a shooting gallery environment, 
where anonymous sharing occurs. Social sharing with a more defined needle sharing 
group is of intermediate risk.   
 Extension of the HIV epidemic among drug users in Asia will predictably 
increase drug related heterosexual transmission. Male drug users commonly have 
female sexual partners who do not use drugs. Heterosexual HIV transmission is 
more frequent among women than men, partly because of the greater numbers of 
infected heterosexual men who tend to be greater users of intravenous drugs. There 
is a greater likelihood of a woman encountering an infected male sexual partner in a 
locale with prevalent HIV and IDU than for a man to encounter an HIV infected 
woman. Moreover, sexual transmission appears to be more biologically efficient 
from male to female. Women who overcome addictions may continue to be at risk of 
HIV transmission through sexual encounters. 
 Female former IDUs whose sexual partners currently inject drugs display a 
higher HIV seroprevalence than do female IDUs whose sexual partners do not inject 
drugs. Most women who inject drugs are in their prime childbearing years. Heroin 
and cocaine are the drugs commonly associated with serpositivity among 
intravenous drug users.  
 Cocaine can effect a "high" by smoking (ie, frebasing), intranasal use, 
injection alone, or in combination with heroin (ie, speedballing). Studies suggest 
cocaine to be more strongly associated with HIV acquisition than heroin or other 
drugs, probably owing to the greater frequency of its use. Non-IDU crack use is HIV 
associated because of exchange of sex for drugs and other high-risk sexual activity. 
 High risk sexual practices and drug use are related behaviors. IDUs are less 
likely to incorporate safe sex behaviors than to use safer needle sharing practices. 
 
HIV-Contaminated Instruments : 
 Use of HIV contaminated instruments used for puncture or injection in other 
non-traditional ways may transmit HIV. A 6 weeks period of acupuncture therapy 
was implicated in the seroconversion of a previously healthy 17 years old boy 
without any known risk factors. Two persons may have contracted HIV from tattoos 
administered in prison with unsterilized tattoo needles59. Adolescent brothers may 
have transmitted HIV through sharing shaving equipment contaminated with blood 
from cuts.  
 Even professionally administered needle sticks or injections may cause HIV 
infection if proper sterilization techniques are not used. The pressure to reuse 
equipment when funds for replenishment of medical supplies are short could explain 
the occurrence of some HIV without the classic risk factors. Epidemics in Romania 
and the former Soviet Union have been documented among hospitalized children 
with HIV seronegative mothers. Shortages of medical supplies have resulted in reuse 
of needles presumably contaminated with HIV. 
 In resource poor areas of Africa, Asia, and Latin America, the potential 
exists for transmission of HIV through unsanitary use of needles. Other areas of 
reported concern for parenteral transmission include tuberculosis screening, jet 
injections, medical waste disposal, neurologic pins, electroencephalographic testing, 
earlobe sampling by stylet, and prenatal diagnostic tests on seropositive mothers. 
OCCUPATIONAL EXPOSURE : 
 Occupational exposure among health care workers has been the topic of 
recent review; deep punctures with large bore needles are the highest risk event60. 
Nonparenteral exposures such as splash exposures carry much smaller risks. Nurses 
are most commonly exposed. Zidovudine use has been associated with partial 
protection in an observational analysis performed by CDC, but it has not been 
demonstrated to protect all exposed health care workers.  
Tuberculosis : 
 Transmission of tuberculosis commonly occurs among drug users, facilitate 
by poor housing and other social conditions5. Pneumonias are also more common 
among drug users, but these do not carry the community risk inherent in 
tuberculosis. An epidemic within an epidemic is apparent, particularly in developing 
countries and among IDUs in the United States : the expanded tuberculosis problem 
facilitated by HIV related immunosuppression. In this way, the worldwide HIV 
epidemic becomes truly a threat to everyone because of the lack of personal control 
over aerosolized exposure compared with sexual or drug use exposure. It adds the 
need for chronic, directly observed chemotherapy and chemoprophylaxis among 
drug users with tuberculosis. In developing nations, isoniazid pro-phylaxis for HIV 
infected patients to prevent tuberculosis has proven efficacious. Although the special 
relationship of HIV and increased tuberculosis risk is an important issue, giving 
added incentive to prevent transmission of the former to inhibit transmission of the 
latter. 
BLOOD AND BLOOD PRODUCTS : 
 In July, 1982, three recipients of factor VIII concentrates for treatment of 
hemophilia were reported to have developed P carinii pneumonia, which suggested 
that transfusion61 of blood and blood products was a plausible mechanism for 
transmission., In December, 1982, a newborn who had received multiple blood 
transfusions for erythroblastosis fetalis was reported to have become progressively 
immunocompromised and developed opportunistic infections, including 
Mycobaterium avium complex. Investigation of the 19 blood donors revealed that 
one was later diagnosed with AIDS.  
 The risk of acquiring HIV infection through blood transfusion has varied by 
region, depending on the area's sero-prevalence among blood donors, and the 
sensitivity of the screening strategies. Circumstances in many developing countries 
remain more urgent. Transmission can occur from unscreened blood given for 
medical purposes, use of unclean needles in medical or traditional health care 
settings, unsterile surgical procedures and births, anabolic steroid use, suboptimal 
hemodialysis, and scarification and tattooing. Resources are inadequate to guarantee 
a safe blood supply worldwide. 
 When untreated, whole blood, fresh frozen platelets, packed cells, and 
clotting factors have been demonstrated to carry HIV. Hepatitis B vaccines derived 
from human or recombinant sources, albumin and immune globulin (including Rh 
(D) immune globulin) have not been found to transmit HIV because of the 
purification processes which inactivates all known viruses. 
 Other related retroviruses are spread through donated blood and plasma, 
including HTLV-I and HTLV-II associated with adult T-cell leukemia and HTLV-I 
myelopathy. HTLV-II has been definitively shown to be caused by HTLV-II. 
Although the risk of acquiring HIV-1 infection in one large study was 3 per 100,000 
units of blood product, the risk of acquiring HTLV-I infection was 24 per 100,000, 
suggesting the need to screen the blood supply for HTLV-I. In 1988, no cases of 
transfusion related acute T-cell leukemia were documented, although causality will 
be very difficult to demonstrate because of the long viral latency. Hepatitis B and C 
risk may presage HIV risk for blood and transplantation recipients.  
Hemophilia : 
 A person with hemophilia was diagnosed with P carinii pneumonia at the end 
of 1981 in the United Sates, suggesting that transmission of an AIDS related 
infectious agent could be spread through blood products. Retrospective studies 
indicate that HIV antibodies were present in serum samples as early as 1978 and 
1979, and fully 50% of one population had seroconverted by 1982. By the end of 
December 1994, adults and adolescents and 221 children (<13 years) with 
hemophilia or one of the rarer coagulation disorders had been reported with AIDS.  
 Among individuals with coagulopathies, persons with hemophilia A and B 
experienced the impact of the AIDS epidemic the most severely. According to CDC 
estimates in the late 1980s, 33% to 92% of persons with hemophilia B were infected 
with HIV, depending on their geographic region. 
 They require the use of factor VIII and IX concentrates in larger and more 
frequent doses than persons with milder clotting disorders. A typical vial of factor 
VIII concentrate contained clotting factors, alloantigenic compounds, and possibly, 
infectious agents from between 2000 to 20,000 blood and plasma donors. Exclusion 
of risky donors, modifications in the application of heat treatment (ie, increased 
temperature and longer exposure times), and the addition of detergent treatment and  
monoclonal antibody purified products have now virtually eliminated the risk of 
HIV transmission from the blood products of industrialized countries. 
Allograft and Organ Transplantation : 
 Transmission of HIV through allograft transplantation has been uncommon 
and represents a minute proportion of all ADIS cases62. HIV or genomic fragments 
can be isolated from all bodily fluids and organs of an infected individual, including 
various blood compartments, tears, conjunctival epithelium, corneal tissue, saliva, 
semen, urine, sweat, vaginal secretions, breast milk, cerebrospinal fluid, alveolar 
fluid, and major organs. Every organ in a seropositive individual is likely to be 
infected with HIV. Donated kidneys have been the most frequently associated with 
HIV transmission. Several liver allograft recipients have been infected with HIV 
through transplantation. HIV transmission has also been documented through bone 
and bone marrow transplantation. Skin allografts can transmit HIV from an infected 
donor. In Australia, 4 of 8 women exposed to HIV transmission from a single 
infected semen donor sero-converted in 1985.  Isolation of HIV from tears, 
conjunctival epithelium, and corneal tissue has been successful, but despite 
inadvertent transplantation of corneas from a seropositive donor, no seroconversion 
in recipients has been reported. Otologic homografts have also been identified as a 
potential vehicle of transmission, although no cases have been reported. Blood 
transfusion, common during the peritransplantation period, may have contributed its 
own risk for acquiring HIV, thereby overestimating the already small risks from 
transplantation. 
 Such episodes became exceedingly rare after institution of HIV testing in 
1985. Organ donors, including semen and ova donors, undergo routine screening, 
including HIV antibody testing. The CDC and the American Fertility Society 
recommend that semen samples intended for artificial insemination should be frozen 
for at least 6 months, followed by another HIV - antibody test from the donor before 
sample use.  
RARE OR PUTATIVE MODE OF TRANSMISSION : 
Insects : 
 There is no evidence of transmission of HIV through inoculation of HIV 
infected blood by insect vectors. Biologic transmission does not seem to occur, 
because HIV is unable to multiply inside insects, and infection of mosquito cells in 
vitro has not been consistently successful. North American and European 
mosquitoes feed typically only once in 3 days, decreasing the probability that an 
infected lymphocyte on the mosquito mouthparts would be viably inoculated to a 
second host. Even mosquitoes that feed daily (eg, certain subspecies of Anopheles 
gambiae in Africa) do not feed on a second person immediately after feeding on the 
first, Small mouthparts limit the amount of potentially infective material that could 
be transferred. Mechanical vector studies of HIV and mosquitoes and bedbugs 
mimicking natural conditions have not demonstrated transmission through blood 
transfer from person to person. 
 In the early 1980s, it was suggested by Florida physicians that arthropod 
transmission explained the high HIV rates in Belle Glade, Florida, Epidemiologic 
investigations, by CDC did not support mosquito borne transmission63.  
Nonparenteral Bloodborne Transmission : 
 Nonparenteral transmission of blood in nonoccupational setting deserves 
consideration. In boxing, forceful blows often cause broken skin and bleeding, 
which could result in mixing of blood from and HIV infected competitor into his 
opponent's wounds64, a noteworthy concern given IDU problems reported among 
several boxers. One case of a bloody soccer accident suggested on field 
transmission, but no molecular evidence of HIV-1 strain similarity was offered. 
 One young traveler was infected in Rwanda after sustaining lacerations in a 
bus accident. Blood dripped into the traveler's wound from other injured passengers 
who tended to him. In this highly endemic area, with seroprevalence rates in blood 
donors from Rwanda approaching 18%, it was postulated that this resulted in HIV 
transmission, because no other risk factors were apparent and the traveler had tested 
negative for HIV antibody when donating blood a few months before the accident.  
Saliva of human bites : 
 Transmission depends on many factors, including the concentration and 
viability of the agent within a given fluid or tissue, access to a port of entry for the 
fluid or medium, the presence of CD4+ cells or other target cells at the site of HIV 
entry, and natural host defenses near the site of entry.  Although transmission 
through saliva is unlikely because of the extremely low viral load, transmission is 
conceivable by means of saliva through a bite wound although longitudinal studies 
and published report involving cases of bites do not offer this possibility much 
support. 
 In 1990, the CDC reported preliminary results of a study, including 89 
household members living with 25 HIV infected children, mostly toddlers, who 
were infected through transfusion. No evidence of casual transmission among 
toddlers biting one another has been shown. None of the household members have 
tested positive for the virus, despite months of close contact before and after the 
child's diagnosis. Testing of 78 individuals household members with polymerase 
chain reaction methods revealed negative results65.  
Casual Contact : 
 There have been a few studies to assess the risk of transmission of HIV 
through casual household contacts as occur between family members. These studies 
failed to demonstrate a HIV infection in household members who did not have 
additional exposure to HIV through blood, sexual activity, or perinatal transmission. 
Sharing of common household facilities such as beds, towels, toilets, baths, showers, 
kitchen utensils, dishes, dishwashers, and clothes washers and dryers was 
documented. Personal interactions included hugging and kissing of the cheek and 
lips, wiping of fecal matter of infants and children by parents, and other family 
casual fluid contact. May of the infected children were infected up to 2 years before 
becoming symptomatic with AIDS, and no specific precautions were taken before 
the HIV infection was recognized. It has been stated correctly that these studies 
remain too small to definitively rule out small risk form casual contact. 
 Swimming pool concern are insubstantial when the antiviral effects of 
chlorine are consider. Even unchlorinated pools have a huge dilutional effect. Food 
handlers would not be expected to be a public risk because of the transmission 
patterns of HIV. Fomites, such as bedclothes or dirty laundry, would be a risk if they 
were bloodied but would not otherwise be considered dangerous. 
Health Care Worker to Patient Transmission : 
 The greatest mystery in the topic of casual transmission of HIV is the 
"Florida dentist" case. Well studied and documented with elegant epidemiology and 
molecular virology, it is clear that a dentist transmitted to five of his patients through 
an unknown route.  Deliberate criminal inoculation, contaminated instrumentation, 
drooling or bleeding from the infected dentist into the mouths of the infected 
patients, sexual contact, or blood contamination all seem unlikely.  It is unknown 
how these patients were infected. In subsequent look-back studies of over 22,000 
patients from 51 HIV infected health care workers, all 113 HIV seropositive patients 
had identified risk factors or strong molecular virologic evidence that the health care 
worker was not the source of the patient's infection. The Florida dentist remains an 
isolated event, suggesting that spread from health care worker to patient is rare.  
This issue has implications for the day care industry and educational systems, as 
well as the rights and treatment of HIV infected individuals, and it can be expected 
to periodically reemerge in the press and the mind of the public67.  
 
VERTICAL TRANSMISSION : 
(Mother to the fetus and infant) 
 The world health  organization estimates that by 2003 a cumulative total of 
37 million adults and 2.5 million children infected world wide with HIV/AIDS. 
Approximately 90% of infected children acquired the infection from their mothers. 
The rising prevalence of HIV infection in women of childbearing age, particularly in 
Africa, Asia, and Latin America, is expected to lead to a marked increase in vertical 
HIV infection. 
Timing, Mechanisms & Risk factors : 
 Direct evidence for the timing of the vertical transmission HIV is difficult to 
obtain, but it appears that HIV may be transmitted from an infected women to her 
infant during gestation (in uteri), during delivery (intrapartum) of post partum 
through breast feeding. The isolation of HIV-1 from or the detection of HIV - 1 
provirus in aborted fetal tissue as early as 10 weeks of gestation has been reported, 
but potential contamination with maternal blood was not always excluded, 
particularly in first trimester fetuses. The intrauterine transmission of HIV -1  also is 
suggested by the isolation of HIV - 1 from fluid and cells and by detection of P24 
antigen in fetal blood obtained at 16-24 weeks by cordocentesis.  The isolation of 
HIV - 1or the detection of HIV - 1 genome in blood samples obtained at birth from 
30% to 55% of HIV - 1 infected infants also suggests the intrauterine transmission 
of HIV - 1. 
 The proportion of infants infected in each trimester of pregnancy is 
unknown, as are the routes or mechanisms of intrauterine infection. Potential routes 
of infecting include admixture of maternal - fetal blood or infection across the 
placenta. Although HIV - 1 has been detected in amniotic fluid, placental 
trophoblasts and Hofbaur cells, the detection of HIV - 1 in placental tissue has not 
correlated with transmission. The importance of the placenta as a barrier to infection 
is suggested, however, by an increased risk of transmission from women with 
placentitis (eg, syphilitic) or women with illicit drug use (particularly vocative drugs 
cocaine) during pregnancy. 
 Indirect evidence suggests that the vertical transmission of HIV - 1 can occur 
during the intrapartum period. The routes and mechanisms of intrapartum 
transmission are unknown but probably include the admixture of maternal and fetal 
blood or mucocutaneous (eg. ocular, gastrointestinal tract) exposure of the infant to 
maternal blood and vaginal secretions. Several cases of the transmission of HIV - 1 
through breast - feeding have been reported. HIV - 1 has been detected by culture 
and by the PCR method in the cellular and Acellular components of breast milk, the 
colostral viral load appears to be particularly high. The risk of breast milk 
transmission appears to be especially high during maternal primary infection, 
Particularly if maternal primary infection occurs in the first few months offer 
delivery for these reasons, the guidelines recommend that women infected with or at 
risk of infection with HIV - 1 abstain from breast - feeding their infants if local 
sanitary conditions and access to infant formulas are good. However, because 
studies in developing nations have demonstrated decreased morbidity and mortality 
in breast - fed infants of HIV - 1 infected women, the benefit of breast - feeding are 
thought to out weight the risks of vertical HIV - 1 transmission in those settings, and 
breast - feeding is currently recommended. 
 Working definitions regarding the timing of infection have been proposed for 
non breast fed populations. Infants are regarded as infected in uteri if HIV - 1 is 
cultured from or HIV - 1 DNA is detected in peripheral blood lymphocytes within 
48 house of birth, Infants are regarded as infected during delivery (intrapartum) if 
HIV - 1 culture and DNA PCR results are negative for blood samples obtained 
within the first week of life and positive thereafter the application of these 
definitions to small chohort studies of non-breast fed populations suggests that 45% 
to 70% of vertically infected infants are infected in utero, and the remainder are 
infected at delivery. 
 Several studies suggest that maternal blood viral load may be an important 
factor in transmission. A three fold increase in transmission was observed in the 
multicenter European Collaborative study when HIV - 1 P24 antigen was detected in 
maternal serum, suggesting an increased risk of vertical transmission with higher 
blood viral load. An increased risk of vertical transmission was observed with 
maternal AIDS. Rates of transmission increased markedly when the maternal CD4 
count was less than for per mm3 or the CD4 : CD8 ratio was less than 0.6 Although 
immunocompetence may be an important factor in vertical transmission, maternal 
HIV - 1 specific immunity may be especially important. 
Natural history of Vertical infection : 
 The tempo of disease progression after vertical HIV - 1 infection is highly 
variable. As a group, however, vertically infected children experience more rapid 
disease progression than children infected at an older age or adults. More than 80% 
of vertically infected children manifest HIV - 1 related symptoms or CD4 T-cell 
depletion by 2 years of age.  
 Viral and host factors appear to contribute to the variability in the natural 
history of vertical HIV - 1 infection. Virus host dynamics in early infancy appear to 
be important determinants of infection outcome and may account for the particularly 
rapid disease progression observed after vertical HIV -1 infection. Virologic 
evaluation may differentiate infants infected in utero from those infected during 
delivery. However data demonstrate a rapid increase in viral load over the first 
month of life in most infants, whether infected in utero or during the intrapartum 
period. Other viral factors that may important in the pathogenesis of vertical 
infection are the genotypic and phenotypic variability vertically transmitted viruses. 
Host factors that may be particularly important in the pathogenesis of vertical HIV - 
1 infection include host genotype, the ability of host cells to support viral 
replication, and virus - specific immune responses. Virus specific cytotoxic T-
lymphocytes are important for the clearance of acute viral infections and suppression 
of viral replication in chronic infections.  
Strategies to Prevent the vertical Transmission : 
 A variety of strategies to  prevent the vertical transmission of HIV have been 
proposed. These include the prevention or therapy of venereal infections, maternal 
nutritional intervention, by passing the route of exposure, the reduction of viral load 
in maternal blood or vaginal secretions, and maternal or neonatal immunotherapy. 
 Attention must be given to concomitant infection and factor such as 
nutritional status that may affect vertical HIV - 1 transmission. Because concomitant 
maternal venereal infections may increase the risk of vertical transmission, efforts to 
prevent or treat infection are important. An increased risk of vertical HIV-1 
transmission with maternal vitamin A deficiency. Vitamine A supplemention would 
offer an inexpensive and easily feasible intervention. The topical application of 
chlorhexidine reduces the vertical transmission of group B streptococcal infections. 
Because as many as 75% of infants may acquire HIV infection at delivery through 
mussel exposure to maternal blood or vaginal secretions, it has been suggested that 
cesarean section may reduce the risk of exposure, particularly if performed before 
the rupture of membranes. Perinatal antiretroviral therapy reduces maternal blood or 
vaginal HIV-1 load. Zidovudin was the first antiretroviral to be given to HIV-1 
infected pregnant women and their infants to evaluate its effects on vertical HIV-1 
transmission. Combination regimens that would potently inhibit viral replication. 
Evaluation of the passive administration of monoclonal or polyclinic antibody 
preparation to mother and their infants for the prevention of vertical transmission. 
 In addition HIV can be transmitted from a mother to her baby through breast 
milk. It has been found that breast-feeding approximately double the risk of 
transmission. So breast-feeding should be avoided. Moreover during intrapartum 
period, invasive procedures like amidogen thesis, fetal scalp sampling, internal scalp 
electrodes, per umbilical cord sampling, should be avoided because of the risk posed 
to fetus by direct contact with maternal blood or secretions. 
CLINICAL MANIFESTATIONS : 
CLINICAL SPECTRUM OF HIV DISEASES : 
 Infection with HIV induces an insidious, progressive loss of immune system 
function, which ultimately results in the opportunistic infections and malignancies of 
the acquired immunodeficiency syndrome (AIDS). The median time from initial 
infection to the development of AIDS is approximately 10 years, although the rate of 
disease progression varies substantially among patients. In the early 1980s, the 
patients were staged primarily on the basis of whether they hand an AIDS-defining 
opportunistic disease process. Infection were catagorized as having asymptomatic 
HIV infection, AIDS related complex (ARC), or AIDS71. ARC symptoms and AIDS 
defining condition are listed in table - V and VI. 
Table - V 
CDC 1993 Classification System72 
Symptoms CDA count 
A B C 
> 500 A1 B1 C1 
200-520 A2 B2 C2 
< 20 A3 B3 C3 
Symptom category : 
A : Acute retroviral syndrome 
  Generalised lymphadenopathy 
  Asymptomatic disease 
B : Symptoms of AIDS related complex  
 Condition, cervical dysplasia, constitutional symptoms, herpes zoster, 
idiopathic thrombocytopenic purpura, listeriosis, oral hairy 
leukoplakia, pelvic inflammatory disease, peripheral neuropathy. 
C : AIDS defining conditions : 
 CD4 count < 200, condidiasis, cervical cancer; coccidiodomycosis, 
cryptosporidiosis, CMV infection, Herpes esophagitis, HIV 
encephalopathy, histoplasmosis, isoporiasis, Kaposis sarcoma, 
lymphoma, mycobacterial disease, P. carinii infection, pneumonia, 
progressive multifocal leukoencephalopenia and salmonellosis. 
Table - VI 
AIDS case definition for surveillance CDC 1987 (for persons above 12 years)73 
1. Two positive test for HIV infection (by ERS test) 
2. Any one of the following criteria : 
 a. Significant weight loss (10% of body wt. with last one month) 
 b. Chronic diarrhoea (intermittent or continuous) 
 c. Prolonged fever (Intermittent or continuous) 
 d. Tuberculosis : Extensive pulmonary TB, disseminated, miliary,   
  extrapulmonary 
 e. Neurological impairment preventing independent daily activities, not  
  known to be due to the condition unrelated to HIV infection. 
 f. Candidiasis of the oesophagus (oral with odynophagia) 
 g. Pneumonitis 
 h. Kaposi's sarcoma 
 i. Other conditions : Cryptococcal meningitis, Neurotoxoplasmosis,  
  CMV retinitis, Penicillium marneffei, Recurrent herpes zoster and  
  multi-dermatomal or disseminated molluscum. 
 Several clinical staging system have been proposed to characterize HIV 
disease Walter Reed classification system not in wide used. Other staging system 
have been based on CD4 counts, a marker that is the best predictor of the relative 
risk for developing HIV related opportunistic diseases. In keeping with this concept, 
the CDC revised the case definition of AIDS to include all patients with CD4 counts 
of less than 200 cells/mm3, whether the patients had developed a true AIDS defining 
condition or not. The revised CDC classification also added three new AIDS-
defining conditions: pulmonary tuberculosis, invasive cervical carcinoma and 
recurrent bacterial pneumonia. Although the new CDC case definition staging 
system represents a substantial improvement over the previous version, it should be 
emphasized that the CDC staging system is intended primarily for use as an 
epidemiologic tool rather than an instrument for use in clinical practice. Although 
CD4 values are the best predictors of relative risk of disease progression. A 
reasonable approach to categorizing HIV disease is to divide the stages illness into 
six categories based on a combination of clinical features and CD4 counts : Initial 
infection, early HIV disease, intermediate HIV disease, late HIV disease, advance 
HIV disease and terminal HIV disease. 
INITIAL INFECTION : 
 Acute seroconversion syndrome, the symptoms of acute serosconversion 
syndrome usually occur within 2-6 weeks after exposure to the virus74. The common 
symptom is fever with lymphodenopathy, pharyngitis, ophthous ulcerations, 
esophagitis, myalgia, arthralgias, diarrhea, nausea, vomiting and headache. Most 
distinguishing characteristic is the presence of flecting, morbilliform skin eruption. 
Initial infection may be asymptomatic. Most symptoms resolve within 14-21 days. 
Symptoms have been reported to have more rapid progression of AIDS. 
 Although this phase is characterised by marked CD4 lymphopaenia. Within 
2-4 weeks after initial infection high levels of circulating virus can be detected by 
culture and PCR. P24 antigen also detected during this phase. During this period 
high level viremia, the immune system begins to recognised and respond to HIV 
antigens, and develop clinical symptoms. Within 1 to 3 weeks antibody become 
detectable. Routine use of antiretroviral treatment is not recommended during the 
acute seroconversion process. 
EARLY HIV DISEASE (CD4>500 CELLS/MM3) : 
 Most individual with high CD4 counts are asymptomatic. Those who have 
any symptoms of infection, lymphadenopathy is the most common. Dermatologic 
abnormalities are most common. Eosinophilic folliculitis, often characterised itchy 
red bumps manifest on the thorax, back and upper extremities. Herpes simplex 
labialis may occur in early inffection75. Oral hairy leukoplakia caused by EB virus, 
and it may be indicator of impending disease progression. 100 million to 1 billion 
new viruses are produce in 24 hours period within an infected individual. Such high 
level production strongly suggests that antiretroviral therapy should be used. 
INTERMEDIATE STAGE DISEASE : (200-500 cells/mm3) 
 The relative risk of developing new opportunistic infection is higher, disease 
remain asymptomatic or demonstrate only mild disease manifestations. Skin and oral 
lesions more common, symptoms recurrent hepes simplex or varicella zoster 
infection, recurrent diarrhoea, fever weight loss and mild oropharyngeal or vaginal 
condidiasis represent the usual manifestations. Symptoms such as myalgias, 
orthralgias headache, and fatigue often present intermitantly. Bacterial sinusitic, 
bronchitis and pneumonia more frequent cause by S. pneumoniae, H. influenzae, M. 
cataralis, mycoplasma. Antiretroviral therapy with zodovudine monotherapy with 
zalcitabine or didanosine. 
LATE - STAGE DISEASE : (50 - 200 cells/mm3) 
 CD4 count less than 200 cells/mm3 patients are having AIDs76. The most 
common opportunistic infection is PCP. Patients are also substantial risk of 
developing other opp. infections including toxoplasma gondii, encephalitis, 
cryptosporidiosis, isosporiasis, tuberculosis, β-cell lymphoma, Kaposi's sarcoma and 
esophageal candidiasis. Constitutional symptoms such as myalgia, arthralgia, fever 
and weight loss along with ARC. Neurological disorders such as mononeuritis, 
cranial nerve palsies, mylepathy, neuropathy and cervical cancer in women, 
carcinoma of rectum in man and other disorder pepillomavirus appears more 
frequently. Antiretroviral combination therapy continued throughout this disease 
stage. 
ADVANCE HIV DISEASE : (< 50 cells / mm3) 
 The risk of developing certain opportunistic infections that are associated 
with more profound immunosuppression becomes significantly higher when the 
CD4 count below 50 cells/mm3.77 MAC disease, cryptococal meningitis, 
cytomegaloretinitis, invasive aspergillosis progressive multifocal 
leukoencephalopathy (PML) histoplasmosis, coccidioidomycosis, bartonellosis, 
infection become more common during this stage. Disorders of brain more common, 
PML, dementia. In wasting, weight loss with dirrhoea. is common, weight loss, 
weight loss includes the side effects of Addison's disease. Primary prophylaxis for 
opp. infection have been used. Standard pro-phylaxis for PCP and MAC disease and 
invasive fungal infection. 
TERMINAL HIV DISEASE : 
 Although the rate of disease progression varies substantially among patients, 
will ultimately succumb to their disease. The diagnosis of terminal stage HIV 
disease is usually based on an ability to control the symptoms of disease because no 
treatments are available for the particular disorder or become ineffective. Provide 
the primary provision of comfort by psychological support, family support and 
aggressive pain management. 
ORAL MANIFESTATIONS79 : 
Causitive organisms Disease Clinical features 
Candida Spp Candidiasis Pseudomenbranous and crythematosis of 
mouth or pharynx 
Criptococcus neoformans Cryptococcosis  Ulcer on Palate 
Histoplasma  Histoplasmosis Lesion of mucosal surface 
HP virus HPV lesion Oral, skin and genital warts 
Herpes virus HSV lesion 
HZV lesion 
Painful lesion on tongue, skin and oral lesion 
CMV CMV infection  Ulcer on mucosal surface 
EBV Hairy leucoplakia Oral lesion on tongue 
MAC Microbacterial 
infection 
Palatal and gingival granulomatous mass 
Other bacteria Periodontal disease Necrotizing ulcer, sever pain 
Kaposis sarcoma - Multiple ulcer on oral mucosa 
Lymphoma  Lymphoma on oral cavity 
Idiopathic 
thrombocytopenic purpura 
 Petechiae, ecchymoses, hematoma on mucosa 
Salivary gland disease and 
Xerostomia 
 Enlarged salivary gland.  
Dry mouth 
DERMATOLOGICAL MANIFESTATIONS80 : 
Causative 
organisms 
Disease Clinical features 
S. aureus Impetigo, Ecthyma Lesion grain and axilla, ulcerated 
lesions 
Pseudomonas  Folliculitis   Follicular pustules bullous  
Streptococcus 
Sp.  
Cellulities Impetigo, eczema, furuncles 
Mycobacteria  Multiple papules or nodules 
HSV  Indolant painful ulcerations  
HIV exanthem  Maculopapular roseola. 
EBV  Eruption with haemorrhagic necrotic 
center. 
V. Zoster  Atypical zoster, particularly prolonged 
time or disseminated 
Pox virus Molluscum 
contagiosum 
Flesh coloured umbillicated papules 
and nodules offace, warts. 
HPV + EBV Oral hairy leukoplakia  Whitish keratinised plagues on tongue 
Candida Candidiasis Candidiasis in submammary areas, 
inguinal andaxilary area. 
Tinea Try 
chophyton 
Darmatophytosis Keratodorma, Saborrhoeic dermatitis 
M. Furfur Pityrosporum infection Hypo or hyper pigmented macules 
Cryptococcus Cryptococcosis  Papules, nodules, ulcers, cellulites 
Spirochaetes Syphilis  Ulcer 
K. Sarkoma 
lymphoma 
 Neoplasia 
Others Saborrhoeic dermatitis, xeroderma, Psoriasis, Reiter's syndrome, 
photosensitivity, popular and follicular eruptions and valscular 
disease. 
 
NEUROLOGICAL MANIFESTATIONS80 : 
Abnormalities Organisms Clinical clues 
Uncommon disorder 
dementia 
K. Sarcoma, Lymphoma, 
Mylopathy, Myopathy, 
Pleocytosis 
 Wasting, ganglia, calcification, 
headache, pain, dementia, loss 
of bladder and bowel control. 
painful dysesthesias, burning 
feet, weakness 
Rare disorder : 
CNS lymphoma progressive 
multifocal 
leukoencephalopathy 
meningitis 
Crypococci M. 
tuberculosis 
Meningial irritation, headache, 
photophobia, confusion, 
lethargy, seizures. 
Cerebral toxoplasmosis 
     Polymyositis 
     Neurosyphilis 
Toxoplasma 
poliovirus T. 
Pellidum 
Confusion, personality, 
change, lethargy genital ulcer. 
Common disorder 
    Seizures, encephalitis 
    Cranial neuropathies 
     Encephalopathy 
Herpes zoster 
CMV 
Mylitis, genital ulcer, 
encephalitis 
Candidiasis 
    Histoplasmosis 
    Mucormycosis 
    Aspergillosis 
    Coccidiomycosis 
Candia, 
Histoplasma 
Mucor Aspergillus  
C. immitis 
Meningitis mental changes 
Bacterial meningitides Listeria, E.coli, S. 
pneumoniae, H. 
Influenzae 
Headache, weakness, 
meningitis 
 
RESPIRATORY MANIFESTATIONS80 : 
Causative 
organisms 
Disease Clinical features 
Pneumocystis 
carinii 
PCP Pneumonia Non specific and insidious, fever, fatigue, 
weight loss, headache, diarrhoea and 
cough 
Toxoplasma gondii Pneumonitis Mimic PCP, dyspnea, cough 
Mycobacterium 
tuberculosis 
Tuberculosis 
Myco acium Tuberculosis 
Fever, lymphadenopathy, cough, weight 
loss, diarrhoea 
H. Influenzae 
Rhodococcus 
Bacterial 
pneumonia 
Fever, cough, dyspnea 
Nocardia Nocardiosis Cough, fever, weight loss 
C. neoformans Cryptococal 
pneumonia 
Cough, fever sweats fatigue 
H. capsulatum Histoplasmosis Cough, fever sweats fatigue 
B. dermatidis Blastomycosis Cough, fever sweats fatigue 
Aspergillus Spp. Aspergillosis Cavity formation 
CMV Pneumonitis Dry cough, dyspnea, interstitial infiltrates 
Kaposis sarcoma  Dry cough, dyspnea, fatigue, fever, night 
sweat, Wt. loss 
Non hodgkin's 
lymphoma 
 Pulmonary masses or nodules, hilar and 
mediastinal adenopathy 
 
GASTROINTESTINAL MANIFESTATIONS80 :  
Causative organisms Disease Clinical features 
HIV Bowel disease Diarrhoea, mucosal 
cellularity 
CMV GI syndrome mononucleo like syndrome 
HSV Esophagitis proctitis Painful, shallow, clean 
based perianal or perineal 
ulcer 
Adenovirus  Diarrheal, disorders 
Hepatitis virus Viral hepatitis ABC & D Liver disease, nausea, 
vomiting 
Cryptosporidium  Cryptosporidiosis Sever diarrhea, slim 
disease, wasting syndrome 
Microsporidia Microsporidiasis Bowel syndrome 
Isospora Belii Isoporiasis Cholangiopathy 
Giardia Lamblia Giardiasis Gay bowel syndrome, 
diarrhea. 
E. Histolytica 
S. Stercoralis 
Cyclospora 
B. Hominis 
Amobiasis Diarrhoea, hyper infection 
syndrome 
M. tuberculosis 
M. Avium 
Granulomatous hepatitis 
intestinal ulcer 
Fever 
Progressive wasting and 
deilitation, diarrhoea. 
Salmonella, Shigella, 
Campylobacter 
Enteric fever, bacterial 
enteritidies 
Abdominal pain, distension, 
diarrhoea 
Candida Candidiasis  Oral thrush 
Histoplasma Histoplasmosis  
Coccidiosis Coccidioidomycosis Chronic febrile illness 
Actinomycetes Actinomycosis Esophageal ulcer 
Kaposis sarcoma  Swallowing disorder, 
luminal obstruction 
Lyphoma, Cancer of 
tongue, esophagus, 
stomach, colon and anus 
 Lymphoproliferative 
disease 
 
HAEMATOLOGICAL MANIFESTATIONS81 : 
 Anaemia is often present generally in advance stages of HIV illness. Several 
conditions may contribute to anaemia in HIV-infected patients. Concurrent 
infections, malignancies, malnutrition and toxic drug treatments, however, in most 
HIV-infected patients the cause of anaemia remains unclear. In AIDS patients, 
leukopenia and lymphopenia are also common and marrow hyperplasia with 
concomitant peripheral cytopenia is often found. 
 A severe type of autoimmune thrombocytopenia has also been described, it 
may occur in all stages of HIV infection. Physical findings in affected patients 
include ecchymosis and cutaneous or oral petechiae. Bone marrow aspirate and 
biopsy finding are consistent with peripheral platelet destruction. 
RENAL MANIFESTATIONS81 : 
 AIDS associated nephropathy is a renal syndrome characterized by 
proteinuria and glomerulosclerosis. The clinical presentation includes the nephritic 
syndrome with or without renal insufficiency. The syndrome produce rapid 
deterioration of renal function, leading to end-stage renal disease within a few 
weeks. On the other hand, nephrotoxic drugs, dehydration, sepsis, hypoxia and 
hypotension may contribute to acute renal failure in AIDS patients. 
CARDIAC MANIFESTATION81 : 
 Congestive cardiomyopathy may occur during HIV infection. Whether it is 
caused by HIV directly or by cardiotropic viruses or another mechanism remains to 
be established. Toxoplasma infection may occasionally cause myocarditis and 
Kaposi's sarcoma may involve the heart. Tuberculosis pericarditis is another 
condition that may complicate the course of HIV illness, and is a common cause of 
pericardial effusion. 
REPRODUCTIVE SYSTEM MANIFESTATIONS81 : 
 Hypogonadism in HIV infected patients has been reported. Amenorrhoea has 
been found in upto 40% of women with AIDS, it cause is unclear, but it is often 
associated with severe weight loss. 
ARTHRITIS18 : 
 A subacute oligoarthritis syndrome and Reiter syndrome associated with 
HIV infection have been reported. The cause of the arthritis is unknown, but HIV 
has been isolated from the synovial fluid. 
 
INFECTIONS ASSOCIATED WITH HIV : 
Atypical Fungal Infections : 
?  Pneumocystic Carinii : 
 Although more than a decade has passed since the recognition of the AIDS, 
Preumocystic carinii (PCP) continue to be acknowledged as the most common 
pulmonary infection in patients infected with HIV. During the early stages of the 
epidemic 60% cases of AIDS had PCP as their presenting illness in the USA and 
80% of all AIDS cases had PCP during their lifetimes82. However, the prevalence of 
PCP has come down in the west with the institution of effective prophylactic 
regimes. Pneumocystic carinii is a single celled eukaryotic organism, which has 
been variously classified as protozoan, a fungus or an undifferentiated protist. 
However, molecular analysis has revealed that it is nearer to fungi than protozoa.  
P.Carinii exists in cyst form and trophozoite form which may be small 1.5 to 2 µ or 
large 3 to 5 µ. The trophozoites may have small or big nuclei depending upon size. 
The life cycle is not exactly known, continuous human exposure to this organism is 
a rule as indicated by the appearance of antibody in more than 80% of humans 
during early childhood.  It is an intraalveolar extracellular parasite.  Infection with P. 
Carinii is transmitted by the respiratory route among rodents.  Epidemiologic studies 
of CD4 + T-lymphocyte (CD4 Counts) with onset of infection have begins with 
HIV, infection. CD4 counts are excellent predictors.  PCP has been seen primarily in 
patients with recent CD4 counts lower than 200 cells / mm3. 
 PCP has a subacute presentation in HIV infected persons. The most common 
symptoms of PCP are fever and nonproductive cough, dyspnea, chest tightness, 
shortness of breath, fatigue and weight loss. In some cases involving disjunction of 
the brain, the retina, the liver or the kidney.  
 The definitive diagnosis of P. Carinii requires the demonstration of cyst or 
trophozoites within tissue or body fluids, given that the organism cannot be cultured 
from clinical material. Three categories of specimens are collected (i) Induced 
expectorated sputum (nebulizer is preferred) (30% to 90% sensitivity) (ii) Broncho - 
alveolar lavage (BAL) (90 to 99% sensitivity) (iii) Pulmonary biopsy (95 to 100% 
sensitivity) Prepare the smears and doing staining.  Various staining methods are :- 
• Giemsa staining  
• Immunofluorescence Staining 
• Modified toludine blue o staining 
• Silver impregnation staining. 
 Currently trimethoprim - sulfamethoxazole (TMP - SMX) is the first line 
agent for PCP. Intravenous pentamidine is highly effective, but highly toxic. 
Protozoan Infections : 
?  Toxoplasma gondii : 
 Toxoplasmosis is a world wide zoonotic infection. Toxoplasmic encephalitis 
was one of the sentinel opportunistic infections observed early in the AIDS 
epidemic. Currently it is recognized as one of the most frequent and treatable 
opportunistic infections of the CNS.  Toxoplasma gondii, an obligate intracellular 
protozoan whose definitive host is the cat, exists in three forms - tachyzoite, tissue 
cyst and Oocyst - all of which are potentially infections for humans.  The infection is 
usually acquired by ingestion of cysts present in inadequately cooked meat or of 
Oocysts excreted in cat feces83.  In AIDS patients reactivation of latent infection 
usually manifests as toxoplasmic encephalitis, chorioretinitis, pneumonia, and 
disseminated disease have also been reported, if there CD4 count decline below cells 
100/mm3. Transmission by oral route and by vertical transmission from mother to 
foetus during an acute infection. 
 Clinical presentation of toxoplasmic encephalitis usually consist of focal 
neurologic abnormalities. Altered mental status characterized by confusion, 
Psychosis or other neuropsychiatric disturbance, cognitive impairment or coma. 
Seizures and pulmonary disease reported, Ocular disease necrotizing  
retinochoroidinitis and encephalities has also been reported. Involvement of other 
organ system such as lungs, heart, muscles, gastrointestinal tract is seen at autopsy, 
but is asymptomatic during the life.  Rarely, patients will present with severe 
symptomatic involvement of one or more of these organ system. 
 Definitive diagnosis is made by demonstration of organisms 
histopathologically in brain tissue.  The presence of tachyzoites in cysts surrounded 
by an inflammatory reaction is diagnostic. Wright - Giemsa stain is useful to 
demonstrate tachyzoites in CSF and bronchoalveloar lavage fluid. Isolation of 
Toxoplasma by tissue culture techniques or animal inoculation. Show the 
trophozoite from culture, tissue or exudate by fluorescent antibody staining.  
Specific antigen detection peroxidase - antiperoxidase method used to identify 
antigen and tachyzoites in tissue.  Serological test indirect fluorescent antibody test, 
Enzyme immune assay, compliment fixation test, Haemagglutination test, PCR, 
latex agglutination technique used for diagnostic testing. 
 First line therapy includes pyrimethamine in combination with sulfadiazine.  
?  Cryptosporidiosis :- 
 With the advent of the AIDS epidemic (1982) Cryptosporidium has been 
more widely appreciated as a cause of diarrheal disease84. It has been estimated that 
30 to 50% of patients in the developing world have developed chronic 
cryptosporidiosis.  Although out breaks are common among immunocompetent 
hosts. These episodes are predominantly self-limited. It has become an important 
contaminants found in drinking water and is an emerging cause of food-borne 
disease. In the 1980s, it was recognized as a cause of a traveler's diarrhea. Person to 
person transmission of cryptosporidium occurs frequently in day-care-centres. 
Nosocomial transmission also occurs in hospital personnel and among patients in 
hospital. 
 The clinical course in HIV-infected patients can be varied. Patients with low 
CD4 counts, especially counts lower than 100 cells/mm3, experience sever, 
unremitting diarrhea. The diarrhea caused by is usually profuse, watery, and 
nonbloody with no leaucocytes but mucus may be seen.  Although it may be cholera 
like in character. Diarrhea is often associated with crampy abdominal pain, fatigue, 
anorexia, nausea, and vomiting and it may lead to malnutrition and dehydration. 
Fever may be present. After it is ingested, the Oocyst excyst in the small intestine 
and sporozoite invade the small intestine.  Although infection in the small bowel 
predominates, other site of the gastrointestinal tract have been involve, and invasion 
of extrahepatic bile ducts may result in acalculous biliary disease. It also causes 
chronic sinusitis and otitis. 
 Diagnosis of cryptosporidiosis is usually made by examination of stool with 
modified acid fast staining. If few Oocyst are present, concentration techniques 
employing sucrose flotation method may be useful.  A monoclonal antibody directed 
against Oocyst wall and an enzyme - linked immunoabsorbent assay have become 
available.  PCR used largely for the detection of environmental contamination. 
 Until recently, no treatment had been proven to be consistently effective in 
the treatment of diarrhea. Symptom - directed therapy with loperamide or Lomotil 
and diet modification may be helpful light microscopy and concentrated Giemsa 
staining of stool or a modified trichrome or chromotrope stain have been used to 
detect organisms. 
?  Microsporidosis : 
 Microsporidiosis has become increasingly recognized as a cause of refractory 
unexplained diarrhea in 15% to 20% of AIDS patients85. Microsporidia cause mild, 
self-limited diarrheal disease in immunocompromised patients. Microsporidia are 
primitive obligate intra cellular spore producing protozoa. Although several species 
have been recognized as causing disease in humans.Only two species have been 
found to infect the gut : Enterocytozoon bieneuri and septata intestinalis. 
Microsporidia appear to invade the enterocyte of the intestine, which may serve as 
the portal of entry preceeding dissemination. Although infection with  E. bieneusi is 
limited to the intestine, the organism has also been found in the biliary system and 
has been implicated in acalculous cholecystitis andd most recently, identified in 
bronchoalveolar lavage fluid in AIDS patients. S.intestinalis can cause more 
disseminated disease because of its propensity to invade macrophages in addition to 
enterocytes and to cause disease in the lungs, liver and kidneys. 
Clinical presentation : Infection with microsporidia is characterized by non bloody 
diarrhea with cramping abdominal pain and gradual weight loss. Malabsorption may 
be present. 
Laboratory diagnosis : Recently, light microscopy and concentrated Giemsa 
staining of stool or a modified trichrome or chromotroe stain have been used to 
detect organisms. 
Treatment : No therapeutic agent has constantly been effective. Recently 
albendazole used as a p romising agent. Patients frequently improve with the use of 
antisecretory drug such as loperamide or lomotil. Nutritional therapy minimizing (fat 
and carbohydrates). 
?  Isosporiasis : 
 Infection of AIDS patients with Isospora belli, acquired by the ingestion of 
Oocysts in food or water contaminated with the faces of infected humans. Endemic 
areas include Indochina, S. America, & Southwestern Pacific. Developing nations, 
where the organism is much more prevalent in the general population.  
Clinical Presentation : Particularly crampy abdominal pain and profuse watery 
diarrhoea of 8-10 stools per day along with weight loss, weakness, anoreixa, & low 
grade fever. Isospora infection may involve the pancreas and biliary tree in AIDS 
patients. Extraintestinal infection involving the liver, spleen, mediastinal and 
mesenteric lymphnodes rare. 
 The diagnosis of isosporiasis is made by the detection of large oval Oocysts 
(20 to 30 µ m by10 to 20 µ m) in the stool by modified acidfast method, or by wet 
mount86.  Biopsy of the small intestine may show organisms within the lumen or 
within cytoplasmic vacuoles in enterocytes, localized mucosal inflammation and 
atrophy. 
 A 10 day course of therapy with TMP-SMX is highly effective.  In patients 
also are intolerant of sulfa, pyrimethamine, metronidazole may be used. 
?  Cyclosporiasis :- 
 Cyclospora is an emerging worldwide cause of diarrhea in AIDS patients. 
The organism is classified in this genus based on in vitro sporulation and excystation 
studies and by electron microscopy.  These organisms reported to cause prolonged 
but ultimately self-limited diarrheal illness in travelers. Epidemics in the USA have 
been associated with fecal-oral transmission through contaminated water and food. 
 Illness caused by cyclospora is characterized by watery diarrhea, abdominal 
cramping, flatulence, weight loss and nausea87.  
 Microscopic examination of stool using modified ZN stain reveals abundant 
sperical bodies 8-10 µ m in diameter. Recently Giemsa, trichrome, chromotrope, 
Gram - Chromotrope, acid fast and safranin stain using as fast, reliable and easy to 
perform procedure. Detection of tissue stage HE stain on biopsy specimen. 
 The response with TMP - SMX. Patients has been also successfully treated 
with trimethoprim-sulfamethoxazole.  
Fungal Infections :- 
?  Cryptococcus neoformans :- 
 C. neoformance is the major cause of meningitis in AIDS patients, and it can 
also cause local organ dysfunction and disseminated disease. C. neoformans is a 
yeast like fungus that reproduces by budding86. It produces no known toxins but it 
does have a large polysaccharide capsule that appears to play a role in protecting the 
organism from host defense mechanisms. There are four subtypes of C. neoformans 
: based on several characteristics, including mating abilities, stereotypes A and D are 
classified as C. neoformans var neoformans and B and C are as C. neoformans var 
gattii. Stereotypes A and D cause disease in AIDS patients. C. neoformanse is a 
ubiquitous fungus that can be isolated from a variety environmental sites, including 
soil and is found in especially high concentrations in pigeon feces. Initial infection 
occurs by the respiratory route, through inhalation of aerosolized organisms after 
exposure to environmental sources. In immunocompromised patients, however, 
especially in-patients with AIDS, the organism in inadequately controlled and can 
cause life threatening extrapulmonary disease, primarily meningitis, or with many 
other opportunistic infections. Cryptococcosis can present in HIV-infected patients 
either as the initial, AIDS - defining opportunistic process or as a later process. 
 The most common site of infection with C. neoformans patients is the CNS. 
C.neoformans usually infects both the brain and the meanings diffusely, producing 
both meningitis and encephalitis. Occasionally, cryptococomas, which are large 
focal lesions, develop.  Headache and fever are the most common manifestations, 
nausea, vomiting, mental status, seizures, or focal neurological abnormalities are 
seen frequently. Pneumonia and fungemia are the most common extraneural 
presentations. Patients with pneumonia may present with fever, productive cough, 
dyspnea and occasionally hemoptysis. Fungemia associated with minimal 
complaint; fever, malaise and fatigue are often the only symptoms suggesting a 
systemic infection. Other sites of infections are Eye, oral, Skin, stomach, colon, 
liver, pancreas and heart. Other processes commonly seen such as Kaposis sarcoma, 
herpes and molluscum contagiosum. The prostate may also be a site of 
asymptomatic infection. 
 Specimen for laboratory diagnosis sputum, CSF, blood, urine, autopsy 
material and pus from skin lesion examine for the India ink and culture examination. 
Diagnosis of extraneural cryptococcosis detecting histopathologically in biopsy or 
other clinical specimen, sections are stained with methanamine sliver stain.  The 
most effective test is the latex test for capsular antigen in CSF or blood. It give 
positive over 90% of meningeal infection.  
 Amphotericin B were routinely used. Important new drug are flucytosine, 
fluconazole, itraconazole have been used.  
?  Candida : 
 Candida are yeasts that exist predominantly in uniecellular forms. They are 
2.5 to 6 µ m ovoid cells that reproduce by budding. More than 150 species exist, and 
at least 10 are pathogenic in humans. Candida organisms are ubiquitous they have 
been recovered from soil, food and hospital environment. 
 Candida species are the most common causative agents of fungal infection in 
HIV - infected persons. Fortunately, these infections are seldom invasive, can 
usually be easily treated, and with appropriate management can often be prevented. 
It was established early in the course of the HIV epidemic that oral candidiasis is a 
marker of an impaired immune system and a prognostic marker for the subsequent 
development of opportunistic infections. Candidal infections of the esophagus, 
trachea, bronchi or lungs are recognised as indicator disease for AIDS89. Whereas 
oropharyngeal candidal infections (and candidal vaginosis) regularly occur in HIV 
infected persons with CD4 counts higher than 200 cells/mm3, esophageal candidiasis 
is indicative of more advanced immunodeficiency and seldom occurs with CD4 
counts higher than 100 cells/mm3. Candida spp. seldom cause disseminated infection 
in patients with AIDS unless there are associated factors such as the presence of 
chronic indwelling catheters or neutropenia.  
 Oropharyngeal candidacies (thrush) is usually diagnosed by the characteristic 
appearance of white plaques on the tongue, bouccle mucosa or palate. Candida 
esophagitis is frequently diagnosed on the basis of the characteristic clinical 
presentations of odynophagia, dysphegia, a feeling of obstruction, substernal chest 
pain or combination of these symptoms, often accompanied by oropharyngeal 
candidiasis. Smear from mucous, sputam, blood, scrapings, CSF are stained with 
PAS or by Gram's method, pseudo mycelium and budding cells examined. Scraping 
are mounted in 10-20% KOH examination. Material is cultured on Sabouraud 
dextrose agar. Biopsy showing tissue invasion by candida.  Detection of antibodies 
against candida are least helpful in AIDS patients. Constantly rising titres are 
suggestive of deep infections. 
 Prophylactic drugs are fluconazole, ketoconazole and Itraconazole frequently 
used.  
?  Histoplasma Capsulation  :- 
 Histoplasmosis is the most frequently diagnosed systemic fungal disease in 
the UK. Histoplasma capsulatum exists in the soil in the mycelial phase but converts 
to the yeast form at the body temperature of mammals. The mycelial from has 
septate, branching hyphae with lateral and terminal spores. The yeast form is ovoid, 
1.5 to 2 µ m by 3.0 to 3.5 µ m and reproduce by budding. Histoplasmosis primarily 
involving reticuloendothelial system. Histoplasmosis is a serious problem in AIDS 
patients. 
 The most common presentation is fever and weight loss. Granulomatous 
nodules in the lungs, hepatomegaly, splenomegaly, lymphadenopathy occur. 
Thrombocytopenia, neutropenia and anemia, septicemia has been reported. 
Cutaneous lesions like rashes, tender pustules, and papules, skin or oral ulcers and 
ulcerated palatal nodules. Gastrointestinal masses, chorioretinitis and pleural 
effusion have also been reported90.  
 The definitive diagnosis by biopsy and culture from tissue. Culture from 
bone marrow, blood, lung biopsy or lavage, sputum, lymphnode, skin or CSF are 
obtained positive.  Diff - quick, Wright - Giemsa or methanamine silver stains can 
lead to a rapid diagnosis from tissue, sputum or lavage specimens. Immunodiffusion 
or complement fixation anti Histoplasma capsulatum antibody test may helpful in 
positive cases. Radio-immunoassay from blood and urine has been used for therapy 
and relapse.  
 Amphotericin B is the highly effective drug.  Itraconazole, fluconazole an 
alternative regimen. 
?  Coccidioides immitis :- 
 Coccidioides immitis is a fungus that lives in the soil as a mold. 
Arthroconidia, produced from the hyphae of the mycelial phase, infect the host after 
they are released into the air and inhaled. In tissues, the fungus grows as a spherules, 
large structures containing hundreds of endospores. Coccidioido mycosis is endemic 
in certain areas in America. This disseminated disease occurs in 1.2% of immuno-
competent patients with coccidioidomycosis who require hospitalization is more 
common in patient with AIDS91. Either the disease reactivated or susceptibility to 
infection in enhanced in patients with AIDS.  
 Because the route of infection of C. immitis by inhalation of arthroconidia, it 
most frequently involves the lungs. The most common presentation is that of fever, 
weight loss and cough.  Diffuse reticulonodular infiltrates on chest radiography are 
characteristic in patients on chest radiography are characteristic in patients with 
AIDS. Pulmonary cavities, hilar adenopathy, meningitis, peritonitis and fungemia 
caused by C. immitis.  
 The diagnosis is easy by culture. Visulization of the distinactive spherules in 
tissue is also diagnostic of invasive disease. Serology may be helpful but 
complement and precipitation serology may negative with 25% patients. 
 Standard treatment is Amphotericin B. Ketoconazole, triazole itraconazole 
and fluconazole are also used. 
?  Aspergillus :- 
 Aspergillus is a common mold found in the soil that frequently cause 
invasive pulmonary and obstructing bronchial disease in immunocompromised 
patients. Relatively uncommon complication of AIDS occurs as a late manifestation 
of the disease92. Spore (conidia) are approximately 3 µm in size hyphae 2 to 5 µm 
wide, are often septet and exhibit Y-shaped branching. A. fumigates and A. Floavus 
are the most common cause of aspergillosis. 
 Common symptom was the incidious development of cough and fever in 
immunocompromised patients with neutropenia. Radiographycally cavitary lung 
disease and diffuse infiltrates were the most common findings.  Other organs, 
including the heart, brain, pancreas and spinal cord may rarely infected in AIDS 
patients. 
 Examination of sputum, blood & skin sample by direct KOH microscopy. 
Isolation from sputum or biopsy sample appearance of hyphae suggestive the 
diagnosis. 
 Response to treatment has been poor. Amphotericin β, itraconazole have 
been used with limited success. 
?  Blastomyces dermatitidis :- 
 β. dermatitidis is an 8-15µm yeast cell with daughter cells forming a bud 
with a broad base.  Pulmonary or miliary  blastomycosis has only rarely been 
reported in persons with AIDS93. Reported other body sites such as skin and bone. 
 Direct microscopy from sputum, biopsy, pus, skin scraping by KOH.  
Characteristic large round cells with refractile wall and broad based single bud seen.  
Culture on sab. agar. serological diagnosis are limited useful. 
 Early therapy with Amphotericin B. Lifetime therapy with Ketoconazole or 
itraconazole may be of benefit. 
?  Penicillium marneffei :- 
 P. marneffei is a dimorphic fungus that grows in tissue as a 3 by 8 µm yeast. 
It is endemic in South east Asia and china and has been reported to be the third most 
common opportunistic infection associated with HIV infection in Thailand94. 
 The disease most frequently present with generalized popular skin rash 
associated with fever, weight loss, lymphadenopathy and anemia. 
 Diagnosis can be made by bone marrow or lymph node biopsy or less 
commonly by blood culture. 
 Amphotericin B and itraconazole is the choice of drug. 
Viral infections :- 
 Viral infections are very common in HIV infected individuals, especially 
those viruses where cell mediated immunity plays a major role in host defence. 
?  Herpes Simplex 1 & 2 : 
 The herpes viruses are a major cause of morbidity & mortality in patients 
with HIV/AIDS infections. Initial HSV-1 infection often occurs during childhood, 
with infection typically developing from infected droplets of orolabial or nasal 
secretion onto susceptible mucosal surface. HSV-2 infection is usually acquired 
from sexual activity. Anorectal HSV-2 infection is a frequent cause of protitis in 
homosexual men. 
Clinical feature95 : 
 Genital or oral infections with more extensive tissue damage, progressive 
HSV perianal ulcers, proctitis, colitis, oesophagitis, oral lesions, preumoniae and a 
variety of neurologic disorder have been observed in AIDS patients. 
 Virus isolation can be done in tissue culture cells like Vero, rabbit kidney or 
human diploid cells. Rapidly determined by electron microscopic examination. For 
rapid diagnosis of skin, mucous membrane lesion scrapings can be stained with 
Giemsa/PAS, immunoflourescence technique & immunoperoxidase stain also. 
Specific IgM can be detected by serology. PCR is useful. 
?  Herpes Viruses - 695 :- 
 HHV-6 has been associated with CNS complications like febrile seizures, 
encephalitis, meningitis and multiple sclerosis.  The most reliable source of HHV - 6 
is saliva. Clinically HHV - 6 B has been recognized as the cause of exanthema 
subitum in infant & other febrile illnesses in young children. Infection seen in retinal 
disorders in HIV infected patients. It has been found in the brain, particularly in the 
oligodendrocytes of children with HIV related encephalitis. HHV 6 can be 
diagnosed by detection of anti HHV 6 IgG or IgM antibodies. Immunofluorescent 
assay or ELISA & viral load determined by PCR. Virus can be isolated from 
PBMCS of patients with AIDS, by co-culture with cord blood mononuclear cells. 
?  HHV-895 : 
 HHV-8 is non pathogenic but highly oncogenic in HIV infection and 
iatrogenic immunsupression. It is involved in the pathogenesis of Kaposi's sarcoma, 
primary effusion lymphoma and some cases of multicentre Cast leman's disease. The 
availability of B cell lines infected by HHV-8 permit serological studies in diverse 
populations. Those assay have strong correlation between HHV-8 and presence of 
Kaposis' sarcoma or B cell lymphomas of abdominal cavity. Therapy is Acyclovir & 
alternative treatment is Foscarnet. 
?  Cytomegalovirus (CMV)95 :- 
 CMV infection is usually seen late in the course of HIV infection and is one 
of the most important & frequent cause of severe disease in this patients.  Primary 
infection with CMV can be acquired at any time throughout life, infection evident 
by presence of CMV antibodies. 30-40% of homosexual men shed CMV in semen 
or urine irrespective of their status.  Viremia may be present in AIDS or ARC 
patients. CMV retinitis and CMV infection of the gastrointestinal tract such as 
esophagitis, enteritis and colitis are the most important presentations. CMV retinitis 
seen in patients with CD4 count 55/mm3 or less. CMV also causes acute pancreatitis, 
endocraniopathies & glandular involvement. 
 CMV can only be cultured in human fibroblast cells. For the demonstration 
CMV using immunofluorescence. CMV isolated from urine, throat swab, buffy coat, 
or other tissues Detection of CMV antigenaemia in circulating neutrophils is a 
sensitive and clinically useful method of detecting viremia. Antigen can detected 
either by ELISA or immunoflourescence. Detection of IgM antibody & PCR using 
for serological test. 
 Therapy Ganciclovir & Foscarnet used. 
?  Varicells zoster virus95 :- 
 VZV or Herpes zoster is recognised as a frequent infection in HIV infected 
patients. VZV is a self limiting infection but in advance HIV severe complications 
can arise. There can be disseminated lesions of lungs, liver or nervous system 
leading to pneumonitis, hepatitis, retinitis and encephalitis. Cuteneous infectin is 
common, may menifest as hyperkeratotic, verrucous lesion. The diagnosis of usually 
clinical. Immunofluorescent assay used for the detection of virus.  Acyclovir & 
foscarnet used as a treatment. 
?  Epstein barr virus (EBV) :- 
 The most common menifestation of primary EBV is infectious 
mononulcosis. Children with HIV/AIDS has discribed the development of 
aggressive muscle tumors during primary EBV infection96. These tumors are result 
of a clonal expression of smooth muscle cells. Reactivation associated with 
hematopoietic malignancies such as Burkitts lymphoma CNS lymphoma and 
nasopharyngeal carcinoma. Virus isolation is rarely used. The EBV Specific 
antibodies EIAS using. PCR may be useful. 
?  Human Papilloma Viruses : (HPV) 
 More than 85 types of HPV have been identified. Severe disease with HPV is 
frequent in patient with HIV infection. The clinical range includes anogenital warts, 
carcinoma in situ in women, intraepithelial neoplasia and cancer in homosexual 
men. Sexually transmitted HPVs are probably the most common of all STDs. 
Although most genital HPV infections are self-limited, & associated with an 
increased risk of developing genital cancers ie cervical, vaginal, valvar, penile and 
anal cancers. Endocervical carcinoma have also been associated with HPV infection. 
The diagnosis of warts is made clinically. As HPV can not be cultivated. Typing 
detection technique of HPV DNA exist, nucleic acid hybridization and PCR. Dot 
blot hybridization & Southern blot hybridization can only done in National centres. 
 
?  Hepatitis Viruses : HBV, HCV97 :- 
 Worldwide coinfection with HIV is exceedingly common among persons 
with hepatitis virus infection. Viruses are present as available for transmission in 
blood and in genital tract secretions. The highest prevalence of HBV occurs among 
those engaging in high-risk sexual behavior or intravenous drug abuse or among 
those requiring frequent exposure to blood or blood products. Defects in CMI in 
AIDS result in a wide variety of hepatic complications including granulomas, 
cytomegalovirus hepatitis, multimicrobial AIDS cholangiopathy, Kaposis sarcoma 
and lymphoma. Kupffer cells are the major hepatic target cell population for HIV. In 
these patients the differential diagnosis includes opportunistic infections and 
neoplasms as well as chronic viral hepatitis due to viruses B,C,D, and G and drug 
hepatotoxicity. Among these chronic viral hepatitis due to hepatitis C virus is 
frequently seen. It presents a more accelerated course in HIV infected patients 
leading to cirrhosis and liver failure in a shorter period of time.  Decompensated 
liver disease like encephalopathy, ascitis and jaundice or complications like 
gastrointestinal bleeding, hapatorenal syndrome and peritonitis are commonly 
diagnosed. 
 Other viruses like Adenovirus, Polyomavirus, Molluscum contagiosum, 
Measles virus & Respiratory synsytial virus are also dials with HIV/AIDS patients.  
 
Bacterial infections :- 
?  Tuberculosis :- 
 Tuberculosis which had declined in the nineteenth and early twentieth 
century, has re-emerged during the last two decades of twentieth century on account 
of the advent of HIV all over the world98. The world wide epidemic of HIV infection 
has resulted in a major secondary epidemic of TB. The first report of TB occurring 
in patients with AIDS appeared in 1983 when an illness associated with sever 
immunosuppression was described in a group of Haitian patients in South Florida 
24% patients had tuberculosis.  Epidemiologic study explained that in many areas 
HIV infection is prevalent among groups already known to be at high risk for TB : 
drug users, the homeless and foreign born individuals, they also suggests that there 
is amore direct association between HIV infection and the development of TB. 
Overlap in at risk group, increased risk of reactivation of latent M. tuberculosis 
infection, high rates of infection after exposure and rapid progression to disease the 
connection between the HIV and TB is important at both individual clinical and 
societal public health levels. The CDC has recommended therefore that HIV testing 
should be offered to everyone diagnosed with TB99. Among adults, TB is the leading 
infectious cause of death worldwide and approximately go million new cases are 
expected during current decade. The majority of these infections occurred in the 
developing countries of Africa, and Asia, where dramatically high rates of HIV 
infection and AIDS have been observed. The high rate of coinfection has resulted in 
TB becoming the most common opportunistic infection associated with HIV disease 
in many part of the world.  In some report more than 50% of AIDS patients in 
Africa, India and Thailand developed clinical TB100. Seropositivity highest among 
patients between 20-40 years old, especially women in that group & patients with  
extrapulmonary TB. 
?  Mycobacterium Avium Complex (MAC) : 
 MAC consists of M. avium, M. intracellular. Infection due to MAC was 
relatively rare in the pre AIDS era. The most common infection was pulmonary. 
However, with the advent of AIDS, disseminated infection with MAC is recognized 
as the most common systemic bacterial infection in patients of AIDS.  Disease due 
to MAC is geographically widespread with reports of MAC in HIV infected patients 
from North & South America, Europe and Australia101. 
?  Other nontuberculous mycobacteria : 
 Very few reports availbale on other NTM infection in patients of AIDS. M. 
haemophilum infections have been reported, mainly causing erythematous nodular 
skin lesions, subcutaneous abscesses, lymphadenitis and occasional joint 
involvement.  M. genavense cause infection rarely leading to bacteraemia in patients 
of AIDS. M. gordonae one of the least pathogenic mycobacteria also lead to 
pulmonary infection. Scattered reports are available on the occurrence of M. 
scrofulaceum and M. celatum infection in AIDS patients102. 
 The clinical manifestations of tuberculosis in patients with HIV infection 
very considerably depending on the severity of the immunosuppression. The 
manifestation very from typical pulmonary presentation. A productive cough, 
hemoptysis, fever and weight loss are common symptoms. Signs of cervical, hilar, 
paratracheal or mediastinal adenopathy are highly suggestive of TB. In pulmonary 
disease bilateral lower lobe infiltration & plural effusion are more frequent in 
patients of TB connected with HIV than others. As compared only 10% HIV - TB 
cases have extra pulmonary manifestations. Lymphadenopathy is very common. 
Pericardial disease, meningitis and miliary disease may be the other manifestations. 
 Tuberculin skin test used for screening test. Aspirate, sputum, lavage, swab, 
blood, CSF, urine, stool all used for the microscopic examination. ZN stain, 
Kinyoun stain, Fluorochrome stain are used for the smear examination. Growth on 
solid media LJ and Middle brook 7H10 & 7H11 agar visualise mycobacterial 
colony.  Advance detection by growth in liquid media with the use of radiometric 
methods (Bactec) Newer diagnostic techniques are DNA probe tech. PCR, Ligase 
chain reaction are recently used. Other serodiagnostic techniques are ELISA, RIA 
limited use. 
 The initial treatment for HIV & TB infection is rifampin, pyrazinamide & 
ethambutol used. Second line drugs are ofloxacin, Amikacin, Aagmentin, 
Ciprofloxacin, Capreomycin, Kanamyein, Rifabutin used. 
?  Other bacterial infections :- 
 Persons with HIV infection are more susceptible to bacterial infections 
because of defects in both cell-mediated and humoral immunity. Bacterial 
infections, multiple or recurrent, recurrent pneumonia and recurrent salmonella 
septicemia have been included in the 1993 AIDS surveillance case definition by 
CDC. The true incidence of Bacterial infection in HIV infected persons is difficult to 
discern and varies with population. Disease like pneumonia, Sinusitis, bacteraemia 
and bacterial enteric infections occur at a rate many times higher than in the general 
population.  
Respiratory tract infections :- 
?  Pneumonia :- 
 The lower respiratory tract is one of the most common sites of bacterial 
infection observed in HIV infected patients. Pneumonia may be community acquired 
or nosocomial. Most common bacterial pathogens are S.Pneumoniae, H.influenzae, 
Klebsiella Spp, S.aureus, P.aeruginosa & other Enterobacteriaceae. Other pathogens 
that have been moraxella catarrhalis, Nocardia Spp. Rhodococcu equi, Legionella 
pneumophila etc. 
 HIV associated respiratory disease includes upper respiratory tract infections, 
acute or chronic sinusitis, acute or chronic bronchitis and bacterial pneumonias. HIV 
infected patients having higher rate of complications including intra pulmonary 
cultivation, abscess formation, empyma and death. Bacterial lower respiratory tract 
infection are manifested as cough with sputum production, variable fever, chills 
chest pain etc. Other symptoms may include headache, nausea and myalgias. 
Bacterial pneumonia appears to be good with appropriate treatment. 
 Primary diagnosis by direct microscopy with the sputum, bronchial lavage, 
bronchial aspirate, samples to stain with Gram stain, modified acidfast stain, 
Gomoris methamine silver stain (Nocardia) and Toludin blue (Actinomycetes) are 
used. Direct fluorescent antibody staining can be done for Legionella. Bacteria can 
be isolated on routine culture media. For Legionella used charcoal yeast extract agar. 
specific bacterial infection conformed by the cultural characteristic. 
 Trimethoprim sulfamethoxazole choice of treatment. 2nd generation 
cephalosporins - cefuroxime & erythromycin have been used.  
 
 
?  Bacteraemia :- 
 Bacteraemia may indicate the presence of a focus of infectious disease or 
may merely present transient release of bacteria into the blood stream. Bacteraemia 
may be transient, continuous or intermittent. Cause of continuous bacteraemia 
include septic shock, bacterial endocarditis, early stage of typhoid fever, brucellosis, 
leptospirosis etc. Intermittent bacteraemia occurs in meningitis, pneumonia, 
Osteomyelitis, undrained abscesses etc.  
 The clinical manifestations of septicemia may include fever, chills, 
hyperventilation, skin lesion and lead to hypotension or shock, major organ system 
failure and disseminated intra vascular coagulation. AIDS patients have recovered 
bacterial agents are S.aureus, enterococci, Pseudomonas, Sligella, Salmonella, 
Bartonella Sp., corynebacterium, Listeria monocytogens. Enteric pathogens 
recovered from HIV patients includes Salmonella, sligella, campylobacter, E.coli, 
clostridium difficile, V.cholerae, S.aureus, plesiomonas, yarsinia and Aeromonas. 
 Blood culture is the main criteria for the bacterial infection. Trypticase soya 
broth, Brain heart infusion broth is used for culture. Isolation of fastidious and rarely 
isolated organisms recovered successfully from blood culture. For the shigellosis 
stool examination is required. Direct microscopy & stool culture are routine 
methods.  
CNS infections :- 
 Infections of the CNS usually occur as part of disseminated disease. The 
major causes of CNS infection in HAV patients may be conventional organisms or 
unusual agent of meningitis including established opportunistic pathogens. 
S.pneumoniae, S.aureus, Nocardia Spp., Listeriamonocytogens, Various gram 
negative bacilli, Treponema pallium, Actinomycets Spp etc are infecting organisms. 
For the identification CSF should be examined for sugar, protein level & cell count, 
direct microscopy, culture & antigen detection tests using. 
 Some of the bacterial Spp. that are more likely to be associated with 
opportunistic infection in AIDS/HIV are Nocardia, Rhodococcus equi, Legionella 
Spp. Listeria, Corynebacterium, camplylobacter & Bortonella Spp.  
 Prevention of the bacterial infection use vaccinations and antibacterial 
prophylaxis.  
 
TUMORS IN HIV INFECTION 
?  Kaposi's Sarkoma & HIV :- 
 In 1981 AIDS was initially recognized by the outbreak of Kaposi's 
sarkoma103. In 1972 the Hungarian physician Moriz Kaposis first described this 
disease as a multiple idiopathic pigmented hemangiaosarcoma. He recognised 
disease as a rare, chronic, coetaneous disorder affecting men, the nature of disease is 
multifocal, the occurrence of visceral involvement and the vascular nature of the 
tumor. This form of KS is known as classic KS, occurs mostly in Eastern Europe 
and N. America. HIV infected homosexual and bisexual men infected with an 
aggressive from of KS known as epidemic or AIDS associated KS. Endemic KS is 
most common in black Africans. Iatrogenic KS has been reported with increasing 
frequency in children & adults because of increased number of organ transplantation 
case & more frequent use of immune-suppressive therapy for autoimmune disorder 
and chemotherapy for cancer. Mucocutaneous KS has also been reported in children 
who developed HIV infection through blood transfusions. In Africa AIDS associated 
KS transmitted by heterosexual contact. 
 Four categories of KS are recognized : Classic, African endemic, iatrogenic 
and AIDS associated. Classic KS manifests with blue, reddish purple machules, 
plaques or nodules and tumors that produce fungating masses with ulceration, on the 
extremities, feet and lower leg, any where on the skin.  In iatrogenic KS cutaneous, 
lymphatic, and visceral dissemination occur. Clinical course similar to classic KS. 
AIDS associated KS involve any location on skin, lymph nodes, gastrointestinal 
tract & other visceral organs. KS is first sing of HIV infection. Pulmonary KS 
manifest with intractable cough, bronchospasm and respiratory insufficiency.  
Progression of KS very greatly with clinical form. Classic KS follow slow and 
indolent course, Endemic KS follows a more aggressive course, AIDS associated KS 
have a rapidly progressive course. Advance biotechnology have made it possible to 
investigate the cellular & molecular events leading to progression of KS. 
 No effective treatment is available for HIV - associated KS. May consist of 
vinblastine, vincristine, etoposide, doxorubicin and bleomycin, alone or in 
combination.  
LYMPHOMAS AND OTHER CANCERS : 
?  Non - Hodgkin's lymphoma (NHL)104 : 
 NHL occurs more frequently in AIDS patients than in other groups.  These 
lymphomas are generally of B-cell origin and include Burkitt lymphoma. They are 
frequently localized in extranodonal sites, including CNS, the bone marrow, and the 
bowel. These lymphomas are generally high grade malignancies and respond poorly 
to chemotherapy. EB virus, together with the immunodeficiency associated HIV 
infection probably plays a major role in development of these B-cell lymphomas. 
AIDS RELATED MALIGNANCIES :- 
?  Primary CNS lymphoma :- 
 Primary CNS lymphoma in 1 to 3% patients with AIDS105. Patients may 
have dramatic focal neurologic deficits, headaches, and seizures, including memory 
loss, confusion and lethargy.  The primary therapy is radiation therapy, followed by 
procarbazine, lomustine, and vincristine chemotherapy.  
?  Hodgkin's disease : 
 An atypical aggressive form of Hodgkin's disease probably occurs with 
greater frequency in patients with AIDS. Bleomycin, vincristine, etoposide, and 
streptozoicn achieved a complete response.  
?  Cervical and Anal cancers : 
 Cervical intraepithelial lesions associated with HPV infections more 
frequently among women with HIV infection106. There is evidence that 
homosexuality and receptive anal intercourse are important risk factors for anal 
rectal cancer. Associated between these tumor and HIV infection to be expected.  
?  Miscellaneous tumors : 
 Numerous case reports of malignancies occurring among HIV infected 
adults, most notably cancers of lungs, testes and skin. Smooth muscle tumors rarely 
occur in children107.  
PEDIATRIC HIV INFECTIONS : 
 HIV infection is often more accelerated in children and in some infants, 
symptoms can manifest during the first months of life, because many organ 
especially brain, yet not mature. Pediatric infection should be considered a family 
disease. World wide about 2.5 million children living with HIV/AIDS, 700000 
children are newly infected in 2003108. About 500 000 children's death due to AIDS 
in 2003. It's seventh leading course of death in children. Vertical transmission is 
main route, account 98% case pediatric infection. Transmission through blood 
product has become rare.  Heterosexual transmission (13-19 year) adolescent is 41% 
with HIV infection. AIDS in children the most current definition of AIDS is age 
dependent decline CD4 counts, and differentiate mild, moderate and severe degree 
of clinical symptoms. New classification system ranges from a stage with no clinical 
impairment (No) to one of severe clinical & immunological suppression (C3) Table. 
Table - VII  
Pediatric HIV classification  CDC 1994109 
Clinical Categories, Based on Signs & Symptoms  Immunologic Categories 
N (None) A (Mild) B (Moderate) C (Severe) 
1. No evidence of suppression N1 A1 B1 C1 
2. Moderate suppression N2 A2 B2 C2 
3. Sever suppression N3 A3 B3 C3 
Table - VIII  
New definition : Based on age specific CD4 counts CDC 1994109 
Age of Child Immunologic Category 
<12 months 
cells/mm3 
1-5 years 
cells/mm3 
6-12 years 
cells/mm3 
1. No evidence of suppression ≥ 1500 ≥ 1000 ≥ 500 
2. Evidence of moderate suppression 750-1499 500-599 200-499 
3. Sever Suppression < 750 < 500 < 200 
Category N  :  Not symptomatic : No sign & symptoms consider to be result of 
HIV infection or who have only one of the conditions listed in 
Category A. 
Category A  :  Mild symptomatic children with 2 or more of the condition listed 
: Lymphadenopathy Hepatomegali, Splenomegali, Dermatitis, 
Parotitis, Recurrent URTI, Sinusitis or otitis media. 
Category B  :  Moderately Symptomatic : Children who have symptomatic 
conditions other than A & C that are attributed to HIV infection. 
Anemia, Bacterial meningitis, pneumonia, candidisasis 
Cardiomyopathy, Diarrhea, Hepatitis, CMV infection, HSV 
Stomatitis, shingles, Leiomyosarcoma, LI, Nephropathy, 
Nocardiosis, persistent fever, Toxoplasmosis, Varicella. 
Category C  :  Severely Symptomatic :Children who have any condition listed in 
surveillance case definition including serious bacterial infections. 
Fungal infections, Viral infections, protozoal infections, Kaposi's 
sarcoma, Lymphomas, mycobacterial infections, wasting 
syndrome & pneumocystic carini pneumonia.  
Table - IX  
AIDS Case definition : For surveillance 1987 CDC. (up to 12 years of age)110 
1. Two positive tests for HIV infection (E/R/S) in children older than 18 
months or confirmed maternal HIV infection for children <18 months. 
2. Presence of at list two major and two minor signs in the absence of known 
causes of immunosuppression. 
Major Signs : 
 (a) Loss of weight 
 (b) Chronic diarrhoea > 1 month duration. 
 (c) Prolonged fever > 1 month duration. 
Minor Signs :  
 (a) Repeat common infections (pneumonitis, otitis, phargngitis)  
 (b) Generalised lymphadenopathy,  
 (c) Oropharyngeal candidiasis  
 (d) Persistent cough more than 1 month,  
 (e) Disseminated maculo popular dermatosis. 
 A Child older than 18 months of age can be diagnosed by ELISA, W. blot, 
IFA test, maternal antibodies measurable in the child for a median of 13.3 (10.4 to 
15.6) months. PCR & virus culture can identify 30 to 50% shortly after birth & 
100% by 3-6 months. Zodovudine approved for the use in children with 
symptomatic HIV infection. 
 
EPIDEMIOLOGY :- 
GLOBAL ASPECT :- 
 The epidemic of HIV infection and AIDS emerged in the last quarter of the 
20th century, and within two decades has affected over 190 countries111. HIV 
distribution is characterized by a marked heterogenecity among continents and 
countries or even within a single country, with geographic areas of HIV prevalence 
of up to 30% of the adult population contiguous with areas of much lower 
prevalence112. These differences are producing a checkered pattern of visible impact, 
with AIDS the leading cause of adult deaths in some population and HIV effects not 
yet detectable in others.  The study of trends in HIV spread has contributed to a 
better understanding of the dynamics and impact of the epidemic in various part of 
the world.  The data indicate the emergence of new epidemic foci shifts in 
transmission pattern in established epidemics and suggest that prevention efforts 
may be influencing the overall course of the pandemic. 
 The world health organization estimated that during 2000 some 5.3 million 
people became infected with HIV and about 3 million deaths from HIV/AIDS113.  It 
is a higher global total than in any year since the beginning of the epidemic.  Around 
half of the people who acquired HIV become infected before they turn 25 and 
typically die of the lifetime called AIDS before their 35th birthday.  This age factor 
makes AIDS uniquely threatening to children. The overwhelming majority of people 
with HIV, some 95% of the global total, live in the developing world.  They grew 
even further as infection rates continue to rise in countries where poverty, poor 
health system and list prevention and care fuel the spread of the virus. So it is clear 
that HIV will continue to be a global problem well in to the twenty first century. 
 The global AIDS epidemic shows no signs of abating 5 million people 
became indicated with HIV worldwide and 3 million died this year 2003114 alone the 
highest ever.  One in 5 adults across southern Africa are now living with HIV/AIDS, 
the higher rate since the beginning of the epidemic. While infection rate across Sub-
Saharan Africa very widely, from less than 1% in Mauritanina to almost 39% in 
Botswana an Swaziland, the breadth of the epidemic indicates that HIV/AIDS now 
has a firm hot on most countries in the region. 
 According to the new report, an estimated 40 (between 34 and 46) million 
people are living with HIV worldwide, including 2.5 (between 2.1 and 2.9) million 
children under the age of 15. Globally, an estimated 5 (4.2 - 5.8) million people were 
newly infected and 3 (2.5 - 3.5) million people died of AIDS in 2003114. Sub 
Saharan Africa the most severely affected region of the world, accounted for over  3 
million of these new infection and 2.3 million AIDS deaths. Everyday in 2003 an 
estimated 1400 people were newly infected with HIV.  More than 95% of those live 
in low and middle-income countries (Table - X).  
Table - X 
Global summary of the HIV /AIDS epidemic, December 2003 
Total 40 million (34-46 million) 
Adults 37 million (31-43 million) 
Number of people  
living with HIV / AIDS 
Children under 15 years 2.5 million (2.1-2.9 million 
Total 5 million (4.2-5.8 million) 
Adults 4.2 million (3.6-4.8 million) 
People newly infected  
with HIV in 2003 
Children under 15 years 700000 (590000-810000) 
Total 3 million (2.5-3.5 million) 
Adults 2.5 million (2.1-2.9 million) AIDS deaths in 2003 
Children under 15 years 500000 (40000-580000 
PATTERNS OF INFECTION AND TRANSMISSION : 
 The pandemic of HIV/AIDS reflects many coexisting subepidemics in 
different regions and populations. Many epidemiological, socio-demographic, 
behavioral, and biologic factors contribute to the differential spread of HIV. The 
character of each subepidemic remains determined largely by the extent to which 
people are exposed to HIV by one or more of the three primary modes of 
transmission : (a) sexual (vaginal, anal an oral); (b) parental, that is, by injection 
(including the sharing of drug insetting equipment), transfusion, or transplantation of 
HIV infected blood, blood components, tissues or organs, and (C) maternal infant, 
from a woman to her fetus or infant.  The vast majority of HIV infections in the 
world is transmitted sexually, most often through heterosexual intercourse.  Notable 
exceptions occur, particularly among certain populations in industrialized countries 
in North America, Europe, and the Pacific Basin, where transmission has occurred 
predominantly through male to male sexual contact and injecting drug use. The area 
characterized by these later transmission modes typically have had a predominance 
of HIV -1 subtype B, the other subtypes appear to predominate in most of the areas 
where heterosexual transmission prevails115.  
 Geographic distribution of recognised HIV-1 group M subtype are not well 
documented.  By 1995 the relatively small number of patients reported with group O 
infection had come primarily from central Africa, particularly Camroon116. 
 Many factors influence the risk of sexual transmission, including specific 
sexual practices, the presence of other sexually transmitted infections and the stage 
of HIV infection in the source partner.   
 Mother to infant transmission has become common in areas with high rates 
of HIV infection among women of childbearing age. In the absence of interventions, 
about one quarter to one third of infants born to HIV -1 infected women become 
infected, regardless of the subtype of HIV - 1 involved117. Most transmission occurs 
during pregnancy or at delivery, breastfeeding also has contributed to overall mother 
to child transmission, at least of HIV - 1118. 
 The transfusion of HIV infected blood, notably to children with malaria-
associated anemia accounted for up to 10% of new HIV infections earlier in the 
epidemic119. Although screening for HIV in transfused blood is generally available, 
the window period during which recent infection is not detectable as well as 
interruptions in the supply of HIV test kits and laboratory error continue to 
contribute to an HIV risk.  The transmission risk posed by clinical injections is 
difficult to quantify but is thought to account for some infections and has been 
associated with significant outbreaks120. 
 In relatively short time, the epidemic has evolved quickly and differently in 
various regions of the world.   
 
EPIDEMIOLOGY BY REGION :- 
?  Sub-Saharan Africa :- 
 Africa, the global epicenter, continues to dwarf the rest of the world on the 
AIDS balance sheet.  Since the start of the epidemic, 83% of all AIDS deaths so far 
have been in this region. At least 95% of all AIDS orphans have been African.  
While no country in Africa has escaped the virus, some are far more severely 
affected than others. The southern part of the African continent holds the majority of 
the world's hard hit countries. 
 As of end 2003, the WHO estimated that 25 to 28 million Adult and Children 
living with HIV/AIDS in sub Saharan Africa121; constituting 75% of the global total. 
Who also estimated that 3 to 3.4 million people are newly infected with HIV. East 
and Central Africa total 50% to 60% of the HIV infections that have occurred in 
sub-Saharan Africa, despite accounting for only about 15% of the total population of 
the region.  Epidemiologic evidence indicates that heterosexual intercourse is the 
predominant mode of transmission with little transmission recognised from male to 
male sexual exposure or injection drug use. HIV seroprevalence rate in pregnant 
mothers was found to be over 20% in majority of sentinel sites in this country. 
?  Western Europe, North America, Australia and New Zealand :- 
 In western Europe 520000-680000 million people living with HIV/AIDS, 
and 30,000-40,000 Adults and Children were newly infected with HIV and 2600-
3400 Adults and child deaths due to AIDS as of end 2003121. 
 In North America 790000 - 1.2 million people living with HIV/AIDS and 
36000-54000 people were newly infected in 2003121. 
 HIV-Infection spread rapidly in this region in the early 1980S primarily 
associated with male to male sexual exposure and injecting drug use, and 
subsequently by heterosexual transmission. 
 Australia & New Zealand estimated 12000-18000 people infected with 
HIV/AIDS and 700-1000 was newly infected in the year 2003121.  Infection with 
homosexual men predominantly affected.  
?  Latin America and The Caribbean :- 
 As of end 2003 WHO estimated 1.3 - 1.9 million people in latin America & 
350000-590000 people living with HIV/AIDS in caribbean. Prevalence in recent 
year 2003 in Latin America is 120000-18000 and 3.50000-590000 in caribbean121. 
Most infections in Latin America were initially among homosexual or bisexual men, 
now it has been increasing heterosexual transmission. In Arjentina the prevalence of 
HIV infection among IDUs from 30% to 50% and in Brazil from 20% - 60%122. In 
most of the Caribbean, heterosexual transmission has been the predominant mode of 
transmission. 
?  South and South - East Asia : 
 Although the extensive spread of HIV in south & south east. Asia began only 
in the mid 80's, the progression of the pandemic in this region has been rapid in 
several populations. WHO estimated that 4.6 - 8.2 million people living with 
HIV/AIDS and 610000-1.1 million adults & children newly infected in the year 
2003. The first epidemic in Thailand began with rapid increase in HIV-1 
seroprevalence among IDUs in Bangkok from 1% to about 40% by the end of 
1988123. The second wave of epidemic occurred primarily among female 
commercial sex workers in 1990. The median seroprevalence increased from 3 to 
9% with more than 60% infected in some group of prostitute in northern Thailand124. 
Commercial sex was major source of both homosexual and heterosexual 
transmission.  Studies in China have shown rapid heterosexual transmission. Studies 
in China have shown rapid spread of HIV-1 among injecting heroin users in Western 
Yunnan province, a region that shares a border with Myanmar (Barma)125. 
Myanmar, Vietnam, Cambodia and Indonesia show increasing HIV rates among 
commercial sex workers126. In Cambodia, the epidemic is spreading mainly through 
heterosexual contact, with prevalence among blood donors of 3.5%. In Vietnam 
predictably rapid increase in seroprevalence were observed among IDUs with more 
than tenfold increase from 2% to 30%, and there is concern that heterosexual 
transmission  of HIV will follow a pattern similar to that of Thailand. The extent of 
the epidemic is less clear in Bangladesh, Pakistan and Indonesia. 
?  East Asia and Pacific : 
 The WHO estimated that there were 700000-1.3 million people living with 
HIV/ADS and 150000-270000 people new infected in East Asia and Pacific region 
by end 2003121. A large proportion of the reported AIDS cases in Japan have been 
among persons with hemophilia who were transfused with HIV-infected blood 
products127.  There is diversity in transmission mode across the region, in Papua 
New Guinea more than 70% of those infected through heterosexual transmission. In 
Yunnan Provicne is an outbreak of HIV infection among IDUs. 
?  Eastern Europe and Central Asia : 
 The magnitude of the HIV problem in this region poorly defined. Most 
infection were attributed to heterosexual transmission in St. Petersburg & Russia. In 
Russia128 - Kalmykia outbreak in 1988 several hundred children infected through 
shared syringes Contaminated with HIV infected blood. In 1989 Romanian 
outbreak, in which several thousand children were involved transmission thorough 
transfusions of unscreened blood.  
 In some Eastern European countries injecting drug use is associated with 
very high rates of HIV infection. 
 In Warsaw, Poland found seroprevalence of 46% among IDUs129. Who 
estimate 1.2-1.8 million people are living with HIV/AIDS and 180000-280000 
people were newly infected in 2003121. 
?  North Africa and Middle East : 
 As of and 2003 the WHO estimated that about 43000-67000 people newly 
infected with HIV. And 470000-730000 people living with HIV/AIDS in the region.  
In morocco HIV prevalence among blood donors was 0.01% in 1993130. In 
Nouakchott, Mauritania the prevalence among blood donors was 4% 1992131. In 
Eritrea, indicated prevalence 25% among sex workers, 2.7% among blood donors 
and 3% among antenatal clinic attenders (Table - XI, Fig. 4). 
Table - XI 
Regional HIV / AIDS statistics and features, end of 2003 
 Adults and  
Children living  
with  
HIV/AIDS 
Adults and  
Children newly  
infected with HIV 
Adult  
prevalence 
rate (%)* 
Adult and  
child deaths  
due to AIDS 
Sub-Saharan Africa 25.0-28.2 million 3.0-3.4 million 7.5-8.5 2.2-2.4 million 
North Africa and 
Middle East 
470000-730000 43000-67000 0.2-0.4 35000-50000 
South and South-
East Asia 
4.6-8.2 million 610000-1.1 million 0.4-0.8 330000-590000 
East Asia and Pacific 700000-1.3 million 150000-270000 0.1-0.1 32000-58000 
Latin America 1.3-1.9 million 120000-180000 0.5-0.7 49000-70000 
Caribbean 350000-590000 45000-80000 1.9-3.1 30000-50000 
Eastern Europe and 
Central Asia 
1.2-1.8 million 180000-280000 0.5-0.9 23000-37000 
Western Europe 520000-680000 30000-40000 0.3-0.3 2600-3400 
North America 790000-1.2 million 36000-54000 0.5-0.7 12000-18000 
Australia and New 
Zealand 
12000-18000 700-1000 0.1-0.1 <100 
Total 40 million 
(34-46 million) 
5 million 
(4.2-5.8 million) 
1.1% 
(0.9-1.3) 
3 million 
(2.5-3.5 million) 
*The proportion of adults (15 to 49years of age) living with HIV/AIDS in 2003, using 
2003 population numbers. 
?  Epidemiology of HIV/AIDS in India :- 
 The presence of HIV was not noticed in Asia and India until the late 1980s, 
South East Asia has now become the epicenter of the HIV/AIDS pandemic. The 
onset of the HIV epidemic in India was heralded by the detection of an HIV-infected 
commercial sex worker and by a case of AIDS in Chennai and Mumbai, respectively 
in 1986. Several epidemiological studies conducted in India between 1986-1996 
established that hetero-sexual transmission was the dominant mode of transmission 
of HIV infection. Other modes included transmission through blood and blood 
products, through sharing of needles and syringes among intravenous drug users and 
from mother to baby.  Evidence suggesting the presence of parallel epidemics of 
both HIV-1 and HIV-2 came from a study conducted Mumbai in 1990. Subsequent 
studies among sexually transmitted disease clinic attenders in Mumbai have shown 
that HIV strains were distributed as HIV-1 in 80%, HIV-2 in 6.0% and dual 14% of 
infected persons with subtype C being the dominant HIV-1 strain among 
heterosexual in southern India. 
 There phases of the HIV epidemic have already unfolded in several parts of 
India.  Including Maharashtra, Tamil Nadu and Manipur. In the first phase, which 
took place during 1980s infection occurred among more venerable groups such as 
CSW and their clients, intravenous drug users, gaymen and single migrant workers. 
The second phase saw infection among population groups where cases of HIV 
infection could not be directly traced back to vulnerable group and occurred in the 
1990s. In the third phase, paediatric HIV infection has emerged as a result of 
substantial levels infection among women of childbearing age. 
 Within a geographic area, as one epidemic matures there is the likelihood of 
waves of subepidemics, with variations in infections rates among Vulnerable groups. 
Across the regions, there is also uneven distribution of HIV infection rate. Factors 
such as the presence of vulnerable groups, the size of these groups, links to other 
population groups and socio-cultural and sexual practices influence the occurrence 
of HIV infection in different populations. The associated epidemics due to 
tuberculosis and STD are likely to compound the impact of the HIV pandemic.  
 In India has a population of one billion. The spread of HIV in India has been 
diverse, with much or India having a low rate of infection and the epidemic being 
most extreme in the Southern State. 96% of the total number of nationally reported 
AIDS cases were found in 10 of 28 state and 7 Union Territories, the worst being 
Maharashtra in west, Tamil Nadu and Pondicherry in the south, and Manipur in the 
north east. In Maharashtra and Tamil Nadu the infections are mostly due to 
heterosexual contact, while infections are mainly found amongst injecting drug a 
users and their sexual partners in Manipur. 
 NACO estimate about 5 million people are living with HIV/AIDS infections. 
NACO estimate about 5 million people are living with HIV/AIDS infections, and 
62785 cumulative AIDS cases reported on Jan 2004132. 
?  AIDS in Gujarat : 
 In Gujarat, the first HIV positive case was reported in August - 1986. The 
number of AIDS cases being reported has been on the rise since 1991 and today 
there are 3596 cases in Gujarat, reported to NACO Jan. 31st 2004. Gujarat State 
AIDS Control Society (GSACS) was registered in 1999 and is responsible for the 
programme management for HIV prevention, surveillance and control. 
?  Global distribution of HIV-2 
 Since 1986, several West African Countries have reported significant rates of 
HIV-2 infections. The discovery of HIV-2 in East Africa prompted numerous 
serologic surveys to identify its geographic distributions. During the past decade, 
significant HIV-2 infection has been well documented in most West African 
countries. A second epidemiologic pattern of HIV-2 infection has been suggested 
from reports of HIV-2 in Portugal and in Mazambique, Angola, Southwestern India, 
and Brazil, low prevalence rates have been documented in other parts of Africa, 
Europe, the American, the middle East and Asia.  Guinea Bissau and Cape Verde 
both HIV-2 endemic regions. Aside these two exceptions HIV-2 has been virtually 
absent in Central & East Africa.  The rates of HIV-2 infection in Portugal and Spain 
are distinctly higher than other European countries.  
 In Portugal HIV-2 accounted for 10% of 12% HIV infections and 48% of 
HIV-2 infected persons had like with Angola. In the HIV-2 infected persons whom 
no link with Africa was established, presumed risk factors were transfusion of blood 
or blood products (74% of cases), heterosexual contact (21% of cases), IDUs (4% 
cases). France was one of the first countries to institute HIV - 2 testing of blood 
donors, and several HIV-2 cases were identified.  In North America, only sporadic 
cases of HIV-2 infection have been reported. Some HIV-2 infections were identified 
in Cuban soldiers returning from campaigns in Africa.  
 India : The rate of HIV-2 is significant in the Maharashtra State of India. Of 
the HIV-Positive samples from patients with STDs or other conditions in Bombay, 
4% were reactive to HIV-2 and 20% to both viruses. A later study men attending an 
STD clinic with a history of homosexual behavior reported a 4.8% rate of HIV-2 
infection and 3.2% of dual HIV infection. Goa, reported a 4.9% rate of HIV-2 
infection among STD patients.  
GENETIC DIVERSITY OF HIV : 
 Human Immunodeficiency virus is a primate retrovirus of the Lentivirinae 
sub family a group that shares the ability to infect their hosts chronically and 
progressively damage the host's immune system.  Genetic variation of HIV is 
extremely high, with rapid turnover of HIV virions, and infected persons maintain a 
substantial viral burden during the entire course of infection134. Related strains share 
genetic similarity, as expressed by the sequence of component nucleotides, and 
methods have been developed to infer the phylogenetic relationship between 
different strains. Two major viral types have been characterised in humans : HIV 
type -1, the predominant HIV type throughout the world, and HIV type - 2, first 
reported and still found primarily in persons from West Africa135.   
 Based on viral genetic sequences, HIV-1 isolates have been classified in to a 
number of subtypes alternatively termed clades or genotypes). This subtypes, 
designated by alphabetical letters, Constitute the major group of HIV-1, group M 
(10 subtypes A through K)136 and group O (g subtypes) and group N (New Virus). 
HIV-2 has also been classified in to at least five subtypes (A to E)137 (Fig. 5). 
 
 
 
 
 
 
 
 Most of the HIV-1 subtypes have been found in Sub-Saharan Africa. 
subtypes A, C, and D have bee found more frequently than others, although others 
have occasional isolates. In Thailand HIV-1 subtypes B was detected in IVDU's 
during the mid 80's. During the late 1980's subtype E was first detected. Mid 1990's 
subtype E had spread very rapidly among heterosexuals138. HIV-1 subtypes B never 
spread to cause a major heterosexual epidemic as did subtype E.  
 A similar situation occurred in India, with HIV-1 subtypes B and C. 
Although B apparently was introduced earlier and expanded among IVDU'S, this 
subtype did not appear to spread as rapidly among heterosexuals as did HIV-1 C. 
Previously associated with a massive heterosexual epidemic in southeastern Africa, 
subtypes C also caused a rapidly - spreading heterosexual epidemic in Western 
India, evidently originating from the Bombay region139.  The results in Africa and 
Asia suggest that HIV-1 subtypes A, C, D and E are well adapted for heterosexual 
transmission but subtype B is less efficiently transmitted by this route. Whenever 
HIV-1 moves very rapidly through a new population, as has happened in Asia for 
subtypes E and C, the viruses isolated show relatively less diversity.  
 An even more distant subtype, designated HIV-O, has been detected in 
Cameroon140. The viruses isolated from this subtype are less related to HIV-1 
subtypes. A through H than the other subtypes are related to each other, yet, HIV-O 
is more related to HIV-1 than to HIV-2141. To emphasize this distance, HIV-1 
subtypes A through H are designated the major group, and HIV-O is designated the 
out group. Although HIV-1 subtypes A through H probably entered independently 
from a chimpanzee host, and HIV-2s almost certainly entered independently from 
Mangabey monkey species West Africa.  Although some HIVS apparently entered 
human population independently from subhuman primate hosts, others presumably 
emerged as recombinants from within a single human host. HIV-1 subtype E is a 
recombinant with a gag and pol gene region from HIV-1 subtype A but a distinctly 
different envelope, presumably from a different human progenitor virus that has not 
yet been identified. Although rare, dual infections have been described with different 
clades of HIV-1 in the same human host.  Instances of dual infection with HIV-1 
and HIV-2, have also been described, although infection with one type appears to 
offer some protection against subsequent infection with another. 
 Simon F et al describing identification of a new group of HIV-1 designated 
from an isolate YBF 30 obtained from Cameroonia Woman suffering from AIDS. 
Her serum did not show anti HIV-1 antibody reactivity to specific HIV group M 
EIA but was reactive to the third generation EIAs and HIV-1 Western blot. They 
developed a V3 loop peptide enzyme immunoassay. The genomic studies revealed 
that YBF 30 structural genes are equidistant from HIV - 1 M and more distant from 
HIV - 1 O. So they suggested that this new group should be name as "N". N falls 
between M and O and also can imply that it is a new strain143. 
The Global dispersion patterns are : 
• Clade B predominants in united state, Haiti, and Western Europe, Clade B 
also predominants in Brazil, but clade F and C is not uncommon. 
• Eastern Europe have been other than B, including clades A,D,C,F and G. 
• Clades A and D predominate in most of Sub-Saharan Africa but in Central 
Africa Six other clade recovered.  
• Clade C predominates in Southern Africa, the Horn of Africa and in West 
Asia (Bombay). 
• Clade B predominates in most of East Asia. 
• Clade E predominates in Thailand. 
 The clear predominance of distinctive genotype i particular countries does 
permit some inferences about the global spread of HIV-1. The HIV-1 epidemics in 
Latin America, Europe, and East Asia may have originated in the United State145, 
because clade B predominates in all these regions. However, it is highly unlikely 
that the HIV-1 epidemics in India (C genotype) originated in the United States or 
Europe146. A more likely source is one of the C clade epidemics in Southern Africa.  
The E clade epidemic in Thailand and Southeast Asia may have originated in the 
equatorial Africa, where clade E viruses are also found.  
EPIDEMIOLOGY OF DISEASE PROGRESSION147 : 
 HIV disease is a continuum of progressive damage to the immune system 
from the time of infection to the manifestation of severe immunologic damage by 
opportunistic infections, neoplasms, wasting or low CD4 lymphocyte count that 
define AIDS. The time it takes to traverse this spectrum varies greatly, ranging from 
1 year or less in some persons to a still unknown upper limit in others that has 
reached nearly 20 years in a few individuals. The period from infection to 
development of AIDS is known as the incubation period.  The period from an AIDS 
diagnosis to death has been studied separately as AIDS survival time. The 
epidemiology of HIV disease progression has attempted to characterize the 
distribution of possible lengths of the incubation period and the AIDS survival 
period, to identify laboratory test useful for prognosis and treatment decisions, and 
to determine cofactors accelerate or retard the rate of disease progression. 
?  Incubation Period :- 
 The median incubation period from HIV infection until development of 
AIDS is estimated at approximately 10 years for young adults.  The estimate varies 
with the age at which infection occurs and is significantly shorter in infants and in 
older adults and varies even between infection at age 20 and infection at age 40. 
Whether the incubation period varies by mode of HIV acquisition has been more 
difficult to determine, but the preponderance of evidence now indicates that, after 
adjustment for age, the incubation period is similar in injecting drug users, those 
infected sexually, and hemophiliacs, whereas incubation time in transfusion 
recipients is shorter, probably because of the large HIV inoculums in infected blood 
transfusions. The incubation period does not appear to very significantly in men and 
women or in different racial groups. 
 Rates of progression to AIDS are very low in the first 2 years after infection 
and increase thereafter. Although patients infected by transfusion, especially infants, 
have developed AIDS in the first year after infection, progression to clinical AIDS 
in healthy adults is rare within 2 years of seroconversion. The progression rate 
increasing for the first 7 years, after which they level off or even drop slightly. 
?  AIDS Survival Time :- 
 The time from first diagnosis of AIDS to death has been characterized 
separately from the incubation time from infection to AIDS as AIDS survival time.  
Incubation time has been altered by the introduction antiviral therapies and 
prophylaxis for opportunistic infections, but AIDS survival time was affected earlier 
by treatments. AIDS survival time is a mean or median value of survival times 
among the large of disease diagnoses that define AIDS. Knowledge of median AIDS 
survival time may not be prognostic for survival in an individual patient. AIDS 
defining diagnoses have a wide range of average survival times. The median 
survival after a single AIDS - defining condition ranged from 3 to 51 months, its 
further broadened in lower CD4 count is on average nearly 2 yrs. The rate of long-
term survival after an initial AIDS diagnosis has been very low. Before 1986 
showed median survival time past initial AIDS diagnosis of 10 to 13 months. 
Overall median survival was 11 months. For patients with opportunistic infections, 
median survival was 9 months. Median survival after an initial Kaposis Sarcoma 
diagnosis was 16 months. 
 Age is a cofactor for shorter survival. Survival was significantly shorter 
among all patients over 40 yrs old.  
 Improved median AIDS survival time was observed in diverse geographic 
locations. Some early improvement in AIDS survival occurring early diagnosis & 
greater awareness of symptoms and increased use of HIV testing. It is also increased 
by anti retroviral therapy. The use of the combination therapy is having a significant 
effect in lengthening survival time.  
?  Laboratory Markers : 
 The length of the AIDS incubation period means that laboratory tests to 
identify persons at high risk of disease progression are needed to guide clinical 
decisions in asymptotic seropositive persons, such as when to begin antiviral therapy 
and prophylaxis against OI. Because depletion of CD4 + T lymphocyte is the 
hallmark and the apparent source of the central immune defect of HIV disease, 
determination of the CD4 lymphocyte count has been the most important laboratory 
marker of disease progression. Absolute CD4 lymphocyte count correlates strongly 
with AIDS - defining disease, has been included in the surveillance case definition 
of AIDS since 1993, and has been used to set indication for therapy. 
 Virus accurate measurement of the quantity of viral RNA in the peripheral 
blood has become as important laboratory marker as CD4 lymphocyte count and is 
now the primary marker for antiretroviral treatment decisions.  The concentration of 
HIV in peripheral blood is very high during the primary infection / seroconversion 
phase, but it stabilize shortly after seroconversion and changes relatively slowly 
thereafter. The result of these analyses has been to make HIV RNA blood levels the 
primary surrogate marker for the effectiveness of therapy in controlling HIV disease.
 In addition to the CD4 lymphocyte count and the quantity of HIV in 
peripheral blood, other laboratory test, primarily measures of generalized immune 
activation, have been shown to predict AIDS in asymptomatic HIV infected persons. 
Serum levels of β2 - microglobulin, serum and urine levels of neopterin, soluble 
CD8, Soluble interleukin - 2 receptor, interferon - α, and serum levels of IgA predict 
development of AIDS.  
?  Cofactors :- 
 Endogenous biologic or psychologic factors, other infections, behaviors, or 
other environmental factors that alter the natural history of HIV infection may be 
cofactors for disease progression.  Many potential cofactors for HIV have been 
investigated. They include genetic factors, age, gender, route of HIV infection, drug 
use, smoking, nutrition, and other infectious diseases. 
 Genetic differences in HLAs have been studied as potential cofactors. Age 
was identified as a cofactor for HIV progression.  The estimated effect of age on the 
risk of AIDS was 1.5 per every 10 years of age. Opportunistic disease that may 
occur in the course of increasing HIV immunosuppression are largely caused by 
infectious agents.   
 Whether the occurrence of disease from OI, either reactivated or newly 
acquired, is simply a marker of HIV mediated immunosuppression or whether these 
infections act, in turn, as cofactors changes host control of the infections agent, 
resulting in disease, and disease process in turn activates HIV. 
 Other cofactors are behaviors such as drug use, smoking and poor eating 
habits. Evaluating Psychological measures, such as depression, as cofactors has an 
analogous problem.   
 
LABORATORY DIAGNOSIS OF HIV INFECTION : 
 The HIV continues to spread around the world, causing nearly 1600 new 
infections a day, with infection rates rising rapidly in much of Asia. Laboratory 
diagnosis is the only method determining the HIV infection status of an individual 
during the long asymptotic period. 
COLLECTION & TRANSPORT OF SPECIMEN148 : 
 Almost all the laboratory procedures for HIV testing are performed on 
patients blood, serum or plasma, hence collect the blood aseptically. Allowed 
clotting for 30 min. and centrifuge of 3000 rpm for 10 minutes.  Preservative should 
not be added. If necessary 5 bromo, 5 nitro, 1-3 dioxane in propylene glycol at a 
final concentration of 0.05% is recommended. Sample are place in leak proof 
containers at 4° C for storage. Transport :  The specimen tube in which serum is to 
be transport, should have leak proof, plastic screw capped.  Disinfect outside area of 
container. Tube is labeled, place in second tightly capped unbreakable, labbeled 
container. This is placed in tharmocol box having ice packs. Performa with detail 
name, age, sex, risk factor, history of previous testing etc should accompany the 
specimen.  A biohazard symbol must be fixed outside the box. Transport of whole 
blood for virus isolation& CD4, CD8 studies : Same as above, transported in wet ice 
so as to reach the laboratory within 24 hrs. For virus isolation, if the specimen 
cannot be transported immediately after collection, it should be frozen (Fig. 6). 
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 HIV testing must always be undertaken after pre test counseling and 
informed consent. The confidentiality of the test result should be strictly maintained 
in most cases. 
PURPOSE OF HIV TESTING150 : 
1. Information is useful for prophylaxis, medical management and treatment. 
2. To assure blood safety and donation safety. 
3. To monitor trends of epidemic. 
4. Identification of asymptomaticv individuals. 
5. To plan personal and family's future if the result is positive. 
6. Counseling amongst those who test negative and who practice high-risk 
behaviors. 
7. To induce behavior change and prevent transmission by counseling in those 
who test positive. 
8. To diagnose clinically suspected cases. 
9. For peace of mind of individuals practising high risk behaviour. 
KINETICS OF HUMORAL IMMUNE RESPONSE : 
 An understanding of the sequence of events that follow the entry of virus into 
the body will help to understand the optimal usage of various HIV tests during 
different stages of HIV disease. Viral entry into the body leads to transient period of 
plasma viremia and p24 antigenaemia. However, the levels of these components 
comedown with concomitant immune response. Humoral response is evidenced by 
formation of antibodies of different classes against different structural proteins (gag : 
P 15, P17, P24 , P55; env : gp41, gp120, gp160 and pol : P31, P51 and P66), regulatory 
proteins (nef, rev, tat) and accessory proteins (vif, vpu). All structural components 
are strongly immunogenic and induce formation of antibodies, whereas 
immunogenicity of regulatory and accessory proteins is variable. 
 The antibodies appear in the blood within 2-8 weeks, after infection but 
usually become detectable after 3-12 wks with the assays available presently. This 
period following the entry of HIV in to the body and the appearance of detectable 
levels of antibodies with the available test kit is called the "Window Period". During 
this period the individual is infected, infectious and non-reactive with the antibody 
detection tests. The antibodies to gag protein (P24 & P55) are first to appear usually, 
though antibodies to env proteins and pol proteins may also be produced 
simultaneously. An infection progress to AIDS antibody to P24 usually declines as 
P24 antigen levels rise concomitant with progression of disease to AIDS. However, 
antibodies to env proteins persist throughout the infection (Fig. 7).  
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 Anti - HIV antibodies may be IgA, IgM, IgG. The IgA and IgM responses 
are inconsistent. IgG response is consistent and better understood.  IgM response 
appears earlier than IgG but the sensitivity of assays available to detect this class of 
immunoglobulins is low and also IgM is detectable for a short period. Detection of 
IgM is valuable for identifying early seroconversion particularly following needle 
stick injury. (2-11 days) and infection in newborn, IgA is the predominant 
immunoglobulin in seromucous secretions (Saliva, colostrum, genito urinary 
secretion etc). Since IgA does not cross placenta and therefore detection of anti HIV 
IgA by HIV - IgA assay in a newborn is diagnostic of congenital HIV infection. 
 The diagnosis of HIV infections can be made on the basis149 : 
1. Detection of specific antibodies to HIV. 
2. Detection of Viral antigens. 
3. Viral isolation and culture. 
1. DETECTION OF HIV SPECIFIC ANTIBODIES150 : 
 Detection of anti HIV Antibes is the mainstay of testing for HIV and 
diagnosis of HIV. Serological tests to detect specific HIV antibodies can be 
classified into :  
 (A) Screening tests (ELISA/EIA Rapid, Simple) 
 (B) Supplemental tests. 
(A) SCREENING / INITIAL TESTS : 
 Screening tests are performed to screen units of donated blood and blood 
products and for surveillance. Most common specimen is blood/serum/Plasma 
Screening assays are : 
(a) ELISA (2-3 hrs) 
(b) Rapid test : (minutes) 
 (i) Dot blot assays 
 (ii) Particle agglutination 
 (iii) HIV spot & comb test. 
 (iv) Flurometric microparticle technologies. 
(c) Simple : Based on ELISA principle (1/2 hrs.) 
(a) ELISA : 
 ELISA is the most commonly performed screening test. It is easy to perform, 
adaptable to large number of samples, is sensitive and specific and cost effective. 
 Different types of ELISA developed; First generation : used antigens derived 
from detergent disruption of viruses grown in human lymphocytes. Second 
generation : use artificially derived recombinant antigens expressed from bacteria or 
tungi. Third generation : use chemically synthesized oligopeptides of about 15-40 
amino acids (synthetic peptides). 
?  Principles of ELISA : 
 On the basis of the principle of ELISA can be divided into : Indirect, 
competitive, sand which, and capture assays. 
 All ELISA consist of either HIV antigen or antibody (depending upon the 
principle) attached on a solid phase and in corporate a conjugate and substrate 
detection system. Viral antigens may be whole virus lysate, recombinant or synthetic 
peptides. The matrix can be wells or strips of a microplate, plastic beads or 
nitrocellulose paper. Conjugates are most often antibodies (IgG sometimes IgM or 
IgA also) coupled to enzymes (alkaline phosphatase or horseradish peroxidase), 
fluorochromes or other reagents that will subsequently bring about a reaction that 
can be visualised. In case of enzyme conjugates the signal generated is a colour 
reaction and in case of fluorochrome it is fluorescence. The substrate used a 4-
nitrophenylphosphate for alkaline phosphatase and O-phynxylencdiamine 
dihydrochloride (OPD) and TMB for horseradish peroxidase, which produce colour 
on being acted upon by the respective enzymes and the colour can be either detected 
visually or measured on a ELISA reader as OD values. 
?  Indirect ELISA : 
 HIV antigens are attached covalently to the solid phase support allowing 
HIV antibodies present in the specimen to bind, and these bound antibodies are 
subsequently detected by enzyme labeled anti human immunoglobulin and specific 
substrate system. If the test specimen contained antibodies colour reaction will take 
place. Indirect ELISA is the most commonly used system.  The indirect ELISA 
produces a colour change directly proportional to the concentration of specific 
antibodies in the specimen. 
?  Competitive ELISA : 
 In this assay the HIV antibodies present in the specimen compete with the 
enzyme conjugated antibodies in the reagent for binding to the antigen on the solid 
phase. If the test specimen contains HIV antibodies, these will compete with the 
labeled antibodies in the reagent for binding to antigen.  So that less or no labeled 
antibodies can attach to the solid phase. Hence, faint or no colour is produced on 
addition of substrate if specimen contained HIV antibodies.  Here reduction and or 
absence of colour indicates the presence of HIV antibodies in the test specimen. 
Development of strong colour means specimen is non-reactive for HIV antibodies. 
?  Sandwich ELISA : 
 This is modification of indirect ELISA to improve sensitivity and specificity 
of the test. Antigen bound to the solid phase binds antibody in the test specimen in 
first step.  Since antibody molecules are bivalent they are still able to bind to another 
molecule. The next step is addition of similar enzyme labeled HIV antigen ie. Same 
antigen as on solid phase. This will attach to the antibody molecule which is already 
bound to the solid phase antigen with one arm. Thus forms a sandwich of antigen + 
antibody + enzyme labeled antigen complex. The next step is addition of specific 
substrate which result in development of colour which is measured by ELISA reader 
one big advantage of sandwich ELISA is that all classes of HIV antibodies can be 
detected. There is also antibody sandwich ELISA which is done to defect P24 
antigen.  
?  Antigen - antibody capture ELISA : 
 Antigen capture ELISA can be based on principle of indirect or competitive 
ELISA, only difference being in the initial step of attaching antigen to the solid 
phase. A monoclonal antibody directed against an HIV antigen is bound to the solid 
support. Than addition of HIV antigen supplied as reagent. This antigen is captured 
by the monoclonal antibody bound to the solid phase. Test specimen appropriately 
diluted is added next HIV antibody if present in the specimen bind to HIV antigen 
on solid support. Remaining principle is same as indirect ELISA. Only advantage of 
antigen capture ELISA is that it is more specific than indirect assay. 
 Anti body capture assays were developed to test specimens with low 
concentration of HIV antibodies or to detect specific class of antibodies (eg. IgG, 
IgM, or IgA.) In this test an antihuman immunoglobulin (IgG, IgM or IgA) is 
attached to solid support. The patient specimen is added. The concentrated 
immunoglobulin in patients specimen binds to the antiglobulins on solid phase. Next 
labeled antigen is added which bind to HIV antibodies of the patient bound to solid 
support. Next, the substrate is added and the OD value is read on the ELISA reader. 
(b) RAPID ASSAYS : 
 A number of rapid assays based on principle of agglutination and ELISA 
have been developed for ease of performance and quick results.  These assays 
generally require less than 30 minutes to perform and do not require special 
equipment's.  
?  Agglutination assays : 
 Agglutination assays incorporate a variety of antigen coated carriers like red 
cells, latex particles, gelatin particles and microbeads. These particles are used to 
support or carry the antigen. HIV antigens are attached to the carrier particles by non 
specific attachment. Agglutination assays have good sensitivity. However, 
specificity is somewhat compromised and prozone reaction may be seen. To 
overcome the prozone reaction, diluted specimen is used to perform the test. During 
the agglutination reaction HIV antibody combines with HIV antigen on the carrier 
particles and since all antibodies are multivalent, a sort of lacttice network is formed 
which can be visualised macroscopically or microscopically.  
?  Dot blot assay/Comb test : 
 These assays are rapid, easy to perform, can usually discriminate between 
HIV-1 and HIV-2. The results are read by development of colour. Sensitivity and 
specificity of these assays compares with ELISA. The assays utilize recombinant or 
synthetic peptides spotted on to nitrocellulose paper/micro particles. The antigen 
containing matrix is housed in a plastic device containing adsorbent pads underneath 
to collect reactants or made as a comb and the antigens are spotted onto the tooth of 
the comb card. Each assay contains an immunoglobulin capture control to validate 
the result. These assays are very good for single test application i.e. in emergency, 
autopsy room and peripheral blood banks. Immunocomb test is similar to blot assay 
based on principle of indirect ELISA.  
?  HIV antibody detection in other fluids : 
 The standard specimens for detection of HIV antibodies are 
serum/plasma/blood. However, detecting HIV antibodies can be detected in oral 
fluids (saliva/oral mucosal transudates).  The levels are less than 1% of the levels in 
serum, but can be detected by sensitive ELISA technology.  The isotype of antibody 
detected is secretary IgA, So appropriate ELISA should be used. HIV antibodies can 
also be detected in urine by ELISA. 
(c) SIMPLE TESTS are also based on eia principle but take a little longer time       
(> 1/2 hr) compared to rapid tests. 
 
(B) SUPPLEMENTAL/CONFIRMATORY ASSAYS : 
 Supplemental tests are performed on serum sample reactive in screening test 
for the purpose of diagnosis and identification of the individual. When a serum 
specimen is reactive by any one of the screening tests it has to be tested again by a 
different system using different HIV antigens or different principle of test to confirm 
the diagnosis. If a specimen is reactive in 2 different systems it has to be tested again 
using one of the supplemental tests which may be a third ELISA/Rapid/Simple test 
or a western Blot test as the case may be. A healthy individual reactive in three 
different system of testing is confirmed to be having HIV infection. 
 Supplemental assays are sensitive as well as specific and are performed to 
rule out false positive reactions. Supplemental E/R/S using different antigen and / or 
principle of test are performed to fulfil the strategy II and III of HIV testing policy.  
 Various supplemental assays are : ELISA with different antigen system 
(recombinant or synthetic peptides) or with different principle of fest which makes 
the test more specific. Western blot (WB), Immunoblot (IB), Line immunoassay, 
Indirect fluorescent antibody test (IFA), and Radioimmunoprecipitation Test 
(RIPA). 
?  E/R/S test as supplemental assays : 
 Supplemental E/R/S are recommended for specimen reactive in the screening 
assay for strategy II & III of HIV testing policy. If the screening assay contained 
virus lysate as antigen the second and third assays should have recombination or 
synthetic peptides as antigens. Use of recombinant and synthetic peptides makes the 
assay more specific while retaining the sensitivity. Alternatively the second and 
third assays can also be based on different principle of ELISA, again done to 
increase the specificity of the screening assay when used as supplemental assays. 
?  Western blot151 : 
 The WB was developed as a method for separating proteins obtained from 
HIV harvested from cell lysates and there by analysing sera for antibody content to 
these specific proteins. HIV is allowed to replicate in continuous lymphoid cell lines 
usually HUT - 78 H-9 cells. Cells are lysed to release viral and Precursor protein 
yields. Virus is then partially purified by centrifugation. The viral protein is than 
placed in the multiple, small aliquotes at the top of a thin slab like polyacrylamide 
gel and electrophoresed from the negative to positive electrodes. When complete, 
the lower molecular weight proteins migrate for in the gel and the higher molecular 
weight. Proteins remain near the origin. The proteins are then blotted to a 
nitrocellulose paper electrophoretically by applying a current across the thin slab of 
gel and nitrocellulose paper.  The paper is dried and cut into the strip of 5 mm width. 
The strips are subsequently exposed to dilutions of patient serum washed and 
incubated with antihuman IgG labeled with an enzyme that produce a colored band 
upon exposure to its substrate. 
?  Indirect immunofluorescence assay : 
 This is a rapid and reliable test using uninfected and HIV infected H-9 (or 
HUT - 78) cells in the long phase. The cells are air dried and fixed to a fluorescent 
glass microscope slide. A small quantity of a 1:10 - 1:20 test serum dilution is 
applied to each well, incubated to allow antibody to react with antigen. Then 
washed, and air dried. Then antihuman IgG labeled with fluorescein isothioacyanate 
is applied to each well, followed by incubation, washing, drying and mounting. Then 
specimens are evaluated for fluorescence intensity, percentage of fluorescent cells 
and fluorescent pattern. IFA can be used for differentiate HIV-1 from HIV-2. 
?  Radioimmunoprecipitation assay : 
 RIPA is infrequently used as a confirmatory / supplemental test because it 
involves a rigorous procedure, requiring the use of radio activity labeled antigens 
and facilities to propagate/culture HIV in continuous cell lines. HIV infected 
lymphocytes are grown in the presence of radio labeled amino acids to permit their 
incorporation into HIV proteins. Soluble viral lysates prepared are reacted with the 
test serum and the mixture is then incubated with protein. A coated sephedex beads. 
The antigen antibody complex is eluted, subjected to gel electrophoresis and the gel 
exposed to auto-radiography. 
?  Line immunoassays : 
 LIA is a variant of the WB test in which optimal concentrations of 
recombinant proteins or synthetic peptides are applied in a band pattern on plastic 
backed nitrocellulose strips. Antigens from HIV-1 and HIV-2 can be added to use as 
a combination assay. LIA makes reading and interpretation of results easier and 
minimises the problem of indeterminate results seen with conventional WB test that 
use viral lysates as antigens. 
 
 
2. DETECTION OF VIRAL ANTIGENS : 
 Persons infected with HIV, particularly early in the course of infection 
detection of viral antigens may be useful. 
(i) P24 Antigen detection : 
 P24 antigen detection was earlier used for prognostic staging and 
management of the infected individual. In USA P24 antigen testing has recently been 
added into the routine blood donor screening for HIV infections, in an attempt to 
reduce the diagnostic Window period. Test or control sera are allowed to react with 
P24 antibody to a micro well. After incubation and washing, goat anti HIV P24 
antibody is added and will bind to the P24 antigen captured on the solid phase. 
Washing is followed by the addition of an enzyme labeled anti goat immunoglobulin 
and the appropriate substrate to produce a calorimetric reaction which is measured 
spectrophotometrically. By using a positive control with a know concentration P24 
antigen a standard curve of OD viruses concentration is generated to quantitative the 
P24 antigen present in test sera. 
(ii) Polymerize chain reaction152 : 
 The method of PCR was first descried in 1985 by scientist at Centre 
Corporation. The principle of PCR is based on a three step cycling process at 
different temperature. Step one is the separation or denaturations of the double 
stranded DNA sample at 95c. If an RNA sequence is to be amplified, it is first 
necessary to convert the RNA sequence into DNA using reverse transcripts. Step 
two is the annealing of two primers to complementary strands of the dissociated 
DNA at a lower temperature (40 to 50c). Each primer usually consist of synthetic 
single strand of DNA (20 to 40 nucleotides in length) and is complementary to the 
positive or negative strands flanking the sequence of interest to be amplified, the 
associated original DNA strands are more likely to anneal to the primers instead to 
each other due to their relatively low concentrations and the excess of primer 
sequences. Step three is called primer extension and involves DNA plymarase 
mediate incorporation of nucleotides complementary to the unpaired or template 
DNA strand to the 3' end of the primer. The PCR is infect to sensitive that it has 
been possible to detect a single cell containing the target B-globin gene. 
(iii) bDNA assay : 
 Discussed after words. 
3. VIRAL ISOLATION AND CULTURE : 
 HIV may be isolated from the blood and other body fluids. Isolation of HIV 
is a specialized procedure requiring sterile facilities. HIV isolation has therefore 
remained mostly for research. HIV is isolated from the peripheral blood 
mononuclear cells (PBMC) or plasma and other body fluids. The activated CD4 + 
Cells are susceptible for HIV infection. Hence autologous or heterologous PBMCs 
activated with mitogen phytohaemagglutinin (PHA) are cultured with the infection 
material. The cultures are maintained at 37c in 5% Co2 atmosphere for up to 28 
days. The cultures are fed with fresh activated PBMCs at regular intervals. The 
presence of virus in the culture supernatant is detected either by demonstration of the 
presence of P24 antigen of enzyme reverse transcripts. The infected cells may also 
demonstrate syncitia in culture. Virus infected cells may also be detected by HIV-
Specific immunofluorescent assay. 
 Two methods normally used for virus isolation are direct method or co-
culture method. In the direct method, PBMCs from the patient are cultured in vitro 
in presence of PHA. In the co-culture method PBMCs from heterologous HIV 
uninfected donor are stimulated with PHA, and after 48-72 hours the stimulated cells 
are cultured along with the PBMCs from the patient (Fig. 8).  
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STRATEGIES OF HIV TESTING IN INDIA : 
 Because of the enormous risk involved in transmission of HIV through 
blood, safety of blood and blood products is paramount importance. Since the 
positive predictive value (PPV) is low in populations with low HIV prevalence, 
WHO/GOI have evolved strategies to detect HIV infection in different population 
groups and fulfill different objectives. The various strategies, so designated, involve 
the use categories of tests in various permutations and combinations. 
1. ELISA/Simple/Rapid test (E/R/S) used in strategy I, II, III. 
2. Supplemental test like WB and LIA are used in problem cases eg. in case of 
interment/discordant result of E/R/S. 
UNAIDS and WHO recommendation for HIV testing strategies according to test 
objective & prevalence of infection in the sample population. 
Objective of Testing Prevalence of infection Testing strategy 
Transfusion / transplant 
safety 
All Prevalence I 
Surveillance > 10% 
 ≤ 10% 
I 
II 
Diagnosis : 
Clinical sings/symptoms  
of HIV infection 
> 30% 
≤ 30% 
I 
II 
Asymptomatic > 10% 
≤ 10% 
II 
III 
Strategy I : 
 Serum is subjected once to E/R/S for HIV. If negative, the serum is to be 
considered free for HIV and if positive, the sample is taken as HIV infected for all 
practical purposes. This strategy is used for ensuring donation safety (blood, blood 
products organ, tissues, sperms etc.). This unit of blood testing reactive (Positive) is 
discarded. Donor is not informed.  
Strategy II :  
 A serum sample is considered negative for HIV if the first ELISA report is 
so, but if reactive, it is subjected to a second ELISA which utilized a system 
different from the first one. It is reported reactive only if the second ELISA confirms 
the report of the first. This strategy is used for surveillance and for diagnosis only if 
some AIDS indicator diseases is present. 
Strategy III : 
 It is similar to strategy II, with the added confirmation of a third reactive 
ELISA test being required for a sample to be reported HIV positive. The test to be 
utilized for the first ELISA is one with the highest sensitivity and for the second and 
third ELISA, tests with the highest specificity are to be used. Strategy II & III are to 
be used for diagnosis of HIV infection. ELISA 2 and ELISA 3 ought to be tests with 
the highest PPV possible to eliminate any chance of false positive results. Strategy II 
is used to diagnose HIV infection in asymptomatic individuals including in high risk 
behaviour. 
DIRECT EVIDENCE OF HIV INFECTION153 : 
 The diagnosis of infectious diseases can be made with certainty by the direct 
demonstration of the Presence of infecting organisms in the clinical specimen 
collected from the patients. While isolation of the infecting organisms is possible in 
many infectious disease, the diagnosis may also be made by detection of nuclear 
material or antigens specific for the infecting organisms in the clinical specimens. 
HIV infection is diagnosed by the presence of anti HIV antibodies in the blood. 
However there are situations where the serology is negative although there is 
definitive evidence of exposure to HIV as seen in patients who are in the window 
period and in health care workers following accidental exposure to contaminated 
bold etc. Also children born to HIV infected mothers present dilemma as antibody 
positively seen in the infants upto 18 months, may be due to maternal antibodies in 
circulation. The diagnosis in these situation may be made by : 
• Detection of P24 antigen 
• Detection of HIV-Specific DNA by PCR. 
• Isolation of HIV. 
  (All ready discussed before) 
• Hetroduplex Mobility Assay (HMA) : HIV-1 specific DNA PCR may also 
used to in Heteroduplex Mobility Assay for determining to which subtype 
the infecting virus belongs.  
LABORATORY DIAGNOSIS OF HIV INFECTION IN NEWBORN : 
 Transplacental transmission of HIV can occur from infected pregnant mother 
to the foetus as early as 8 weeks of gestation or may be even earlier. Diagnosis of 
HIV infection in infants born to seropositive mothers is difficult because maternal 
antibody (IgG) to HIV crosses the placenta and can persist for upto 15 months 
making the distinction between maternal and neonatal IgG difficult. The test which 
can be undertaken to diagnose HIV infection in neonates before 15 months of age 
are : 
?  Detection of IgA and / or IgM anti HIV antibodies : 
 These antibodies do not cross placenta. The IgA class of HIV antibody assay 
using W.B. technique in infected children at 3 months of age. IgM class of 
antibodies are produced by infected infants by 6 months of age.  Production of IgM 
is erratic, false positive results are obtained due to rheumatoid factor and polyvalent 
nature of IgM leading to nonspecific binding. 
?  Estimation of P24 antigen : 
 The immune complex dissociation assay which involve pretreatment of 
serum / plasma to librate P24 antigen complexed with P24 antibody prior to 
performance of ELISA are quite sensitive in identifying HIV infected infants.  
?  PCR : 
 The technique specifically amplifies viral DNA sequences of interest. It is 
possible to identify one infected cell in the specimen as also latent HIV infections. 
Various reports indicate the specificity of PCR to be invariably > 95% regardless of 
age of testing while sensitivity range from 15% in neonates (within 48 hrs. after 
birth) to more than 95% in infants over 1 months of age. 
?  In-vitro antibody production assay : 
 The method is tedious and involves in vitro culture of antibody producing β 
lymphocytes from peripheral blood. The HIV antibodies are detected in culture 
suppurate from truly infected infants. 
?  In-Vitro isolation of Virus : (blood, tissues) 
 The method is time consuming, expensive and not sensitive. This is due to 
the lower number of available cells cultured and paucity of infected cells in the 
sample that are present. Additionally, it may take upto 6 weeks or longer to obtain a 
result. 
?  Indirect indicators of HIV infection154 : 
 This includes various non specific markers like hypergamaglobubulinemia, 
absolute lymphopenia, hematologic abnormalities, low CD4 count and clinical 
markers like wasting syndrome, recurrent bacterial infections, Opp. infections, 
malignancies, Pneumonia etc. Which point towards AIDS. However, these 
parameters are employed to supplement the conventional serodiagnosis of HIV 
infection.  
LABORATORY TEST FOR MONITORING STAGE AND PROGRESSION 
OF HIV INFECTION : 
 Infection with HIV may develop to AIDS at different rates in different 
individuals, with a spectrum varying from rapid progression to long term non 
progression. This variability marks it essential to have test which can accurately 
assess the stage of infection in an individual, as well as predict its course and 
monitor its progression.  These test are very valuable during the period of clinical 
latency and subsequently, supplement various clinical parameters, which are also 
extremely important in categorizing the infection / disease stage. Response to anti-
retroviral therapy is also monitored using this prognostic test. The tests are classified 
into : 
(A) Viral markers  : Plasma HIV RNA load. 
   Viral antigenaemia eg. P24 antigen. 
(B) Surrogate markers  : Virus specific markers. 
(C) Non Specific markers  :  Cellular markers. 
   Soluble markers of immune activation. 
(A) VIRAL MARKERS :  
(a)  Plasma HIV RNA load : 
 Plasma viral load (HIV RNA) Quantification is presently considered the best 
method for monitoring progression and response the best method for monitoring 
progression and response to anti-retroviral therapy.  Active replication of virus 
occurs in all clinical stages of infection. It is possible to detect and quantify virus 
throughout the course of HIV infection. The viral load usually ranges between 102 
and 107 HIV RNA copies/ml in untreated individuals though it may be lower in 
those on treatment. The techniques available for quantifying viral RNA are : (i) 
Quantitative RNA - PCR, (ii) b DNA assay, (iii) Nucleic acid sequence based 
amplification. 
(i) Quantitative RNA PCR : 
 This test is based on parallel amplification of HIV RNA (142 bp sequence 
from gag gene) from the sample and a known amount of quantitation standard (QS) 
RNA,  using RT-PCR with the same set of biotin-labeled primers to give different 
products (amplicons). These are detected in separate well of a micro well plate by 
hybridization with immobilized HIV and QS specific probs. The bound biotinylated 
amplicon is quantified colorimetrically by measuring the optical density (OD), 
obtained by using avian hose radish peroxidase (HRP) conjugate and an appropriate 
substrate. The HIV RNA copy number can be then calculated by extrapolating from 
the known input number of copies of QS RNA.  To cover a while range of HIV 
RNA copies possible in plasma of infected persons, a number of dilutions are put up. 
(ii) Branched DNA assay : 
 The DNA assay is based on amplification of the signal instead of the target. 
A target probe complementary to both the target sequence and the capture probe 
hybridizes with both of these. Another sequence on the target probe then hybridizes 
with an "amplifier" branched DNA. An enzyme labeled probe, which can bind to the 
multiple branches of the amplifier branched DNA, is allowed to hybridize with it.  
This amplified label is detected by a luminometer and quantified by its action on a 
chemiluminiscent substrate. The quantity of the target in the sample can be 
determind from this. 
(iii) Nucleic acid sequence based amplification : NASBA. 
 This technique uses 3 enzymes reverse transcriptase, RANASE H & T7 
RNA polymerase at a single temperature (37c), to generate multiple copies of the 
target HIV RNA, by a strategy similar to that used by retroviruses for their 
replication. RT enzyme and a primer designed with the T7 RNA polymerase 
promoter sequence at one end, are utilized for synthesis of an RNA - CDNA hybrid 
containing the T7 promoter from the target. From this, the original RNA target 
strand is removed by addition of RNAse H and dsDNA is generated by the DNA 
polymerase activity of RT and a second primer. Multiple copies of RNA are then 
generated by T7 RNA polymerase enzyme. This RNA enters another similar cycle 
and the amount of RNA multiplies expotentially with each cycle. 
 Present status of HIV RNA load - are more than 10 fold lower in long-term 
non-progressors than in individuals with progressive disease. A viral load of > 
100,000 copy equivalents/ml by bDNA assay, within 6 months of seroconversion 
increases the risk of progression to AIDS within 5 years by more than 10 fold.  
Persistently detectable viremia & high baseline levels carry a poor prognosis, while 
risk of progression is low at copy numbers < 10,000/ml. Apart from being an 
extremely useful predictor of progression, viral load responds very well to anti 
retroviral therapy & can be used to monitor it. 
(b) Viral antigenaemia - P24 : 
 Already discussed before. 
(B) SURROGATE MARKERS : 
?  Virus specific markers : 
 A viral characteristic associated with progression is the conversion of strains 
from non-syncytium inducing (NSI) phenotype to a syncytium inducing (SI) 
phenotype. This change of character has now been associated with the ability to 
infect cells with certain chemokine coreceptors. HIV specific antibodies have also 
been used as markers of progression, though they are not considered particularly 
sensitive. Decline in or absence of antibodies to various HIV antigens including P24+, 
P17, gp120, gp41 and nef gene product have been used as surrogate markers in the past. 
(C) NON SPECIFIC MARKERS :  
(a)  Cellular markers :  
 A number of non HIV - Specific cellular markers have been used for staging, 
monitoring progression and assessing response to therapy. One of the most useful is 
the absolute CD4 + lymphocytes in the blood. Other lymphocyte phenotypic 
markers associated with progression include an in crease in indicators of immune 
activation on T lymphocytes like CD38, HLA - DR, IL - 2R, CD45RO and markers 
of apoptosis.  
CD4 count : 
 The most commonly used cellular marker is the CD4 lymphocyte count. Its 
decline is the hallmark of HIV infection and the rate of loss in each person is unique. 
CD4 cell number changes during HIV infection in the following stages : 
• Rapid diction for 6-18 months at the time of seroconversion. 
• Plateau of gradual decline that can last at least several years during the 
asymptomatic period. 
• Sleeper decline for several months just be for AIDS develops. 
• Continued CD4 cell decline until death. 
 CD4 cells count is doing by flow cytometry, microsphere assay and by 
Enzyme immunoassay (EIA). 
(b) Soluble markers : 
 A large number of soluble markers of immune activation have been 
evaluated as prognostic indicators in HIV infection. 
(i) Neopterin : 
 Neopterin (6-D-erythro-trihydroxy propylpterin) is a product of guanosine 
triphosphate catabolism which is derived from macrophages and B cells stimulated 
by interferon gamma and reflects its activity, while being stabler. Neopterin is 
present in both urine and serum.  Urine and serum neopterin levels are elevated in 
patients with asymptomatic HIV infection as compared to seronegative individuals. 
It is an early marker of HIV infection. The levels rise further on progression from 
pre-AIDS to clinical AIDS. Since neopterin levels are stimulated by HIV infection, 
measurement of neopterin level can be useful in monitoring progression and 
evaluating antiviral therapy. However, since it is a non specific marker, besides HIV 
infection, high neopterin levels in urine and serum may be found in numerous 
infections and inflammatory disorders, collagen vascular diseases and in advance 
stage of certain malignancies. 
 The tests are based on competitive ELISA.  The plates are coated with 
polyclonal anti-neopterin antibody raised in animals eg. Sheep/rabbit. The neopterin 
in the test sample competes with enzyme (alkaline phosphatase or peroxidase) 
conjugated neopterin. The enzyme conjugate is detected by addition of the substrate 
and a lower OD corresponds to a higher level of neopterin in the sample. 
(ii) Beta - 2 microglobulin : 
 It is a nonspecific but relatively sensitive marker for immune activation.  
Elevated levels are also seen in certain HIV high risk groups such as haemophiliacs 
and drug abusers. High serum beta 2 m levels especially during the first year after 
seroconversion to HIV positively, were associated with progression to AIDS. Its 
measurement may be useful in evaluating anti-viral therapy. 
 Beta - 2 microglobulin is present in most biologic fluids at low concentration 
and can be measured in serum or plasma by using ELISA test. Other soluble 
receptors TNF and IL -2 are also present in kits.  
Alternatives to classic tests : 
 As technology evolves alternative to the classics tests and  testing arise. Each 
offers one or more attractive features that may simplify collection, testing or 
interpretation of results. 
Saliva tests : 
 Non envasively collected specimens, such as oral fluids (saliva), have been 
used for HIV testing as an alternative to blood samples. These fluid, containing 
crevicular fluid from capillaries beneath the tooth-gum margin, are transudates of 
blood, therefore, they include the same fluid (plasma) that is used for serum base 
testing. The concentration of antibodies in oral fluid is about 1/400 of that is plasma; 
however because of the dilutional effect of fluids from the salivary glands and fluid 
testing necessitates extremely sensitive tests that are able to detect small quantities 
of antibodies the testing technology to detect these low quantities is now availables 
is oral fluid test both ELISA and rapid tests are accurate. 
 As of 1998 USA FDA has approved ELISA and W.B. specifically for testing 
oral fluid. The use of oral fluids for testing offers advantages, such as ease of 
collection, group collection, collection from persons in whom blood is difficult to 
obtain and an increase in collection compliance. 
Urine test : 
 Intact IgG antibodies are found in urine, but their exact origin is unknown. 
Urine collection is simple, noninvasive and inexpensive and the sample can be 
stored at RT for extended period of time. The use of urine for testing is appropriate 
for physicians officers, health clinics and developing countries where health care 
personnel may not be professionally trained or where clean needles for drawing 
blood may not always be available. Recently FDA approved ELISA and WB for use 
to test urine for antibodies to HIV. 
Home collection testing : 
 Recently, home collection, but not home testing, has been approved by the 
FDA for HIV. These collection devices are filter paper for the collection of whole 
blood via fingerstick. The samples are mailed to a lab. eluted, and used for ELISA 
testing. Result and Cons. are made available by telephone. 
QUALITY ASSURANCE PROGRAMME156 : 
 The diagnostic test to dated antibodies to HIV have sensitivity and specificity 
which are not absolute. In all these tests we have false negative or false positive 
results, which are inherent and cannot be avoided. The percentage of false positive 
results will increase as the prevalence rate of person with HIV antibodies in a 
population decreases. So consistent production of reliable results requires a stringent 
overall assurance programme, which would control technical conditions before, 
during and after each assay.  The quality Assurance Programme ensures that the 
results reported by the laboratory are correct, reliable and accurate as far as possible. 
It also ensures use of the most reliable tests for the dianosis of HIV infection.  
Guidelines to improve quality of testing : 
(i) Condition of specimen : All specimens must be suitable. Use of lipaemic, 
haemolysed and contaminated sera should be avoided. All samples include 
information like name, date, identification number, test request form which 
include Age / Sex, physician name, risk group, reason, route. Anonymous 
testing only code number and date mentioned.  The sample serum/plasma to 
be tested should be at 37c & well-mixed before testing.  Presently all the test 
kits distributed by the NACO, are sent for testing serum or plasma only.  
Therefore, these kits may not be reliably detect presence of antibodies in 
other body fluids.  
(ii) Controls used in the tests : Each test run requires a set of controls to 
validate the results. Controls must be treated in the same manner as unknown 
samples. The assay is valid and the results are reliable when the controls 
produce acceptable results.  
 (a) Internal Control : The controls (positive & negative) are included in 
each test kit, and to be included in each test run.  These are essential 
for quality control measures. 
 (b) External Control : These should be included with each test-run to 
monitor consistent performance and lot to lot variation which can not 
be detected using internal control. These controls are made from 
pooled test kit controls or made from pooled sera from HIV positive 
or negative individuals in each laboratory. 
 (c) Standardization of Controls : Reproductibility and quality of internal 
& external controls must be standardized by intra run reproducibility 
and inter run reproducibility. The control samples (Internal or 
external) are tested at least three times on the same test run. This will 
indicate intra run reproducibility. This exercise is then carried out on 
test runs on three consecutive days to determine inter run 
reproducibility.  These samples may also be evaluate at the National 
Reference Centers. 
(iii) Accuracy of EIA : Since no assay can be 100% sensitive & specific, it is 
likely to give false negative as well as false positive results. 
?  Any EIA may false negative : 
(1) during early stage of HIV infection. Generally 2-24 weeks also as 
long as 42 months. 
(2) On late stage disease. 
(3) Technical error. 
?  The EIA may false positive :  
(1) Certain condition increase false positively rates of ELISA, Auto 
immune diseases, multiple preganancies, multiple transfusions, hyper 
a gammaglobulinaemia, chronic alcoholics, Hepatitis B immunisation 
& antipolystyrene antibodies.  
(2) Technical error  
(3) Human error. 
(iv) Reporting : All test results must be kept  confidential and should never be 
discussed in public, & followed by pretest and post test counseling.  
Proficiency testing of Laboratory : 
 Proficiency testing is synonymous with External Quality Assessment (EQA). 
Recently National AIDS Control Organisation has formulate Quality Assessment 
Programme. Under this coded panels of known HIV antibody positive and negative 
sera are provided, handle exactly the same manner as the routine HIV testing in 
ELISA. 
Quality Control of HIV kit :  
(a) Monitoring different lots of kit : This is done by a technique called 'parallel 
testing' in which performance of new lots of kit with the previous lots via a 
common control material (external & controls of previous lots) is compared. 
If all controls produce expected results, the new lot has passed the parallel 
tests and may be used for routine testing. 
(b) Monitoring different kits : For safe blood banking kit should be correctly 
identify all antibody positive sera. Test kit should 100% sensitive. For sero 
surveillance and serodiagnosis kit with a high sensitivity and high specificity 
is needed. 
 
 
BIO-SAFETY IN HIV LABORATORY155 : 
 There is no vaccine for prevention of HIV/AIDS & treatment is expensive. 
Hence prevention of infection is the cornerstone of control of this epidemic. It is 
extremely important that the laboratory workers should be aware of the risks 
involved in their day to day work and apply effective infection control practices to 
reduce the possibility of transmission of these fatal infections to a minimum. Bio-
safety in a HIV testing laboratory may include (A) Precautions in relation to blood 
and body fluids (B) effective use of sterilisation and disinfection and (C) safe 
disposal of hospital waste. 
 Universal precautions apply for : Blood, all other body fluids containing 
visible blood, semen & vaginal secretions, CSF, synovial fluid, pleural fluid, 
peritoneal fluid, Pericardial fluid and amniotic fluid. Universal precautions do not 
apply for the risk of HIV transmission is extremely low or negligible these includes 
faeces, nasal secretions, Sputum, Sweat, tears, urine and vomitus. Universal 
Precautions include : Barrier protection, hand washing, safe techniques, safe 
handling of sharp items, safe handling of specimen, safe handling of spill of 
blood/body fluid, use of disposable/sterile items, safe techniques including 
mechanical pipetting device & immunisation with Hepatitis β Vaccine.  
(A) General bio-safety guidelines for laboratory workers : 
(i) The laboratory door should have a symbol of BIOHAZARD; NO 
ADMITTANCE. Laboratory should be well ventilated so personnel do not 
breath in contaminated air. 
(ii) Eating, drinking, smoking and application of cosmetics are prohibited in 
Laboratory. Sandals and open style shoes do not afford proper foot 
protection and are not to be used.  Contact lenses should not be worn. 
(iii) Laboratory and work tables should be scrupulously cleaned with liquid 
detergents and disinfectants. Laboratory work surface should be 
decontaminated once a day after completion of day's activity and 
immediately after spill of viable material with disinfectant. 
(iv) Biological safety cabinets and other devices, caps should be used whenever 
handling hazardous specimens. 
(v) Blood & other specimen containers should be labeled with a warning sing. 
Outside of container should be cleaned with sodium hypochloride in case of 
visible contamination. 
(vi) Gloves/Gown should be worn in laboratory working with infective materials. 
(vii) Hand should be washed immediately after contact with blood and before 
leaving the laboratory. 
(viii) Mechanical pipetting devices should be used. Mouth pipetting is strictly 
prohibited. Careful techniques should be followed to minimise the creation 
of aerosols.  
(ix) Accidental wounds from sharp instruments should be avoided. 
(x) Paper work should not be done on potentially contaminated surface. 
(xii) All potentially contaminated materials and wastes from the laboratory should 
be disposed after decontamination preferably by autoclaving. A label with 
globally accepted biological hazard sigh should be applied.  
(B) Effective use of sterilisation and disinfections : 
 Thorough cleaning and drying with detergents and water remove most 
organisms from an object / surface and should be carried out meticulously before 
sterilization. All contaminated glass wares/items after prior disaffection should be 
dismantled before cleaning. Cold water is used for protein materials and prevents the 
release of aerosols by the surface of the water, after drying it ready for sterilization.  
Environmental Cleaning :  
 Floors, surface, skin and drains should be cleaned with warm water & 
detergent. If there is spillage of blood, body fluids or sputum, disinfections before 
cleaning is recommended. Surface cleaned with freshly prepared 0.5 - 10% sodium 
hypochlorite. 
Disinfections :  
 Either thermal or chemical processes are used for disinfections. Thermal 
disinfections is preferred whenever possible. It is more reliable, leaves no residue, is 
more easily controlled & is non toxic.  Boiling (100c) for 20-30 mins is very simple 
& reliable method for inactivation of all micro organisms including HIV, HBV and 
mycobacteria. Chemical disinfectants is for heat labile equipment's. Alcohol, 
chlorine, 2% glutaraldehyde & phenol are used. 
Sterilisation :  
 Sterilisation is carried out by stem under pressure, dry heat, gas or liquid 
chemicals. HIV is a fregile virus and is adequately inactivated by autoclaving at 15 
lbs 20 min at 121c or hot air oven at 160-180c for 1 hour. 
(C) Safe disposal : 
 Laboratory wastes are potential hazards. Infectious waste can transmit 
numerous diseases in the community and put those who handle waste and live on its 
proximity, at risk.  
Guidelines for Waste disposal : 
(i) All biomedical wastes should be treated and disposed of strictly in 
accordance with the options mentioned in the table. 
(ii) Waste which cannot be incinerated (Plastics) should be pretreated by 
disaffection and disposed of in an environmentally sound manner. 
(iii) Waste should not be dumped, discharged or disposed in any place. 
(iv) All precautions and personal safety measures should be taken (gloves, 
masks, clothing, gumboots, goggles etc).  HBV vaccine is recommended 
again from handling or exposure. 
(v) All treatment and disposal facilities should be located at a specified area 
away from hospital public place & residential areas.  
(vi) When the treatment option is burial, the pits should be located away from 
agricultural land, residential areas and safe water sources. 
(vii) All plastic should be disinfected, shredded and disposed of Recycling of 
disposable should be prevented. 
(viii) All liquid waste should be disinfected & flushed in the sinks at the point of 
generation. 
(ix) Biomedical waste should not be disposed of on open land and municipal 
dustbins.  
Table - XIII  
Container and Colour Coding for disposal of bio-medical wastes 
Waste 
Calgary 
Waste Class Type of Container Colour 
Coding 
Treatment/ Disposal 
Option 
No.1 Human 
anatomical 
waste, blood & 
body fluids 
Single use 
containers/plastic 
holding bags 
Red. Incineration/Deep 
Burial. 
No. 2 Animal & 
Slaughter house 
waste 
Single-use 
containers/plastic 
holding bags/sacs 
Orange Disinfections & 
Deep Burial.  
No. 3 Microbiology & 
bio-technology 
waste 
Single-use 
containers/plastic 
holding bags. 
Yellow Autoclaving/ 
Microwaving & 
incineration. 
No. 4 Waste Sharps Re-usable/single use 
sturdy containers of 
plastic, glass or 
metal. 
Blue Shredding & Deep 
Burial. 
No. 5 Discarded 
Medicines 
Re-usable/sturdy 
card board/glass/ 
plastic holding bags 
Blue Shredding & Deep 
burial. 
No. 6 Solid Wastes 
(linen) 
Plastic bags/sacs. Yellow/ 
Black 
Disinfections and 
machine cleaning. 
No. 7 Disposable 
(Other than 
sharps) 
Reusable/sturdy 
containers/plastic 
holding bags. 
Yellow/ 
Black 
Disaffection-
chemical/ 
Autoclaving, 
Shredding, Burial. 
No. 8 Liquid wastes NA NA  
No. 9 Chemical 
Wastes 
Sturdy containers/ 
plastic holding bags. 
Yellow / 
Black. 
 
TREATMENT :  
 The development of therapy for HIV infection is one of the most remarkable 
stories in modern science. 
 The effectiveness of current therapy is reflected by the observed decline in 
HIV mortality. These drugs have improved survival times, they do not halt the 
progressive destruction of the immune system that characterised by HIV infection. 
The HIV infection is associated with viral replication and progressive 
immunodeficiency. Therefore treatment should be targeted both to restore the 
immune system and to inhibit viral replication. 
(I) Antiviral agents157 :  
(A)  Drugs : 
(a) Nucleoside reverse transcriptase inhibitors (NRTI) : 
 Zidovudine (AZT)  Didanosine (ddI) 
 Stavudine (d&T)  Zalcitabine (ddc) 
 Lamivudine (3TC) 
(b) Non NRTI :  Delvirdine, Nevirapine Efavirenz. 
(c) Protease inhibitors :  Indinavir  Saquinavir 
    Ritanovir Nelfinavir 
    Amprenavir. 
(B) Monoclonal antibodies : 
 Monoclonal antibodies to viral envelop components 
 Monoclonal antibodies to viral receptors. 
 Recombinant Soluble CD4 (rs CD4) 
(C) Interferons :  IFN - α 
   IFN - β 
(D) Oligonucleotides : 
 Antisense : directed against tat and rev sequences. 
 Sense/decoy 
 Ribozymes (HIV-specific) 
(E) Dominant negative mutants : 
 For Tat, Rev, Gag and Env.  
(II) Immunorestoration / immunopotentiation : 
(A) Cellular engineering : 
 Bone marrow transplantation. 
(B) Genetic engineering : 
 Augmentation of anti HIV immune response by : transfixion of patients 
fibroblast with murine retrovector expressing gPl 160 and reintroduction into the 
patient. 
(C) Engineering with biologic molecules : 
 - Interferon's  - Interlukin - 2 
 - Thymic hormone  - IL - 12 
 - Intravenous Y-globulin. 
(D) Pharmacologic engineering : 
 Isosprinosine  Imuthiol 
 Enkephaling  Azimexon 
 Retinodis. 
(III) Combination treatments : 
 (A) Cellular engineering and antiviral agents. 
 (B) Engineering with biologic molecules and antiviral agents. 
 (C) Pharmacologic engineering and antiviral agents. 
 (D) Chemotherapy and interferon. 
 (E) Combination of two or more antiviral agents. 
(IV) Gene therapy : 
 It is generally believed that gene therapy would be directed to treat persons 
already infected with HIV, rather than as a prophylactic measure. The strategy will 
involve introduction of gene into cells that specifically interferes with HIV 
replication or that causes the death of infected cell, thereby preventing virus spread.  
 Zidovudine alone was recommended in the past. New anti-retroviral drugs 
with various modes of action become available in the 1990s,  & it was shown that 
combinations of drugs belonging to different groups could greatly reduce the 
chances of drug resistant HIV mutants emerging. Drug such as zidovudine, 
combined with a group NRTl drug such as didanosine has a much greater effect than 
each drug alone and limited to the emergence of drug resistance. The most dramatic 
improvement in therapeutic efficacy followed the introduction of protease inhibitors 
and the use of a suitable triple combination that included on of these drugs with two 
NRTI drugs. The latter type of triple combination drug therapy is sometimes referred 
to as highly active anti-retroviral therapy (HAART) & is increasingly becoming 
recommended as standard therapy rather than double drug combination therapy. 
HAART has a particularly potent beneficial effect when administered to a 
previously untreated patient who is symptomatic with established but not too 
advanced HIV disease. Such as patent typically has a high plasma HIV load derived 
mainly from HIV actively replicating in a short lived population of CD4 
lymphocytes and the CD4 count is falling. When HAART is administered there is a 
marked fall in viral load, the CD4 lymphocyte count increases with restoration of 
immune function, there is clinical improvement, delayed clinical onset of AIDS and 
substantially longer survival. 
 The current main objective of HAART is to obtain the maximum 
suppression of HIV replication for the longest duration possible.  The limitation of 
HAART involves a lack of effect on 'resting' HIV infected lymphocytes, and other 
cells where the HIV genome is integrated as HIV DNA in the human DNA. Resting 
cells may become activated in due course to cause HIV replication and release of 
virus to infect other cells, so even HAART is given early on in HIV disease and 
continued for a few years, infection may appear if the treatment is stopped. Also 
there may be sanctuary sites, such as the brain, where there may be many such 
resting cells and also where some if not all the drug in a combination may have 
difficulty in penetrating the tissue and suppressing the replication of HIV - drug - 
resistant mutants might emerge after therapy. Lifelong drug therapy is currently 
recommended.  
 When to start anti-retroviral drug treatment of HIV infection : 
1. Established symptomatic HIV disease any base line viral load and CD4 count 
test - strongly recommended starting therapy. 
2. Asymptomatic HIV disease & CD4 count < 500 per mm3 HIV RNA > 5000 
copies per ml. plasma. strongly recommended starting therapy. 
3. Asymptomatic HIV infection & CD4 count > 500 per mm3 
 • CD4 count rapidly decline & HIV RNA > 500 copies/ml 
 • CD4 count not yet rapidly decline but HIV RNA > 30000 copies/ml. 
  Consider starting therapy. 
4. Asymptomatic HIV infection & CD4 count in normal range (600-1200/mm3) 
HIV RNA < 5000 copies/ml plasma. 
 Therapy not yet recommended in current guidelines but considered by some 
it HIV RNA detected. 
PREVENTION158 : 
 WHO has recommended the following prevention measures : 
(1) Sexual Contact : 
 Most HIV infection is transmitted through sexual intercourse with an 
infected partner. The risk increases with the increase in No. of sexual partners. It can 
be prevented by :  
• having only one uninfected partner. 
• always using condoms with new partner. 
• availing STDs. 
• establishing comprehensive STD treatment programmes59. 
• educating children about safer sex before they become sexually active. 
• teaching HIV positive about sasfe 'sex'. 
 
(2) Blood160 :  
 All blood & blood products are to be screened. This also applies to donation 
of semen, cornea, bone marrow, kidney and other organs since, HIV can spread 
through any one of these tissues. This can be prevented by. : 
• Screening blood for HIV 
• Discouraging donation from people known to be HIV positive or to be at 
high risk. 
• Prohibiting donation by professional blood donors. 
• Only giving B.T. when absolutely necessary. 
(3) Sharing needles : 
 Contaminated needles, syringes or other skin piercing equipments should not 
be shared with others. HIV transmission by sharing needles can be prevented by : 
• Ensuring that staff uses a sterile needle & syringes for each patient. 
• Disinfecting, cleaning and sterilizing all needles and syringes before reuse. 
• Ensuring clinics having adequate supplies of needles and syringes to meet 
patients need. 
(4) Mother to child transmission : 
 The children born to HIV infected mothers are at risk of acquiring HIV. This 
can be prevented by :  
• educating women about HIV 
• Counseling HIV positive women about the risks and providing good 
contraceptive advice and materials. 
(5) Drug abuse : 
 The drug abuse are at high risk of acquiring HIV infection. This can be 
minimized by : 
• educating children about the risk of using intravenous drugs. 
• organizing drug rehabilitation programs. 
• Providing addicts with clean syringes and needles to avoid the sharing of 
equipment between addicts. 
 
(6) Health Care workers161 : 
 Well documented studies show no increased risk to health worker to acquire 
HIV. Any risk of HIV can be virtually eliminated through good clinical and 
laboratory practice. 
• handling all the specimens carefully. 
• availing needle stick injuries. 
• following safe laboratory practice by using plastic wares, wearing gloves, 
cleaning up accidental spillage with Na DCC, disposal of all waste carefully. 
POST EXPOSURE PROPHYLAXIS162 : 
 Most exposures do not result in infection. The risk of infection varies with 
type exposure and other factors such as : The amount of blood involved in the 
exposure, The amount of virus in patient's blood at the time of exposure and whether 
post exposure prophylaxis was taken within the recommended time. Prevention is 
the mainstay of strategy to avoid occupational exposure to blood/body fluids. 
 An occupational exposure that may place a worker at risk of HIV infection is 
a percutaneous injury, contact of mucous membrane or contact of skin with blood, 
tissue or other body fluids to which universal precautions apply.  At the time of 
exposure immediately follow: 
(i) Needle sticks and cuts should be washed with soap & water. 
(ii) Splashes to the nose, mouth or skin should be flushed with water. 
(iii) Eyes should be irrigated with clean water, saline or sterile irritants. 
(iv) Pricked finger should not be put into mouth, reflexly. 
 In some cases, HIV postexposure prophylaxis (PEP) may be recommended 
and it should be started as soon as possible, preferably within a few hours, late PEP 
(after 72 hrs) may still be useful as early treatment of HIV infection, in case 
infection has occurred. The decision to start PEP is made on the basis of degree of 
exposure to HIV and HIV status of the source from whom exposure/infection has 
occurred.  Person should be provided with pre test counseling and AZT be started & 
taken sample for testing. In case the test non reactive, 2nd sample collected after 6 
weeks and 3rd at 12 weeks after exposure, and tested for HIV antibodies by RT-
PCR. 
 Recommendation for preventing transmission of HIV include refraining from 
blood, semen, organ donation, abstaining from sexual intercourse, women should 
not breast feed their infants. Drugs recommended in India is Zodovudine (200 mg 
shly) and lamivadine. Used in combination, ZDV & 3TC are very effective. The 
optimal course of treatment is unknown; Since 4 week of ZDV appears to provide 
protection against HIV infection. In case of pregnancy ZDV taken during 2nd and 
3rd trimesters. 
AIDS VACCINES : 
 Identification of a new pathogen can result in the development of accurate 
diagnostic test, therapies and preventive vaccines. Since HIV-1 and HIV-2 were 
identified as a cause of AIDS a preventive vaccine however has not been identified, 
despite intense academic, pharmaceutical and government research. 
 Ideally such a vaccine would163 prevent HIV infection or limit it to a 
transient asymptomatic infection that is unlikely to be transmitted to others. Recent 
evidence from human suggests that transient infections can occur and studies in 
nonhuman primates suggest that some vaccines allow only transient infection or may 
reduce the severity of subsequently established infection. 
 Challenges to the development of an HIV vaccine include : The vast and 
rapidly increasing genetic diversity of HIV. 
• Lack of understanding about the biology of the virus host interaction. 
• The complexity of the required clinical trials.  
 However, the reasons for optimism that a vaccine will ameliorate, it not end, 
the HIV epidemic are the long term, if temporary control of viral replication by the 
human immune system during HIV infection, successes in vaccinating primates 
against HIV, SIV and SHIV, and the possibility that a partially effective vaccine 
might significantly diminish the epidemic. 
 One of the most important problem is that the virus is often intracellular and 
can be transmitted from cell to cell without entering the extracellular fluid.  This 
means that immunological mechanisms that may be capable in removing circulating 
viruses, will be powerless once the virus is intracellular.  Moreover, the HIV attacks 
the T-helper cells, which are necessary for an effective immune response. Once 
infected these cells contain an integrated proviral genome for life. Thus to be 
effective a vaccine against HIV must prevent the virus from establishing 
infection164. 
 The second problem is that the major neutralizing antigenic area of the virus 
(Known as principal neutralizing determinant PND) is subject to mutation. The PND 
is located on the outer coat of the virus envelop on a surface glycoprotein called 
gp120. The V3 loop of the gp120 has a hypervariable region in a sequence of 24 
aminoacids. This means that antibodies elicited be one strain of the virus may not be 
able to neutralize another strain. There are still major gaps in our under standing of 
the biology of HIV infection in man. We knew that the outer viral surface contained 
epitopes which stimulate a protective immune response, that this immune response 
can be measured in terms of titres of antibodies, that these antibody titres were 
protective and could be evaluated in experimental animal models and these models 
provided an excellent predictor of human response. None of this is available for a 
vaccine against HIV. It is not known of the antibodies produced after vaccination are 
protective or not, and role of cell mediated immunity in protection against disease is 
largely unknown. Moreover, there is no animal model on which the vaccine can be 
tested. Though the chimpanzee has been used as a model.  This animal does not 
develop the disease AIDS, though it can be infected with HIV. 
 At present 3 different approaches to developing a vaccine against HIV. The 
preventive vaccines are preventing the infection before exposure.  The therapeutic 
vaccines is to reinvigorate the already infected immune system allowing it to combat 
more effectively the HIV induce damage to the immune system. Parinatal 
vaccination has aim to blocking the transmission from mother to baby. Of the three 
preventive vaccination has made the greatest progress : 
• Killed vaccine : Killed SIV vaccine do not induce protective immunity but 
may prevent the emergence of clinical disease. 
• Live attenuated vaccine : These are prepared from genetically engineered 
strains lacking some crucial genes, so that the resulting virus produce a 
harmless infection this technique has been successfully used with SIV. 
• Recombinant viral particles : Vaccine prepared by recombining env 
protein with vaccinia virus has been tried in Zaire in a group of healthy 
volunteers.  A cytotoxic T-lymphocytes (CD8 T cells) response was 
obtained. The overall effect of recombinant vaccine has not been established 
in human. 
 The Global programme on AIDS of WHO in collaboration with two vaccine 
manufacturers and national scientists, is conducting trial of the HIV-MN 
gp120/alum vaccine in Thailand and trials of HIV-MN gp120/alum vaccine in 
Thailand and trials of HIV-MN V3 peptide/alum vaccine in Thailand and Brazil.  
 A consortium consisting of the U.S. department of defense (DOD) scientists 
a vaccine manufacturer and Thai Public health leader and scientists is developing a 
bivalent clade β HIV Sf2 gp120/mg 59 and clade E gp120/MF 59 vaccine to be 
tested in Thailand. 
 In the case of HIV/AIDS infection prophylaxis of opportunistic infection 
also has increased life expectancy. Live virus OPU, MMR and bacterial BCG 
vaccine has not been recommended for immunocompromised persons because 
replication of live attenuated agents may be enhanced, where as inactivated bacterial 
and Viral vaccines DPT, influenza, Pneumococcal, HbcV and IPV are 
recommended. In the case of children with HIV/AIDS OPV and varicella not 
recommended, DPT, IPV, MMR, Penumococcal, influenza, Hepatitis β and Hib are 
recommended.  
 
WORLD AIDS DAY165 : 
 World AIDS day has a special place in the history of the AIDS pandemic. 
Since 1988 December 1st has been a day bringing messages of compassion, hope, 
solidarity and understanding about AIDS to every country in the world, North & 
South, East & West. World AIDS day emerged from the cell by the world summit of 
Ministers of health on programmers for AIDS prevention in January 1988 to open 
channels of communication, strengthen the exchange of information & experience 
and forge a spirit of social tolerance.  Since then, world AIDS day has received the 
support of the world health assembly, Governments, communities and individuals 
around the world. Each year, it is the only international day of coordinated action 
against AIDS.  Each year there is a particular theme chosen for World AIDS Day.  
?  The themes have been as follows : 
1988  Communication. 
1989  Youth  
1990  Women & AIDS 
1991  Sharing the challenge 
1992  Community Commitment 
1993  Time to Act.  
1994  AIDS and the family 
1995  Shared Rights, shared Responsibilities 
1996  One world, One Hope. 
1997  Children Living in a World with AIDS. 
1998  Force for change : World AIDS campaign with young people. 
1999  Listen, Learn, Live 
2000  AIDS : Man make difference. 
2001  I care do you  
2002  Live & let live (Stigma & discrimination) 
2003  Live & let live (Stigma & discrimination) 
 Young people can & have played a vital role in AIDS & HIV prevention and 
support work.  Young people can make a huge difference in arising awareness of 
AIDS of HIV by talking about AIDS & HIV in & outside school and college, by 
holding fund raising events for AIDS  charities or by wearing a red ribbon to show 
support.  
 The red Ribbon is an international symbol of AIDS awareness that is 
increasingly being worn by people all year round to demonstrate their care and 
concern about HIV and AIDS, and to remained others of the need for their support 
and commitment.  
 MATERIAL AND METHODS 
 
 Diagnostic testing for any infectious agent is an important aspect of disease 
control. Since the recognition of AIDS in 1981, in the very next year virus was 
isolated; and a diagnostic test was formulated soon after.  Through these newer 
techniques, the immunologic foot prints of the viral infection are detected rather than 
the virus itself.  Out line testing of all donated blood was initiated in most developed 
countries by 1955. In the year since, detection method have been refined to be more 
specific, more sensitive and more rapid. 
 In 1985 only a first generation test was available using an HIV lysate as 
antigen in both ELISA and W.B. by 1988 recombinant sub unit antigens of HIV 
brought up more specific test. This was second generation tests.  Then was the 
advent of ear of third generation test based on sub cellular fractions like synthetic 
peptides genetic probes, PCR, nuclei acid hybridization as also recombinant DNA 
technology, for large scale production of gag, pol and env proteins of HIV, which 
subsequently became the basis of most commercial test166. We in India reacted 
timely to detect whether this virus has reached our country also.  1985 the Indian 
council of medical research and in 1987 National AIDS Control Programme 
established a task force and initiated HIV screening of presumed risk group to detect 
the presence of this virus in India.  Since that time we have come a long way having 
established an extensive surveillance network in the whole country167. 
 In the present study the HIV seropositivity prevalence was carried out in 
various groups as follows :  
Group - I Symptomatic group 
 Included patients who presented with signs and symptoms which were 
suggestive of AIDS, viz. Unexplained fever, weight loss more than month 
duration's, diarrhea more than 1 months, generalized lymphadenopathy, 
disseminated fungal infections, multiple non healing ulcers.  And the cases of 
pulmonary tuberculosis : who were admitted in the infectious ward of the G.G. 
Hospital and T.B. Hospital, Jamnagar. 
Group - II  Asymptomatic group 
 Included persons who were at very high risk of getting HIV infection but 
who had no clinical signs and symptoms suggestive of AIDS viz.  STD patients, 
promiscuous heterosexual groups people whom had sexual intercourse with multiple 
partners, homosexual and Haemophiliacs. Cases coming to the skin and V.D. opp. of 
G.G. Hospital, Jamnagar. And Multitransfused patients from paediatric ward of G.G. 
Hospital Jamnagar.  
Group - II  Healthy group 
 In this group we included blood donors of G.G. Hospital Jamnagar, and 
Antenatal mothers attending the PPTC of G.G.  Hospital Jamnagar.  
Collection of Study material : 
• Sterile plain bulb for collection of blood. 
• Disposable syringe and needle. 
• Storage vials 
• Disposable gloves. 
 5 C.C. of blood was collected from each patient ascetically in plain bulb.  
Details as regarding the patients age, sex, education, address, marital status, history 
of exposure, history of drug addiction, STD and Jaundice and other necessary data 
were obtained from the cases. 
Processing of the clinical material : 
 On arrival of the laboratory, the blood sample was placed at 4c for 1 hrs to 
facilitate better separation of serum.  The separated serum was centrifuged at 3000 
rpm for 10 minutes to obtain a clear serum sample. The sample were transferred to 
storage vials and preserved at 20°c until used. (for longtime storage at 70°c is 
advised). 
 Screening for HIV antibodies : 
 All samples were tested by any three of the following assays. As per 
WHO/GOI strategies. 
• Different ELISA. 
• Immuno Comb II - HIV – 1 & 2 Bispot. 
• HIV TRI - DOT 
• Comb AIDS - RS 
• Capillus HIV - 1 / HIV - 2 
• Bio Line SD HIV - 1/2.3.0 
• Western blot. 
 We also send the sample at NARI pune, for final confirmation. 
Now we are using following three tests : 
(1) ELISA : ENZ aids HIV 1 + 2. 
(2) Comb Aids - Rs : HIV 1 & 2 Immuno Dot test. 
(3) HIV TRI - DOT. 
 
(1) ENZ AIDS HIV 1 + 2168 : 
 Enzaids used synthetic and for recombinant antigens, ensures highest level of 
specificity and sensitivity of the detection system (Fig. 9). 
?  Principle : 
 The antigenic peptides/proteins are absorbed onto the wells of a microplate.  
These antigens are selected from immunodominant regions of HIV - 1 & 2, So as to 
provide maximum level of sensitivity.  A special sample diluent is developed using 
proprietary formulation to minimise the non-specific binding. Test serum and 
control,s along with sample diluent are added to the respective wells and incubated. 
If antibodies to HIV - 1 or / and 2 envelope proteins are present in the specimen, 
they, will bind to the antigens coated on the solid surface. A wash step removes non 
specifically bound material. A conjugate consisting of enzyme horse radish 
peroxidase, chemically coupled to anti human immunoglobulin is added to each well 
and incubated. The conjugate binds to HIV antibodies that are already bound to the 
immobilized antigens.  A wash step removes nonspecifically bound conjugate. The 
substrate for the enzyme peroxidase and the chromogen 3,3', 5,5' 
Tetramethylbenzidine (TMB) are added to all the wells and incubated further, 
resulting into a blue coloured complex.  The reaction is terminated by the addition of 
a stopping solution yielding a stable yellow colored end point. The intensity of 
colour is proportional to the concentration of anti HIV - 1 and / or HIV - 2  present 
in the test specimen or control.  
?  Sample : 
 Serum or plasma can be used.  Specimen can be kept at 2-8°c for four weeks 
only. Grossly haemolysed or contaminated samples should not be used in the test. 
Use of fresh sample is recommended.  Do not use heat inactivated sample. 
?  Reagents : 
1. Sample Diluent : 
 Contains Tris buffer, proteins and preservatives.  
2. Conjugate : 
 Peroxidase labelled anti human immunoglobulin containing protein 
stabilizers and 0.01% Thimerosal as preservatives. 
3. Washing Buffer : 
 Concentrated (10X) buffer containing Tween - 20 and 0.01% Thimerosal 
preservative. Before use, dilute by adding one volume of concentrate to 9 volumes 
of distilled water. 
4. Negative Control : 
 Anti - HIV negative human serum, negative for Anti - HIV -1 and Anti HIV 
- 2 and containing 0.01% Thimerosal as preservative. 
5. Positive Control :  
 Inactivated serum containing anti - HIV antibodies and 0.01% Thimerosal as 
preservative. 
6. Colour reagent : 
 Buffer containing hydrogen peroxide and 3,3', 5,5' Tetramethyl benzidine 
(TMB) in solution. 
7. Stopping Solution : Mineral Acid. 
8. Microwell Strips : 
 Coated with HIV 1 + 2 Recombinant and synthetic peptides.  
?  Storage and Stability : 
 All kit components are stable until the expiration date, when stored between 
2-8°c. Unused strips should be stored along with silica gel bag. Once diluted, the 
washing buffer is stable for one week when stored at 2-8°c. 
?  Setting up the test : 
(1) Washing buffer : Dilute the concentrated buffer 1:10 (1+9) with distilled or 
Deionized water. 500 ml of diluted buffer is enough to wash all the 96 wells. 
If all the strips are not to be used at a time, prepare proportionate amount of 
diluted washing buffer.  
(2) General blank, Positive and Negative controls must be included with each 
run. All liquid reagents must be gently mixed before use, & kept at room 
temperature except colour reagent. 
?  Assay Procedure : 
1. Bring all the reagents to room temperature before use, except colour reagent 
(to be stored at 2-8°c, till use).  Remove the required number of 
Microwells/Strips from the packet. Label the wells appropriately. 
2. Leave the Reaction Blank well empty. 
3. Dispense 200 µ of sample diluent to rest of the required wells.  Use three 
Negative and one Positive control in each run. Add 10 µ of Negative, 
Positive and test serum samples to the respective wells.  Mix properly and 
cover the strips with adhesive strip cover.  Incubate for 30 minutes at room 
temperature (20-30°c) 
4. Remove and discard the adhesive strip cover.  Decant the contents of well 
into a waste container. Fill the wells with diluted washing buffer (approx.  
350 µl) allow soak time of 30 seconds and then decant it in a waste 
container. Repeat for 4 more times. Drain wells on a disposable absorbent 
pad or towel and tap firmly to remove excess of fluid. Take care not to 
scratch the inner surface of well with pipette tips or tissue paper. (Add next 
reagent immediately) 
5. Add 50µl of conjugate to each well, except the one used for the Reaction 
Blank Control. 
6. Mix the contents of Micro wells by agitating the strips gently for 5-10 
seconds. 
7. Cover the strip with fresh adhesive strip cover and incubate for 30 minutes at 
room temperature (20-30°c). 
8. Remove and discard the adhesive strip cover.  Wash strips as in step 4, five 
times with diluted washing buffer. 
9. Add 100µl of colour Reagent into each well including Reaction Bank 
Control. 
10. Leave at room temperature for 15 minutes in dark. 
11. Stop the reaction by adding 100 µl of stopping solution in all wells. 
12. Mix the contents of microwells by agitating the strip gently for 5-10 seconds. 
13. Using either monochromatic (450 nm) or bichromatic (450 + 630 nm) mode, 
absorbance reading must be taken after blanking with A1 well. 
14. Calculate the cutoff value & report the results. 
?  Determining Cutoff Value : 
1. Negative control mean : (NCX) The absorbance of individual Negative 
control must be grater than 0.010 OD units and less than or equal to 0.200 
OD units. 
2. Positive Control : To consider the assay run to be valid, the absorbance value 
obtained for the positive control should be at least 1.00. If not, the assay 
must be repeated making sure that the procedure is being properly followed. 
3. Blank : The absorbance value (OD) of reagent blank should fall between 
0.000 to 0.100 in bichromatic mode. 
4. Cutoff Value : The cutoff value is the mean O.D. of the Negative control 
plus 0.225 ex : NCX = 0.065 cut off value = 0.065 + 0.225 = 0.290. 
 For the assay run to be valid, the positive and negative controls must be 
within the acceptable range.  It they are not, technique or reagents should be 
suspected to be at fault and the assay should be repeated. 
?  Interpretation of Results : 
 All the samples with the absorbance less than the cutoff value should be 
considered Negative for anti HIV and the absorbance equal to or more than cutoff 
value must be considered positive for anti HIV.  Non reactive results in a test for 
detecting antibodies against HIV - 1 and / or HIV - 2 do not exclude HIV infection 
with absolute certainty, if the patients happens to be in the window period. Further 
conformation of a reactive result with another techniques. 
?  Sensitivity and Specificity : 
 The test system is a 100% sensitive & specificity. 
(2) HIV - 1 + 2 IMMUNO DOT TEST - COMB AIDS – RS169 : 
 Comb aids - Rs test is an vitro, visually read Dot immunoassay intended for 
the qualitative detection of IgG/IgM antibodies to the HIV - 1 & 2 in human serum 
or plasma (Fig. 10). 
?  Principle : 
 Dot immunoassay employs the same principle as EIA, whereby immobolized 
antigen - antibody complex is visualized by means of colour producing 
(chromogenic) reaction. In combaids - Rs the coloured end - point is developed by a 
colloidal Gold - Protein - A signal reagent.  Each arm of the comb is spotted with a 
circular spot near the tip, by an optimally standardised blend of HIV - 1 and HIV - 2 
recombinant antigens and synthetic peptides. 
 When incubated with a specimen containing HIV - 1 and HIV - 2 antibodies, 
these antibodies bind specifically to the peptide antigens. The antibody peptide 
complex is directly visualized after incubation with the protein - A - Colloidal Gold 
Signal Reagent. A positive result is indicated by the presence of magenta red 
coloured dot on the surface of the comb where peptides have been spotted. 
?  Sample :  
 Serum or plasma can be used. For short-term storage, specimens can be 
stored at 2-8°c, However, they should be frozen (-20°c or lower) for a long term 
storage. Grossly haemolyzed and contaminated samples should not be used. 
?  Kit Contents : 
 1, Washing Buffer 2, Colloidal Gold Signal Reagent, 3. Sample diluent, 4. 
Negative control, 5. Positive control, 6. Antigen Coated combs. 
?  Storage & Stability :  
 All kit components are stable until the expiration date shown on the label, 
when stored between 2-8°c. Combs are highly sensitive to moisture so unused comb 
should be stored along with the silica gel bag. Once diluted, the washing Buffer is 
stable for one week it stored at 2-8°c. 
?  Setting up the test : 
 Washing solution : Dilute the concentrated washing buffer 1:5 with distilled 
water by adding 15ml Con. buffer to 60 ml distilled water. Fill the wash tray with 
washing solution. Taking care to avoid foaming. Use 75 ml. diluted washing 
solution to wash four Combs.  
?  Assay Procedure : 
 All kit components and samples to be tested should be at room temperature 
before starting the test clearly mark all samples to be tested and record their identity 
before starting the test. 
1. Mark the sample numbers on the microtest wells and add two drops (0.1ml) 
of sample diluent to each well. 
2. Add two drops (0.1ml) of sample or control to each of the above wells 
containing sample diluent. Mix the sample with diluent. 
3. Cut foil pouch and carefully remove the required number of combs. Mark the 
sample numbers on the comb and place it into rows of corresponding 
microtest wells.  Incubate at room temperature for 10 minutes. 
4. In the mean time dispense the Colloidal Gold Signal Reagent into another set 
of wells which have not been previously used. Add 4 drops (0.2 ml) of 
colloidal gold signal reagent to each well. 
5. Remove the comb from the sample containing wells and blot the tips of the 
arms on absorbent material. Do not blot the reactive surface of the comb.  
Hold the comb vertically with tips painting down and immerse into the wash 
solution. Wash by carefully moving the comb forward and backward in the 
wash solution for a total of ten times. Blot the tips of the arm again. 
6. Place the comb into wells containing colloidal Gold signal reagent. Incubate 
at room temperature for 10 min.  After incubation repeat the washing 
procedure as above. 
7. Place the comb on a clean surface, reactive side up. Do not blot or wipe the 
surface of the comb.  Allow the comb to air dry completely before reading 
the results.  
?  Interpretation : 
 A positive result is indicated by the presence of magenta red coloured 
spot/dot near the tip of the arm of the comb.  The absence of coloured spot indicate 
that the sample is free of HIV - 1 & 2 antibodies. 
 Positive Control - must produce coloured spot on tooth of the comb.  
 Negative Control - absence of any coloured spot, indicating absence of 
antibodies to HIV - 1 & 2. 
 When reading the combs, examine them in moderate light, preferably against 
white surface. The surface of the comb should be perpendicular (at a 90° angle) to 
the eye.  Faint uncolored spot may be visible which does not represent true 
reactivity.  Sensitivity & specificity indicated 100%. 
 
(3) HIV TRI – DOT170 : 
 The HIV Tri-Dot test is a visual, rapd sensitive and accurate immunoassay 
for the differential defection of HIV 1 & HIV - 2 antibodies in human serum or 
plasma (Fig. 11). 
?  Principle : 
 HIV antigens are immobilized on a porous immunofiltration membrane. 
Sample and reagents pass through the membrane and are absorbed into the 
underlying absorbent. As the patient's sample pass through the membrane, HIV 
antibodies, if present, bind to the immobilized antigens. Conjugate binds to purple 
DOT (S) against a white background. 
?  Kit Contents : 
1. HIV tridot test device - packed individually. Device has membrane with 1 
control and 2 test dots, one each for HIV - 1 & HIV - 2. 
2. Buffer solution - containing BSA, Sodium azide. 
3. Protein - A - Conjugate in liquid form containing sodium azide. 
4. Negative Control : lyophilized normal human serum tested non reactive for 
HBsAg, HCV, HIV - 1 & 2, contains 0.05% sodium azide, Reconstitute with 
diluent B (add whole of it). 
5. Positive control : lyophilized rabbit serum positive for antibodies to HIV - 1 
& 2 contains 0.05% sodium azide.  Reconstitute with entire of diluent C. 
6. Diluent - B & C. 
?  Storage:  
 Store the kit at 4°C - 8°c. The components are stable for 12 months from the 
date of manufacturing, when stored at 4-8°c. Do not freeze the kit. 
?  Test Procedure :  
 Bring all the reagents and specimens to room + temperature (20-30°c) before 
beginning the test. 
1. Add 3 drops of buffer solution to the center of the device. Allow it to soak.  
2. Hold the dropper vertically and add 1 drop of patients sample. (serum of 
plasma).  
3. Add 5 drops of buffer solution; allow it to soaked. 
4. Add 2 drops of liquid conjugate directly from the vial. Again allow it to 
soak. 
5. Add 5 drops of buffer solution and read result. 
?  Interpretation of Results : 
• Negative result : If only one dot (only the control dot) appears, the specimen 
is non reactive for antibodies to HIV - 1 & 2. 
• Positive result : 1. If two dots, one for the control and the other for HIV - 1 
appears, the specimen is reactive for antibodies to HIV -1. 
• If two Dots, one for control and other for HIV - 2 appear, the specimen is 
reactive for antibodies to HIV - 2. 
• If all three dots, one each for control, HIV - 1and HIV - 2 appear, the 
specimen is reactive for antibodies to both HIV - 1 & HIV - 2. 
• Invalid test : If no dot appears after the test is complete, either with clear 
background or with complete pinkish/purple background, the test indicates 
error. The specimen should be retest on a new device. 
• Every Samples retested irrespective of positive or negative for quality 
control. As well as 20% HIV seropositive & 5% HIV seronegative sample 
sent at NARI Pune for confirmation.  
 OBSERVATIONS & RESULTS 
 
 A total of 53,671 blood samples from blood donors and 12,165 serum 
samples from clinically suspected cases of HIV, Tuberculosis patients, Sexually 
transmitted disease patients, Multitransfused thallassaemic children and Antenatal 
women were screened for HIV infection as under : 
 The samples were classified in symptomatic, Asymptomatic is healthy 
groups and detect HIV seropositivity by ELISA, Comb-Aids, and HIV Tri-dot test.  
TABLE - XIV 
GROUP WISE THE NUMBER OF CASES SCREENED 
Group  
No. 
Group No. of tested 
Samples 
No. of HIV 
Seropositive 
Percentage 
A 
 
Symptomatic: Pt's with clinical 
sign & symptoms which were 
suggestive of HIV infection & 
patients. 
4265 1103 25.86% I  
B  TB patients. 2000 124 6.2% 
II  Asymptomatic :-     
A Pt's attending STD clinic at 
G.G. Hosp. Jamnagar 
2700 126 4.6%  
B Multitransfused patients  
(Thallassaemic Children)  
200 05 2.5% 
III  Healthy Group :-     
 A Pregnant women attending the 
antenatal clinic at G.G. Hosp. 
Jamnagar. 
3000 07 0.23% 
 B Blood donors who donate 
blood at G.G. Hosp. Jamnagar 
53671 199 0.37% 
  TOTAL 65836 1564 2.3% 
GROUP - I : TUBERCULOSIS (TB) PATIENTS 
 
Table - XV 
Incidence of HIV seropositivity in TB patients 
Total No. 
Screened 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Percentage 
Positivity 
2000 124 1876 6.2% 
  Table - XV shows HIV seropositivity among clinically suspected cases of 
tuberculosis with the over all prevalence rate of 6.2%, a total 124 cases being 
positive out of 2000 screened (Graph - 1). 
 
Table - XVI 
Gender wise distribution of HIV seropositivity Aamong TB patients 
Gender Total No 
Screened 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Rate of 
Positivity (%) 
Male 1565 110 1455 7.02% 
Female 435 14 421 3.2% 
TOTAL 2000 124 1876 6.2% 
 Table - XVI shows the HIV seropositivity in TB patients in relation to sex 
with positivity rate of 7.02% among males, a total of 110 being positive out of 1565 
screened and positivity rate of 3.2% among females, a total of 14 cases being 
positive out of 435 screened. Rate of positivity is more in male patients than female 
patients.  
 
 
 
 
Table - XVII 
Incidence of HIV-seropositivity in TB patients with relation to age 
Age Group Total No 
Screened 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Rate of 
Positivity (%) 
0-20 151 10 141 6.62% 
21-30 770 59 711 7.66% 
31-40 595 29 566 4.87% 
41-50 340 17 323 5.00% 
> 50 144 09 135 6.25% 
TOTAL 2000 124 1876 6.2% 
 Table - XVII shows the incidence of HIV Seropositivity among clinically 
suspected TB pt's in relation to age, with the higher positive rate of 7.66% in the age 
group 21-30 years, a total 59 being positive out of 770 screened. This age group is 
more prone for TB & HIV infections (Graph - 2).  
 
GROUP - II : STD PATIENTS (SEXUALLY TRANSMITTED DISEASE) 
Table  - XVIII 
Incidence of HIV Seropositvity in STD patients : 
Total No. 
Screened 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Percentage 
Positivity 
2700 126 2574 4.66% 
  Table - XVIII shows HIV seropositivity among STD patients who attend the 
STD clinic at G.G. Hosp. Jamnagar with over all prevalence of 4.66%, a total of 126 
being Seropositive out of 2700 screened.  
 
 
 
Table - XIX 
Incidence HIV Seropositivity in STD pt's in relation to sex : 
Sex Total No 
Screened 
No. of HIV 
Seropositive 
Rate of 
Positivity (%) 
Male 795 45 5.66% 
Female 1905 81 4.25% 
TOTAL 2700 126 4.66% 
 Table - XIX shows that out of 795 male tested 45 were HIV Seropositive 
(5.66%) and out of 1905 female tested 81 were HIV Seropositive (4.25%) Rate of 
positivity is high in male STD patients than female.  
Table - XX 
Incidence of HIV Seropositivity in STD patients relation to Age & Sex 
Male Female Total Age 
Years Tested +ve +ve% Tested +ve +ve% Tested Positive +ve% 
< 20 45 02 4.44 135 03 2.22 180 05 2.77 
21-30 321 23 7.16 810 37 4.56 1131 60 5.30 
31-40 279 13 4.65 695 25 3.59 974 38 3.90 
>40 150 07 4.66 265 16 6.03 415 23 5.54 
TOTAL 795 45 5.66 1905 81 4.25 2700 126 4.66 
 Table - XX Shows HIV Seropositivity more in male patients and is more in 
21 to 30 age group. Out of 795 male screened 45 (5.66%) were positive & age group 
21 to 30 years (7.16%) is more prone for infection. In female out of 1905 screened 
81 (4.66%) were HIV Seropositive & age group 21-30 (5.30%) is more effective 
(Graph - 3).  
 
 
 
 
 Table - XXI 
Local distribution of STD patients 
Local Male Female Total 
Rural 290 695 985 
Urban 505 1210 1715 
TOTAL 795 1905 2700 
 Table - XXI shows urban people are more infective than rural. Out 2700 
screen for STD 1715 were urban as 985 were rural.  
Table - XXII 
Incidence of STD and types of STD 
Male Female Total Disease 
Tested +ve +ve% Tested +ve +ve% Tested Positive +ve% 
Genital Uncler 435 25 5.74 145 05 3.44 580 30 5.17 
Urethral Discharge 205 04 1.95 - - - 205 04 1.95 
Genital Discharge - - - 1554 61 3.92 1554 61 3.92 
Genital Ulcer &  
Discharge 
16 02 12.5 80 03 3.79 96 05 5.20 
 Genital Warts 139 14 10.07 126 12 9.52 262 26 9.81 
TOTAL 795 45 5.66 1905 81 4.66 2700 126 4.66 
 Table - XXII shows different types of sexually transmitted disease. Out of 
795 STD male screened 16 were infective with genital ulcer & discharge 2 (12.5%) 
were HIV Seropositive & 139 infective with genital warts 14 were (10.07%) HIV 
Seropositive. In female out of 1905 patients screened 126 were infective with genital 
warts, 12 (9.52%) were HIV Seropositive. So in STD group genital discharge with 
ulcer & warts are more common (Graph - 4).  
 
 GROUP-II : MULTITRANSFUSED PATIENTS (THALLASSAEMIC CHILDREN) 
Table - XXIII 
Incidence of HIV Seropositvity in Thallassaemic patients : 
Total No. of 
Tested Sample 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Percentage 
% 
200 05 195 2.5% 
  Out of 200 multitransfused thallassaemic children 05 were seropositive for 
HIV by ELISA, Tri-dot or Comb-Aid test. The rate of positivity is 2.5%. 
 
Table - XXIV 
Incidence of HIV Seropositivity in thallassaemic children  
with relation of Age & Sex 
Age 
Sex 
 <2 yrs 2 to 4 >4 to 8 > 8 to 13 TOTAL 
Tested 46 40 49 22 157 
Male 
Positive 0 1 2 0 3 
Tested 14 12 09 08 43 
Female 
Positive 0 0 1 01 02 (4.65%) 
 Above table shows that out of 157 male patients, 3 (2.36%) were HIV 
Seropositive. Out of 3 Seropositive 2 belonged to age group >4 to 8 and 1 belonged 
to age group 2 to 4 No positivity found in other age group. Out of 43 female patients 
2ee (4.65%) were found HIV Seropositive. Out of 2 Positive patient 1belonged to 
age group >4 to 8 & 1 belonged to >4 to 13 age group. HIV Seropositivity is more in 
male patient and in >4 to 8 years age group (Graph - 5).  
 
 
 
Table - XXV 
Incidence of HIV-Seropositivity in thallassaemic children with relation  
to number of blood transfusions 
No of blood 
transfusions 
Total 
Tested 
Positive Percentage 
0-50 61 1 1.63% 
51-100 70 2 2.85% 
101-150 39 2 5.12% 
151-200 22 0 0.0% 
<200 08 0 0.0% 
TOTAL 200 5 2.5% 
 Table - XXV shows HIV Seropositive patients who had received about 50 
blood transfusions. Two patients had received about 100 & 2 about 150 blood 
transfusions, indicating that the incidence of HIV infection increases with 
transfusions.  
Table - XXVI 
Distribution of Thallassaemic children according to  
the Age of the number of transfusions 
Age No. of 
Transfusions <2 2 to 4 > 4 to 8 > 8 to 13 TOTAL 
0-50 18 23 15 5 61 
51-100 2 08 54 6 70 
101-150 0 02 14 23 39 
151-200 0 02 06 14 22 
<200 0 00 00 08 08 
TOTAL 20 35 89 56 200 
 Table - XXVI shows numbers of transfusions in relation with the age. HIV 
Seropositivity is more in > 4 to 8 age group Children  & out of 200 children 70 
children had received 51-100 blood transfusions (Graph - 6).  
GROUP-III : ANTENATAL MOTHERS 
Table - XXVII 
Incidence of HIV Seropositvity in Pregnant women  
No. of Pregnant 
Women Screened 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Percentage 
% 
3000 07 2993 0.23% 
  Table - XXVII shows HIV-Seropositivity among pregnant women with 
overall prevalence of 0.23%. A total of 7 cases being HIV Seropositive out of 3000 
screened. 
Table - XXVIII 
Incidence HIV-Seropositivity in relation to Age 
Age of Group No. of Sample 
Screened 
No. of HIV 
Seropositive 
Percentage 
Positivity 
16-20 812 00 0.0% 
21-30 1513 06 0.39% 
31-40 495 01 0.20% 
>40 180 00 0.0% 
 Table - XXVIII shows age wise distribution of 07 HIV Seropositive cases 
with highest incidence in age group 21-30 years of 0.39% (Graph - 7). 
Table  - XXIX 
Incidence HIV Seropositivity in relation to different trimester of pregnancy 
Trimester No. of Sample 
Screened 
No. of HIV 
Seropositive 
Percentage 
Positivity 
I 641 1 0.15% 
II 859 1 0.11% 
III 1500 5 0.33% 
 Table - XXIX shows that maximum number of cases were positive in third 
trimester of pregnancy. 5 were positive out of 1500 (0.33%) screened (Graph - 8). 
Table - XXX 
Incidence HIV Seropositivity in Pregnant women whose husband has a HIV. 
No. of Pregnant  
women screened 
No. of HIV  
Seropositive mother 
No. of HIV  
Seropositive husband. 
3000 7 3 
 Table - XXX shows that out of 3000 cases screened for HIV Seropositivity 7 
Pregnant women were HIV Seropositive. Out of 7 positive women only 3 husbands 
were HIV Seropositive.  
Table - XXXI 
Incidence of HIV Seropositivity according to the  
education status in pregnant women  
Education No. of Sample Screened No. of HIV  
Seropositive 
Percentage  
Positivity 
Illiterate 1190 04 0.33% 
Up to Primary 864 02 0.23% 
UP to Higher Secondary 830 01 0.12% 
Graduate & above 116 00 0.00% 
 Table - XXXI shows HIV - Seropositivity is more in Illiterate pregnant 
women. Out of 1190 women 4 were HIV Seropositive (0.33%). 
 
GROUP-III : BLOOD DONORS 
Table - XXXII 
Incidence of HIV Seropositvity in Blood Donors 
No. of Blood Donors 
Screened 
No. of HIV 
Seropositive 
No. of HIV 
Seronegative 
Rate of  
Positivity 
53671 199 53472 0.37% 
 Out of 107343 blood donors 199 were Seropositive for HIV by ELISA, Tri-
dot or Comb-Aid test, The rate of positivity in blood donors is 0.37%. 
Table - XXXIII 
Incidence HIV-Seropositivity in blood donors relation to Age 
Age Group in years No. of Sample 
Screened 
No. of Sample 
HIV-Seropositive 
Percentage  
% 
18-20 4021 09 0.22% 
21-30 24375 101 0.41% 
31-40 18230 72 0.39% 
>40 7045 17 0.24 
TOTAL 53671 199 0.37% 
 Table - XXXIII shows age group wise Seropositivity for HIV in blood 
donors, the highest positivity in age group 21-30 years is 0.41%, which shows in 
table (Graph - 9). 
 
Table - XXXIV 
Incidence of HIV-Seropositivity in blood donors relation to gender 
Sex Total No 
Screened 
No. of HIV 
Seropositive 
Rate of 
Positivity (%) 
Male 50796 197 0.38% 
Female 2875 02 0.06% 
TOTAL 53671 199 0.37% 
 Table - XXXIV shows sex wise HIV Seropositivity in blood donors. HIV- 
Seropositivity in male is 0.38% and in female is 0.05%. So the Seropositvity rate is 
more in male patients than female. 
 
 
 
 
Table - XXXV 
Incidence of HIV Seropositivity according to category of blood donors 
Category No. of Sample 
Screened 
No. of Sample  
HIV-Seropositive 
Percentage  
Positivity 
M 36414 189 0.51% 
Replacement Donors 
F 460 01 0.21% 
M 14382 08 0.05% 
Voluntary Donors 
F 2415 01 0.04% 
 Table - XXXV shows that HIV Seropositivity is found more in replacement 
(0.51% male and 0.21 female) donors as compared to voluntary donors (0.05% male 
and 0.04% female). Out of 199 HIV Seropositive sample 190 (0.51%) are 
replacement donors and 8 (0.05%) are voluntary donors (Graph - 10). 
 
 DISCUSSION 
 
 The HIV/AIDS epidemic represents the most serious public health problem 
in the world / India.  There is no denial of the enormity of the problem. The 
prevalence of the infection in all parts of the country highlights the spread from 
urban to rural areas and from high risk to the general population. It is estimated that 
4.5 million Indians were infected with the virus.  Migration of labor, low literacy 
levels leading to low awareness, gender disparities, prevalence of sexually 
transmitted disease and reproductive tract infections are some of the factor attributed 
to the spread of HIV (AIDS). 
 A large variety of assays are available today to test the presence of anti-HIV 
antibodies. In present study was undertaken to find out the incidence of HIV 
seropositivity in different groups like : 
Group - I : Symptomatic : 
 Patients who presented with signs and symptoms which were suggestive of 
HIV/AIDS and - TB patients. 
Group - II : A symptomatic : 
 Person who were at very high risk of getting HIV/AIDS but who had no 
 clinical signs and symptoms suggestive of HIV/AIDS. 
 - Sexually transmitted disease patients &  
 - Multitransfused Thallassaemic children 
Group - III : Healthy individuals : 
 - Antenatal mothers & 
 - Blood donors. 
 The present study results are compare with other places and workers are as 
under. 
 
 Group - I  TUBERCULOSIS 
 In April 1993, WHO declared tuberculosis as a global health emergency to 
curb the epidemic and called for immediate action. Tuberculosis is responsible for 
27% of preventable deaths worldwide and in one of the most common preventable 
infections disease in India171. 
 Tuberculosis has becomes a major threat to HIV infected people all over the 
world.  This impact has been experienced in many African, Asian and American 
countries. The association of TB with HIV infection was first recognized in Haitians 
and intravenous drug users172. The growing epidemic of HIV has breathed new life 
into an old enemy-tuberculosis.  Over the past few years, with the increase in HIV 
infection, TB has become a common clinical presentation of HIV infection.  The 
HIV epidemic spurs the spread of TB and increases the tuberculosis risk for the 
whole population. For those who are HIV positive, the TB risk is especially great 
and the outcome often fatal.173-175 
 India has an enormous reservoir of tubercular infection, thus co-infection 
with HIV increases the rate of TB reactivation and mortality.  Knowing the HIV 
status of TB patients has important benefits. TB & HIV are strongly associated and 
can be thought of as interacting synergistically. Most importantly, TB can be the 
'yellow flag' that leads to the discovery of an unsuspected HIV infection, opening the 
door to the benefits of anti-retroviral treatment, preventive therapy for other 
opportunistic infection and counseling to reduce HIV transmission176. 
 In India, under National Tuberculosis Control Programme 1.5 million cases 
are detected every year but still 1200 cases die due to it daily177. TB had re-emerged 
in countries were it was supposed to be on a decline. Global explosion of HIV 
infection coupled with chaotic with TB, the world today is threatened with 
untreatable epidemic of TB. India has an enormous reservoir of tubercular infection, 
thus co-infection with HIV increases the rate of TB reactivation and mortality.  Here 
describe the prevalence of HIV infection in TB patients in Jamnagar. 
 The present study carried out a total of 2000 suspected cases of tuberculosis 
were screened to detect HIV antibodies, ELISA, HIV seropositive sample 
conformed by another test HIV - Tridot & Comb Aids.  
 In the present study 124 out of 2000 clinically suspected patients of 
tuberculosis were found HIV seropositve. With the prevalence rate of 6.2%. The 
incidence of HIV seropositivity in TB Pt's in various parts of world and the India is 
as : 
Incidence of HIV seropositivity in TB Pt's from different parts of world 
Sr. No. Author 
Year of 
Publication 
Place 
Percentage 
positivity 
1. Pitchenic AE178 1987 - 31.0% 
2. Onorato et al179 1994 UK 7.4% 
3. Shandera et al180 1997 Africa 20.0% 
4. Ackah et al181 1998 Abidjan 440.7% 
5. Horsburgh et al182 1998 US 41.0% 
6. Faggiano F183 1999 Itali 25.6% 
7. Bowen et al184 - London 23.0% 
8. Robert J. et al185 2000 Paris 28.0% 
9. Punnotok J et al186 2000 Thailand 22.0% 
10. Nicholosn O et al187 2000 UK 10.0% 
11. Kiwanuka J.P. 188 2000 Uganda 48.9% 
12. Salgueiro 189 2004 Santiago 2.4% 
 The highest rate of incidence of HIV seropositivity in clinically suspected 
cases of tuberculosis is found in Sub-Saharan Africa 202 & it is found as high as 
70%. 
 The researchers recorded pt's with tuberculosis at Grady Memorial Hospital 
Atlanta by Horsburgh182 out of 1203 patients identified with TB, 493 (41%) were 
HIV seropositive similar high rate also detected at Uganda by Kiwanuka JP188 
48.9%, and Ackah at Abidyan 44.7%. 
 In a hospital in Paris Robert J185, the prevalence of HIV infection among TB 
patients increased from 2% in 1983 to 28% in 1993. Same prevalence rate also 
detect by Punnotok J Thailand,186  Bowen184 at London, Faggiano F Itali183, 
Shandera Africa180, and Pitchenic AE178, 22%, 23%, 25.6%, 20% and 31% 
respectively. 
 In the present study, out of 2000 tuberculosis patients screened only 124 
(6.2%) were found to be HIV seropositive. This rate of Seroprevalence is 
comparable with the rate in UK & it is found (7.4^%) very near by, and Nicholson 
UK is 10.0%. 
 In the Santiago the rate is as low as 2.4% study by Salgueiro et al189.  
 India also conducted the study among patients with tuberculosis and HIV 
seropositivity have shown wide variation in the prevalence of HIV seropositivity. 
Incidence of HIV seropositivity in TB Pt's from different part of India. 
Sr. 
No. 
Author 
Year of 
Publication 
Place 
Percentage 
Positivity 
1. Kulshreshtha R. 190 1997 Lucknow 1.04% 
2. Mohanti KC 191 1998 Mumbai 33% 
3. Mohanti KC 192 1999 Mumbai 74% 
4. Jain S.K. 193 2000 Delhi 1.52% 
5.  Deivanayagum 
CN194 
2002 Chennai 4.42% 
6. Talib SH 195 2002 Aurangabad 4.70% 
7. Kumar P 196 2002 Delhi 13.95% 
8. Solomon S 197 2002 Madras  1.6% 
9. Dey SK 198 - Calcutta 0.67% 
10. Ramchandra R 199 2003 Chennai  4.7% 
11. Sharma S.K. 200 2003 Delhi 9.4% 
12. Prasad R 201 2004 Lacknow 2.8% 
13. Present Study - Jamnagar 6.2% 
 A study conducted  by KEM Hospital in Mumabi by K.C. Mohanty191 from 
1987 to 1999 HIV seropositivity shows 2.4% to 74%, Jain SK et al193 at Delhi from 
sentinel surveillance of the tuberculosis patients clinic. Showed prevalence of 0.68 
to 1.52% in 1998. This data clearly indicate that percentage of the disease increased 
by the year. 
 Present study, HIV seropositivity rate 6.2% also comparable with 
Deivanayagum chennai194, Talib SH at Aurangabad195 and Ramchandra R 
Chennai199 showed 4.42% and 4.7% respectively.  
 Sharma S K200 showed slightly high 9.4% prevalence at Delhi. Some studies 
from other parts of India shows very low prevalence rate. Dey SK198 Culcutta, 
Solomon S197 Madras and Prasad R201 Lucknow showed very low HIV 
seropositivity among TB patients it is 0.67%, 1.6% and 2.8% respectively. 
 This deviation of HIV seropositivity may be due to co-infection, 
substantially under estimated because of under diagnosis of HIV infection or un-
responding an un co-operative nature of patient. In the region such as the Western 
Pacific & South East Asia, WHO data indicates that HIV/TB co-infection is much 
less common than it is in Africa, although it is likely that the incidence of co-
infection is substantially under estimated because of under diagnosis of HIV 
infection203. 
 In the present study as shown in table, out of 2000, 1565 male TB patients 
screened for HIV seropositivity 110 were found to be HIV seropositive and out of 
435 females of TB patients, only 14 were HIV seropositive. The rate of incidence 
for male (7.02%) is higher than females (3.2%). The result shows the males are more 
prone than females. Because males are generally labour & have a nutritional 
deficiency. 
 The results are also comparable with Salgueiro189, showed that 568 male out 
of 946 and Horsburgh182, showed that 380 out of 493 were males. Onorato IM179 in 
his study found that the median age of all 337 persons with TB screened was 33 
(range 24-67 years) 10 (3%) being co infected with HIV & all were males. 
 In present study incidence of HIV seropositivity is more in the age group of 
21-30 years. (7.66%) Other age groups shows only slightly low infectivity rate, so 
all the age groups of TB patients were susceptible for HIV infection. 
 So the infection with TB and HIV represents a major public health problem 
in many parts of the world204. 
 The association of TB with HIV was so compelling that WHO included TB 
in HIV positive individuals to AIDS case definition. Hence TB in HIV infected 
person falls in high priority area and deserves better attention that present205. 
Group - II : SEXUALLY TRANSMITTED DISEASE (STD). 
 Heterosexual contact has emerged as the single largest cause of the spread of 
HIV in south East Asia. The growing evidence available from all over the world 
undoubtedly indicates that the incidence of HIV infection is higher in conditions of 
presence of sexually transmitted diseases. It is established that the presence of 
STD'S increases the risk of HIV by 8-10 times206. 
 Women are at greater risk of being infected by their male partner because 
transmission from male to female is more efficient than from female to male. During 
sexual intercourse, damage to the lining of sexual organs can transmit HIV from the 
infected partner to the uninfected on by exchange of body fluids. It is easier for the 
virus to be transmitted if the uninfected partner is already suffering from STDs 
because in this case the lining is already damage. It is also possible that the virus is 
transmitted to WBC which are normally found on the lining of various openings of 
the body such as the genital areas. Irritation, infection and damage to the lining spurs 
the WBC to rich here in large number to repair damage and offer protection from 
infection thereby increasing their concentration locally. This is turn increases the 
risk of HIV transmission. STDs remain serious public health problem in Asia and 
rank among the top five diseases in adult who seek health care services In India the 
prevalence of HIV in STD varies from 1.5% to 23%. 
 HIV is sexually transmitted disease so why the STD is stated in high risk 
group. For the prevention of HIV the rate of STD should be reduced. So NACO 
started STD surveillance clinic at every state. State stared center in their cities. 
Gujarat Started Sentinel Surveillance from 1994 in the 8 centres. The prevalence rate 
of last five years was 2.5 to 6.17% in STD patients. So the Gujarat is in medium 
prevalence state207.  
Incidence of HIV seropositivity in STD Pt's by different Indian workers 
Sr.No. Author Year of  
Publication 
No. Tested Percentage  
Positivity 
1. Quinn et al208 1988 4028 5.20% 
2. Kamat H.209 1989 599 5.17% 
3. Chandra M.210 1991 2086 14.0% 
4. Malvika Kohli211 1991 2500 2.07% 
5. Jivrajani H.212 1992 1150 5.40% 
6. Dr. Parasuram213 1992 2293 5.40% 
7. John J.J.214 1993 832 2.64% 
8. Brajachand SN215 1994 - 4.8% 
9. Sharma V.K.216 1996 4539 1.12% 
10. Srikrishnan A K217 1997 774 5.9% 
11. Godkari D.A.218 1998 302 23.5% 
12. Elmy S. Rasul219 1999 - 29.0% 
13. Bajaj J K et al220 2000 3124 10.9% 
14. Kumar B. et al221 2001 53 5.66% 
15. Present Study - 2700 4.66% 
 In present study 2700 blood samples of STD patients were tested for HIV 
seropositivity.  Out of that 126 samples were observed HIV seropositive. The rate of 
HIV seropositivity is 4.66% out of 2700 patients 795 were male is 45 (5.66%) and in 
female 81 (4.25%). The females were more attendees of STD clinic than males, but 
seropositivity rate is found higher in males. 
 The maximum number of patients was between 21-30 years of age maximum 
positivity is also found in this group. This group is sexually active group so 
positively rate higher than other age group. 
 Brajachand S.N.215 the sentinel surveillance for HIV infection at Manipur. 
The aim of study was to seen the paint prevalence of HIV infection among the 
various risk group in selected sentinel population and to see the trend of HIV 
infection. The sample were collected from STD clinic and tested for HIV antibody 
by ELISA. The seropositivity in STD patient was 4.8%. Our finding is exactly 
correlate with this findings. 
 Mallika Kohli211 in span 21/2 years, approximately 2500 STD cases 
attending the out patient & their spouses were screened for HIV infection using 
ELISA. A total 124 patients (118 male, 6 female) were ELISA positive, 66 
conformed by W.B. test. HIV seropositivity rate 2.07% observed. 
 T. Jacob John214 at Vellore (1993) screened 832 patients of STD clinic. 22 
(2.64%) were HIV seropositive. While in 1986 (0.16%) were positive. The rise in 
the prevalence rate has been gradual at vellore, where as it has been more steep in 
Bombay. In Bombay rate during 89-90 was 4.3% thereafter the rise was more rapid 
in 1993 26.0% Sharma V.K.216 also screened 4359 STD cases they got 1.12% rate of 
HIV seropositivity.  So all these workers results were lower than our study.  
 Quinin et al208, Kamat H209, Jivrajani212, Dr. Parsuram213, Shriskrishna AK217 
and Kumar B221 screened STD patients. Their seropositivity should 5.2%, 5.17%, 
5.4%, 5.4%, 5.9% and 5.66% respectively. This seropositivity rate was slightly 
higher than our study rate.  
 Chandra M210 showed that 2086 patients suffering from all type of STD were 
screened for HIV seropositivity. Of these & out of 57 patients presenting with 
genital ulceration showed HIV antibodies indicating incidence of 14% HIV infection 
in genital ulcer disease. 
 Bajaj J K220 at Aurangabad also screened 3124 STD patients. HIV 
seropositivity rate 10.9% was observed. Among 3124 patients 266 (78%) were male 
and 75 (22%) females. Males were more than female in positively rate. These ratio 
similar like our study. Overall HIV seropositivity higher than our study. 
 Godkari D.A.218 detected HIV seropositivity 23.5% at Pune. Elmy S. Rausl at 
Gawahati also found 29.0 rate in STD patients. There results showed very high 
prevalence rates than our study rate. 
 Our results are comparable with the global study results. 
Incidence of HIV seropositivity in STD patients in different parts of the world 
Sr.No. Authors Years Place Percentage Positivity 
1. Simonsen et al222 1988 Nairobi 11.20% 
2. Komatsu R. et al223 2000 Tokyo 0.9% 
3. Kjm AA et al224 2000 Santrancisco 7.1% 
4. Sullivan P.A, et al225 2001 Australia 0.0% 
5. Rest V et al 226 2002 Germany 0.17% 
6. Sugihantono A.227 2003 Indonesia 0.5% 
7. Klausner JD228 2004 OUSA 40.6% 
8. Belza M J et al229 2004 Spain 0.7% 
 Sullivan PA225 at Australia, Studied 427 pregnant women with STD, but the 
rate of HIV seropositivity was 0%. 
 Komatsu R223 at Tokyo, Resl. V.226 at Germany, Sugihantono A at 
Indonesia227 and Belza M. J.229 at Spain also studied the HIV seroprevalence rate in 
STD patients and it is 0.9%, 0.17%, 0.5% and 0.7% respectively. Prevalence rate of 
HIV seropositivity is very lower than our study rate. 
 Klausner J.D.228 USA screened 1361 patients of STD. Out of them 553 
(40.6%) were HIV antibody positive. This rate is very high. 
 Kim A A224 et al at San Francisco 564 msm (men who have sex with men) 
surveyed. HIV seropositivity rate found 7.1% this is slight higher than our rate. 
 The STD associated with genital ulcer diseased was studied by Simonsen 
et222 al 1988 in Nairobi, demonstrated that men who reported frequent sexual contact 
with prostitutes and who has currently diagnosed genital ulcer were significantly 
more likely to infected with HIV antibodies. He detected 11.2% HIV antibodies 
positive out of 340 men. This rate is higher than our results.  
GROUP - II MULTITRANSFUSED PATIENTS (Thallassaemic children) 
 Thallassaemia is the commonest single gene disorder in India223. They from 
a heterogenous group of conditions resulting from a wide variety of mutations of 
genes which code for hemoglobin synthesis. Beta thallassaemia major is the 
hemozygous from, inherited recessively and resulting in reduced or absent beta 
chain production. It's distribution is concentrated in a belt stretching from the 
mediterranean through the Middle East, India and South East Asia. It also occurs in 
parts of West Africa231. 
 In India regional carriage rates have been estimated at between 0.6 and 15% 
Maximum number of cases belonged to Sindhi, Punjabi and Gujarati Community232. 
 The mainstay of management of thallassaemia patients is regular blood 
transfusion and iron chelation. Transmission of various infections is a known 
complication of chemotherapy regimens. Thallassaemia major patients are exposed 
to the risk of various transfussion transmitted infections (TTI) due to repeated blood 
transfusions. It has been calculated that for every unit of blood transfusion, there is 
1% chance of transfusion associated problems, including TTIS233. A linear 
correlation between increased number of transfusion and the increased incidence of 
TTIS, has also been reported234. The major transfusion transmitted agent are HBV, 
HCV, HIV, T-Pallidum and plasmodium Spp. Also it may give rise to transfusion 
acquired iron overload. 
 Transfusion of HIV via infected blood and blood products is among the 
major routes of HIV transmission235. HIV is a potentially dangerous virus 
transmitted through blood and children receiving multiple blood transfusions are at a 
greater risk to get it. In fact transfusions may be responsible for as many as 22% of 
all cases of HIV infection in children236. 
 Beta thallassaemia major children, being transfusion dependent, constitute an 
important risk group for HIV infection. The reported HIV seroprevalence rate in 
such children very from 1.09-38.5% in different part of the world. 
 Parenteral transmission due to blood & blood product is the most efficient 
route, the risk being over 90% in a single episode. So screening of blood/blood 
product recipients has attracted wide attention in India. 
 In the present study 200 serum samples of thallassaemic children were 
screened for anti HIV antibodies. 5 children were seropositive (2.5%) for HIV 
infections.  
Incidence of HIV seropositivity in thallassaemic children as  
discovered by different workers 
Sr. No. Authors Year os  
Publication 
No. Tested Positivity % 
1. M.A.F. ElHazami et al237 1989 212 2.35% 
2. Manorama Bhargava et al238 1991 185 0.54% 
3. Khan M.A.239 1992 203 8.37% 
4. Amrapurkar D.N. et al.240 1992 40 2.5% 
5. S.K. Bichite et al.241 1992 50 6.0% 
6. Surjitsingh et al.242 1993 100 0.0% 
7. V.P. Chaudhury et al.243 1993 91 0.0% 
8. A.P. Dubey et al.244 1993 75 9.3% 
9. S. chandra et al.245 1993 22 0.0% 
10. S. Sen et al.246 1993 203 8.9% 
11. Sudarshan Kumar et al.247 1994 223 3.5% 
12. Chaudhury N. et al.248 1995 19 0.0% 
13. Renu Vohra et al.249 1995 89 8.9% 
14. Sur D. Chakraborty AK250 - 330 0.9% 
15. Present Study - 200 2.5% 
 In the present study 5 out of 200 samples of patients with thallassaemia 
major syndrome were positive for anti HIV antibodies showing an incidence of 
2.5%. Out of five positive patients 3 were males & 2 were females, belonging to the 
age groups 3 were in > 4 to 8 & 1 in age group of 2-4 years and 1 of > 8 to 13 years 
of age group. Out of five seropositive patients 1 had received more than 40 blood 
transfusion, 2 were more than 50 and 2 were more than 100 transfusion.  
 All the blood units have been screened for anti HIV before issuing, as HIV 
screening is mandatory in all blood banks. All the blood units were anti HIV 
seronegative. The parents of all the HIV positive children were screened for HIV 
infection. They all were HIV seronegative. So one reason for the HIV seropositivity 
in the thallassaemic children could be due to the presence of a seronegative infective 
stage in the HIV infected blood donor called the window period. 
 Frequency of HIV markers were investigated in multi transufused 
thallassaemic patients by M.A.F. EL. Hazmi et al237 who reported only 5 
thallassaemic out of 212 (2.3%) were positive for HIV, and D.N. Amrapurkar 
(1992)240 studied 40 thallassaemic in which 2.5% were HIV seropositive. Both the 
study is similar to our results. 
 Khan M.A.239 screened 203 multi transfused children with thallassaemia 
attending the thallassaemia clinic of Charak Plika hospital, New Delhi for anti HIV 
antibodies by ELISA test. All positive cases were confirmed by western blot test. of 
the 203 children screened 17 (8.37%) were HIV seropositive. A.P. Dubey et al244 
found 7 out of 75 multi transfused children seropositive for HIV antibody (9.3%) 
Renu Vohra249 screened 89 thallassaemic 8 (8.9%) were HIV seropositive. S. Sen et 
al246 screened 203 thallassaemic children 18 (8.9%) were seropositive. These all 
studies shows the very high prevalence rate than present study. The reason for such a 
high rate of seropositivity is speculative, since most of the blood these children 
received was from voluntary donors. S.K Bichile et al also showed very high rate 
(6%) of HIV seropositivity in thallassaemic children. 
  Surjitsingh et al242 and V.P. Chaudhary et al243 screened blood samples of 
thallassaemic patients for anti HIV antibodies by ELISA. All patients were negative 
for anti HIV antibodies. Surjitsingh screened 100 patients. These patients had been 
on a regular transfusion programme for periods varying from 1-12 years. All the 
children were seronegative. Similar results also shown from S. Chandra et al245 and 
Chaudary N. et al248. They screened 22 and 19 samples. They all were seronegative. 
These results indirectly reflected the absence of, or a very low HIV seropositivity in 
voluntary blood donors of the region. The patients were transfused with blood from 
the blood bank society with obtained its supplies from voluntary donors only. 
 Sudarshan Kumar247 screened 223 multitransfused patients in the age group 
of 1-25 years. 8 children (3.5%) showed HIV seropositivity. One reason for this 
seropositivity could be that all these positive cases had received blood from other 
blood bank also.  Possibly unscreened ones. Which would have been transfused as. 
 In the present study, low incidence of HIV seropositivity (2.5%) is seen. The 
reason for the low incidence is that routine screening of blood units for HIV 
infection has become mandatory before issuing. So, this routine screening will detect 
HIV infection (unless the donor is in window period) and thus save the recipient 
from HIV infection. Other reason of low incidence in a hospital proper selection of 
healthy blood donor is undertaken before transfusion.  
 
GROUP - III PREGNANT WOMEN ATTENDING THE ANTENATAL  
  CLINIC AT G.G. HOSPITAL JAMNAGAR. (Antenatal Group) 
 Over the past decade, the global epidemic of HIV infection has become a 
major focus of preventive, therapeutic and community health care in all parts of the 
world. The importance of the problem cannot be over state when we consider the 
situation in a developing country like ours where the major route of transmission is 
heterosexual. This leaves the providers of care to women with a particularly acute 
problem and the responsibility to care for two patients the prospective mother and 
the fetus. Transmission of HIV infection from mother to infant are called 'vertical 
transmission." 
 Perinatal transmission of HIV affects nearly 5,00,000 infants each year world 
wide, most of them born in developing countries251. Recent sentinel surveys 
amongst pregnant woman in Maharashtra has shown a seroprevalence rate of 0.25% 
to 1%252. Considering 25 million births per year in our country, a seroprevalence 
amongst pregnant women is of 1% and a vertical transmission rate from mother to 
child is around 30%253, we would expect to have 7500 HIV infected neonates born 
every year. Reducing burden of pediatric morbidity from mother to child 
transmission of HIV is important. Mother to child transmission rates have shown to 
have wide variations amongst different populations254 Transmission rates ranging 
from 14% to 33% have been reported in the USA and Western Europe255. In 
developing countries rates are as high as 43% have been reported256. 
 HIV transmission from mother to child can occur during antipartum (in 
utero), intrapartum (during labor and delivery) or postpartum (breast feeding) 
period. 
 Most studies suggest that 25% to 35% of transmission occurs during 
antepartum257-259. 7,89. Although transmission does take place even in early 
pregnancy260, transmission is more frequent at late pregnancy, mostly at the time of 
labour or delivery261. 
 Evidence suggest that 70% to 75% of vertical transmission occurs during 
labor and delivery262. Increased transmission is noted with increased duration of 
rupture of membranes prior to delivery263. 
 Prospective studies have suggested an increased risk of transmission 
associated with postpartum (breastfeeding)264,265. Dunn et al266 in a meta analysis 
have estimated that the postpartum transmission world wide from HIV is 14% 
Particularly high when maternal primary infection occurs in the first few months 
after delivery267. 
 By the May 1986 the ICMR established a nation wide HIV testing scheme. 
In 1987 Oct. first HIV seropositive infant was detected268. In 1998 NACO started 
ANC Sentinal surveillance in Gujarat they reported 0.00% to 0.50% of HIV 
seroprevalence rate269. In 2003 started (PPTC) (Prevention of Parents to child trans) 
programme. 
 The present study was under taken to Findus the seropositive rate among 
women attending antenatal clinic at G.G. Hospital, Jamnagar. A total of 3000 cases 
were studied for the presence of HIV-antibodies, out of which 7 cases were found 
HIV seropositive, indicating 0.23% positivity rate. 
 Several studies have been conducted in world or India to investigate the 
prevalence of HIV in pregnant women.  
Prevalence of HIV seropositivity among pregnant women in India 
Sr. No. Author Place Percentage Positivity 
1. Singh et al270 Manipur 0.86% 
2. Lakshmi et al271 Tirupati 1.5 
3. Khorsed et al272 Bombay 0.1 
4. T. Jacob John273 Vellore 0.05 
5. Pal A. et al.274 Allahabad 0.0% 
6. Ramanamma et al275 Visakhapattnam 1.83% 
7. Ravindra Kumar et al276 Delhi 0.16 
8. Prabijot et al277 Bombay 8.04 
9. Lals et al278 Miraj 4.5 
10. V. K. Sharma et al279 Delhi 0.4 
11. Present Study Jamnagar 0.23% 
 The results suggest that HIV seropositivity rate among pregnant women 
ranged between 0% to 8% and average rate was 1.5% 
 In present study HIV-Seropositivity rate is 2.3% in pregnant women, In 
comparison to our results lower incidence of HIV seropositive have been shown by 
Pal et al274. 0%, Ravindra Kumar276 0.16% at Delhi, T. Jacob John273 at Vellore 
0.05% and Khorsed et al272 at Bombay 0.1 rate. 
 Slightly high prevalence rate then our study shown V.K. Sharma at279 Delhi 
was 0.4% and Singh et al shown 0.86% positivity among pregnant women at 
Manipur. More over geographical area also effects overall HIV prevalence. The 
Subjects of this study reside in the vital geographical zone through which the 
international trafficking of drugs occurs from golden triangle. (Myanmar, Thailand 
Loas) to Manipur via the international border of Manipur and Myanmar 232 cases 
were screened by Singh et al out of which 2 were HIV seropositive. The husband of 
both was IVDUs and both were HIV positive. It is likely that seropositive mother 
got infection through heterosexual transmission. 
 In present study 7 female were HIV seropositive 4 husbands of seropositive 
female were HIV positive. By the counseling the detail history, it was apparent that 
the women were monogamous, but their husband had sex with multiple partners. 
Thus the prevalence of HIV seropositivity in majority (90%) of infected women is a 
reflection of the prevalence of HIV infection due to sexual promiscuity of their 
husband. 
 Ramanamma et al275 study result shows the HIV seropositivity among 
antenatal women was 1.83% can be consider higher, probably it may be representing 
the logarithmic trends in the increase of AIDS in all risk groups, women of 
reproductive age being one of them. More ever Vishakhapattnam is a major port city 
in India, and as such large number of floating population can be expected for rapid 
spread of HIV. 
 Lakshmi et al271 1.5% was the prevalence rate in Tirupati, which was higher 
in comparison to our study. Tirupati is a place of pilgrimage which is frequented by 
20,000 to 30,000 people a day from various parts of the country.  More ever sexual 
promiscuity is also prevalent as a result there is steady rise in HIV positivities in 
high-risk group and hence the rise in percentage positivity among general 
population281. 
 Lals et al278 also showed the higher result 4.5% at Miraj Maharashtra. 
Prabijot et al277 showed that women attending antenatal clinic is 8.04% which is 
highest among all the studies. Bombay is over flooded population due to the 
population movement towards these large urbanized areas to secure job282. Moreover 
large number of prostitutes provides sexual services in cities like Bombay, it is 
reported that prostitutes have the highest and their male clients the next highest 
prevalence rates and they constitute the primary chain of transmission to general 
population282. 
 As regard to age, in present study most of the cases were in age group 21-30 
years. Out of 1513 cases screened 6 (0.39%) were HIV seropositive in this group. In 
the study done by Ramanamma et al275, majority of seropositive were in the age 
group 21-30 years. Which correlates with other our findings. The high prevalence of 
HIV seropositivity in the age group 21-30 years is due to large numbers screened 
because this age group is reproductive age group. 
 In present study HIV seropositivity rate is shown in different trimester of 
pregnancy, More seropositivity 0.26% is shown in 3rd  trimester of  pregnancy. This 
is because of the more number screened in 3rd trimester in PPTCT. 
 In the present study 0.23% HIV seropositivity found among pregnant 
women. It can be considered low in comparison with other studies but it is important 
to note that HIV infection has already affected such a healthy group. 
Prevalence of HIV seropositivity among pregnant women in the world280 
Sr. No. Country Percentage Positivity 
1. California USA 0.8% 
2. U.K. 0.6% 
3. Paris (France) 4.14% 
4. Norway 0.07 
5. Nigeria 3.0 
6. Nairobi (Africa) 17.0 
7. Sweden 0.09 
8. Thailand 1.6% 
9. Vietnam 0.8% 
10. Pakistan 0.0% 
11. Japan 0.0% 
12. Indonesia 0.0% 
13. China Hong Kong 0.1% 
14. Cambodia 3.5% 
15. Burma 2.3% 
16. India 3 1% 
17. Cameroon 2.0 
 The prevalence of HIV seropositivity among pregnant women in the world is 
range from 0% - 17% shows in the table280. Pakistan, Japan, Indonesia shows the 0% 
rate but in the Nairobi it is very high 17%. In the China Hong Kong rate is 01% but 
Z Huang K studied a survey in highly epidemic villages it is very high 32.2% 
seropositivity rate in pregnant women284. 
 The increase in the number of HIV in pregnant women is continuously 
increasing. Increase in the number of HIV among pregnant women indicates, the 
increase in vertical transmission. Virtually, all the HIV infection that now occur in 
children mostly by vertical transmission, i.e. from mother to child. Vertical 
transmission of HIV to the foetus occurs is 15-33% of pregnancies285. 
 Early diagnosis of HIV status of pregnant women is required, for the women, 
herself, her baby and obstetrician, NACO started the antenatal survey for pregnant 
women. They started 200 sites for the antenatal surveillance all over the India286. 
Out of 200 sites 8 sites started in Gujarat. Out of 8 sites in Gujarat one is at 
Jamnagar. Gujarat is a low prevalence state categorised by NACO. HIV prevalence 
rate in antenatal women is less than 1%. 
 Those women who desire to continue pregnancy can be told that there is no 
evidence that babies born of such mother are at increased risk of prematuring or 
growth retardation287. All succumb to the disease by 5 years. The uninfected 75% 
are likely to be orphaned by 5 years of age and suffer all its adverse consequences. 
To prevent this calamity MTP in the first trimester should be performed. 
 Motherhood is women's desire, women who desire to continue pregnancy 
should be provided with adequate perinatal care, intensive neonatal care and 
precautions should be taken to prevent accidental spread of HIV infection while 
providing health care. Zodovudin & ACTG 076 proved to be effective in reducing 
perinatal transmission, should be offered to all HIV infected women. 
 Moreover, routine testing by voluntarily is necessary, strict universal Bio-
safety precautions should be followed, proper health education and counseling also 
advocate to prevent further spread of HIV transmission in antenatal women. 
GROUP-III BLOOD DONORS 
 There is no fluid, which can to tally substitute blood in the human body. In 
many cases transfusion of blood becomes necessary to save the life of an individual. 
Therefore, blood should be pure and free from contamination. In case of transfusion 
of infected blood it is almost sure that such blood would carry transmissible diseases 
like HIV, HBsAg, malaria and syphilis. HIV is one of the latest additions to the long 
list of already existing diseases that can be transmitted through transfusion.288 
 The use of blood transfusion in clinical practice has brought untold benefits 
to countless individuals. But the risk transmitting an infectious disease is associated 
with every transfusion. With the report increase in HIV Seropositivity amongst 
blood donors in the state Tamil Nadu and Maharashtra, Govt. of India recommended 
mandatory screening of all blood and blood products before transfusion. India's first 
HIV Seropositive blood donor was detected in 1987 in Tamil Nadu. Since then 
serosurveillance centers were established in major cities. By the end 1993 100 Zonal 
blood testing center were established mainly in urban areas to screen all the blood 
donors for HIV antibodies289-292. 
 Based on it some workers have undertaken isolated studies of prevalence of 
HIV Seropositivity in blood donors. Replacement donors, majority of whom are 
men, are considered as an indicator of the trend of HIV infection in the general 
population and these figures for blood donors can be used as a proxy for prevalence 
figures for general population. On similar basis a trend analysis is carried out on 
infections of HIV / AIDS, Hepatitis syphilis three main disease, transmitted by 
transfusion, may reflect the prevalence status of these disease in general 
population293-298. So transfusion transmitted diseases (TTDs) are the most common 
cause of transfusion associated undertaken to find out the prevalence and trend of 
HIV Seropositivity in blood donor population attending Guru Gobind Singh 
Hospital, Jamnagar.  
 HIV has been transmitted by whole blood, cellular components, plasma and 
clotting factor concentrates as well as in cellular fraction of blood. Seroprevalence 
dater from different parts of India has shown ELISA reactivity in the donated unit of 
blood. Blood of these donors have been used for making blood products by 
manufactures without appropriate HIV neutralization methods299. Consequently in 
India person receiving blood or blood products repeatedly would be at risk for HIV 
infection.  
 In the present study a total of 53671 donors blood samples were screened for 
the presence of HIV. Commercially available solid phase immunoassay was used for 
the detection of HIV antibodies. Only negative blood allowed to be transfused. If 
blood is found to be positive for HIV, it should be discarded. The donor is not to be 
informed. If donor wants to know the result, pretest and post-test counseling 
regardless of the test result should be carried out and then only result should be 
informed300. 
 The presence of HIV Seropositivity in the blood of healthy donor poses 
serious risk for recipients. This study was undertaken to determine the incidence of 
HIV Seropositivity in blood donor population. 
Incidence of HIV Seropositivity in Blood donors from different parts of India 
Sr. No. Author Year Place No. tested Positivity 
1 Lina Deodhar301 1990 Bombay 47922 0.9% 
2 Chandra M.302 1991 Bombay 30632 0.6% 
3 Kulshreshta R.303 1992 N. Delhi 11256 0.17% 
4 Bhushan at al304 1993 Vellore 79591 0.10% 
5 Ramani T. V.305 1994 Vishakhapttam 394 5.06% 
6 Brajachand S. N.306 1994 Pune - 2.2% 
7 Purnima Rao307 1994 Pune 44190 0.69% 
8 Joshi S. R.308 1994 - 34098 1.2% 
9 R. Sambasiva Rao309 1995 Pondicherry 19023 0.55% 
10 Gupta et al310 1996 Chundigarh 2787 0.82% 
11 Kumars et al311 1996 - 85500 0.23% 
12 Patil A. V. et al312 1996 - 38776 3.59% 
13 Shashikala S. Tallur313 1997 Hubli 19705 1.74% 
14 Sujater V. apur314 1998 Delhi - 0.06% 
15 Rajesh Kulshrestha315 1999 Lacknow 39965 0.53% 
16 Chaudhari N.316 2000 Lacknow 62288 1.28% 
17 Varma N. et al317 2001 Delhi 144 1.06% 
18 Kapur S.318 2002 Delhi - 0.68% 
19 Rasheed M.V. 319 2004 Hydrabad - 0.14% 
20 Present Study - Jamnagar 107343 0.37% 
Incidence of HIV seropositivity among blood donors in world 
Sr. No. Author Year Place No. tested Positivity 
1 Aberle Grasse J.320 1995 USA - 1.8% 
2 Sohmunis G. A.321 1997 Argentina - 2.4% 
3 Yan Y. Zhengz322 1999 Fujian 569873 0.12% 
4 Shandera W.323 1999 Africa - 0.39% 
5 Brain F.324 2000 - 10000 0.17% 
6 Williams A. E.325 2000 USA 100000 0.03% 
7 Osterhaus A. D.326 2000 Somalia 256 0.00% 
8 Chiavetta J. A.327 2001 Canada 2 Million 0.10% 
9 Zacharian328 2001 Malawi - 2.2% 
10 Kiwanuk N.329 2002 Uganda 6868 3.92% 
11 Durosinmi M. A.330 2002 Nigeria 16080 2.30% 
12 Kwesigabo G.331 2002 Tanzania 454 11.9% 
 In our present study, of the 53671 blood donors tested during study. HIV, 
Seropositivity were observed in 199 (0.37%) cases. 
 The age group most commonly affected by HIV infection is 21-30 years i.e. 
sexually active group  
 This is comparable with the studies by Purnima Rao et al Pune24 and R. 
Sumbasiva Rao26 Pondicherry where maximum number of HIV Seropositive blood 
donors are between age group of 21-30 years. 
 Maximum prevalence of HIV Seropositivity in 21-30 years age group could 
be, because the individuals in this group are more independent and economically 
stable as compared to lower age groups. 
 The HIV Seropositivity in this study is less in female than in males. In all the 
studies also males are more than female. Males are considered more independent 
and they go outside their abode to earn their living. They have more chances of 
getting exposed to unprotected sexual practices and acquired HIV infection, thus 
blood donated from these high risk. Male donors are more likely to transmit the 
infectious agent to the recipient. But with todays modernization, female are also 
getting exposed to the outside world and the prevalence of HIV Seropositivity in 
female may increase in the near future. 
 HIV Seropositivity in this study is less in voluntary donors (0.04%) than 
replacement donors (0.52%). Y. Munde at al332 Thailand have observed more 
prevalence of HIV infection replacement donors than in voluntary donors. Similar 
study of A. Moniatis et al333 also shows more prevalence of HIV among replacement 
donors than volunteer. Because replacement donors are patients relatives only so 
there is no choice in donor selection. These findings correlates with the observation 
of the present study. 
 Brain F. (2000)324, Shandera W. (1999)323, Africa, Lina Deodhar (1990)301, 
Bonbay, Chandra M. (1991)302 Bombay, Kulzhreshtha R. (1992)303 New Delhi, 
Purnima Rao (1994)307 Pune, R. Sambashiva Rao (1995)309 Pondicherry, Gupta et al 
(1996)310 Chandigarh, Kumars et al311 (1996) and Rajesh Kulshreshtha (1992)315 
Delhi all the studies shows the similar prevalence of HIV Seropositivity, .0.17%, 
0.39%, 0.9%, 0.6%, 0.17%, 0.59%, 0.55%, 0.82%, 0.23% and 0.53% respectively 
from world and India. 
 Williams A. E. (2000)325 USA, Yan Y. Zhengz (1999)322, Chiavetta J. A. 
(2001)327 Canada, and Bushan et al (1993)304 Vellore shows a very low prevalence 
of 0.03%, 0.12%, 0.10% and 0.10% respectively. 
 Aberle Grasse J. (1995)310 USA, Schmunis G.A. (1997)321 Argentina, 
Kiwanuk N. (2002)321 Uganda, Durosinmi M.A. (2002)326, Nigeria, Zacharian 
(2001)328 Malawi Brajachand SN (1994)306 Pune, S.R. Joshi (1994)308, Patil A.V. 
(1996)312 Shashikala Tallur (1997)313 Hubkli shows a slightly and higher prevalence 
of 1.8%, 2.4%, 3.92%, 2.30%, 2.2%, 2.2%, 1.2%, 3.59% and 1.74% respectively 
than present study. 
 Kwerigabo G. (2002)331 from Tanzania shows the very high prevalence rate 
11.9% and Osterhaus A.D. (2000)322 Somalia shows very low 0.00% rate from blood 
donors. 
 Indian studies by Ramani TV (1994)305, Visakhapattam shows very high rate 
5.06%b and Sugata Kapur (1998)31 Delhi shows very low 0.06% HIV Seropositivity 
in blood donors. So prevalence of HIV Seropositivity in Indian range is from 0.05 to 
5.5% present studies shows that there is low rate of HIV Seropositivity in blood 
donors, and it is because of selection of blood donor is proper manner 
 HIV infected donor represents the major source of transmission of HIV 
infection, and they are the largest group who are not aware that they are infected. 
 The present study was therefore carried out to assess such an incidence of 
HIV infected cases among blood donors. 
 SUMMARY 
 
 For a decade the world has struggled to come to terms with HIV/AIDS. Most 
of the human faces of this epidemic are of young people, including pregnant women 
& their children. 
 In the present study three groups were studied  
Group - I : Symptomatic  
 Patients who presented with signs and symptoms which were suggestive of 
HIV/AIDS - TB patients. 
Group - II : Asymptomatic 
 Persons who were at very high risk of getting HIV/AIDS but who had no 
clinical signs and symptoms suggestive of HIV/AIDS - Sexually transmitted disease 
patients, - Multi transfused Thallassaemic patients  
Group - III : Healthy individuals - Antenatal mother and Blood donors 
• HIV antibodies were detected ELISA & Rapid Tests. 
• Samples for transfusion safety purpose one E/R/S is used; for surveillance 
and diagnosis of full blown AIDS cases two E/R/S are used; and for 
asymptomatic individual three E/R/S are used. 
• Out 12,165 cases were studied for the presence of HIV antibodies by three 
different methods 1365 were found HIV seropositive. So the over all 
incidence rate of HIV seropositivity is 11.22% 
Group I : 
• 2000 cases of clinically suspected cases of tuberculosis were screened 124 
were seropositive for HIV antibody So the prevalence of HIV-Seropositivity 
in tuberculosis patient is 6.2%. 
• HIV seropositivity rate is more in male 7.02% than female 3.2% case of 
tuberculosis. 
• 21-30 age group is more susceptible (7.66%) for HIV infection. 
Group II : 
• 2700 cases of STD were screened out of these 126 were seropositive for HIV 
antibodies. 
• So the prevalence of HIV seropositivity among STD patients is 4.66% 
• HIV seropositivity rate is more in male (5.66%) patients than female (4.25%) 
patients. 
• 21-30 years of age group is more (5.80%) susceptible for STD. 
• Urban people are more infective than Rural. 
? 200 cases of multi transfused thallassaemic children were screened and 5 
were seropositive for HIV antibody. Rate of HIV seropositivity is 2.5%. 
• Out of 5 HIV seropositive children 3 were male & 2 were female. 
• Out of 5 HIV seropositive 3 were from age group of > 4 to 8. 
• Out 200 cases 70 were transfused by more than 51-100 transfusion HIV 
seropositivity rate was more in 101-150 transfusion group (5.12%). 
Group III : 
• Out of 3000 cases of pregnant woman only 7 were found HIV seropositive. 
So incidence of vertical transmission is 0.23% is low in general population. 
• Out of 7 HIV seropositive mothers 6 were from age group of 21-30 years. 
• Antenatal women are more seropositive in the III trimester of pregnancy 
0.33%. 
• Three husbands were HIV seropositive from 7 positive women. 
• Illiterate women were more positive (33%) than illiterate one. 
? A total of 53671 blood donors were studied. Out of them 199 were HIV - 
seropositive, Prevalence rate is 0.37% in blood donor.  
• HIV seroprevalence more in male (0.38%) than female (0.06) donors. 
• HIV Seropositivity is more in replacement donors than in Voluntary donors. 
• 21-30 years of age group is more prevalent (0.41%). 
 CONCLUSION 
 
 In Indian context, it is difficult to estimate the exact prevalence of HIV 
because of the varied cultural characteristics, traditions and values with special 
reference to sex related risk behaviours. The Western African model of making 
estimates cannot be easily applied the Indian scenario. However, it is possible to 
have an estimate at different levels of risk and the HIV prevalence, It may be used 
for planning of HIV/AIDS prevention and control. This estimation can also be useful 
for mapping of specific vulnerable groups & areas. 
 We concluded that the prevalence of HIV seropositivity is entered from high-
risk group to lower risk group and in general population. Our group wise conclusion 
is : 
Group - I : Tuberculosis Patients : 
 The present study reveals the rising trends of HIV infection among 
tuberculosis patients, so the urgent upgrading of microbiology laboratories to help in 
early diagnosis and prompt treatment of tuberculosis is extremely relevant in Indian 
context. 
• All the persons with tuberculosis should be questioned about risk factors for 
HIV infection and whether or not risk factor are elicited, urged to have HIV 
test. 
Group : II  Sexually transmitted disease patients : 
 HIV infection is increasing dramatically in patients of sexually transmitted 
diseases. 
• Screening of HIV antibody prevalence in STD cases is likely to help in the 
understanding of the reality of the spread of HIV infection. There is an 
immediate need for comprehensive and national efforts to control STDs and 
changing high-risk behaviors. 
• Treatment and control of STD offers a rational approach to the control of 
HIV. 
• To raise awareness levels regarding HIV/AIDS in rural and slum areas and 
other vulnerable group of the population. 
• Wide spread voluntary testing of individuals who are practicing high risk 
behaviour together with counseling of infected individuals is recommended. 
• To make people aware about the services available under the public sector 
for management of reproductive infection RTI / STD. 
Multi transfused Thallassaemic Children : 
 Patients with Thallassaemia are at higher risk of HIV transmission, through 
blood transfusion. 
• Therefore to prevent HIV infection from blood transfusion all but absolutely 
essential, transfusion should be avoided. 
• Mobilising people for voluntary donation, self exclusion technique among 
donors, and Judicious use of blood/blood products will go a long was in 
helping to control transfusion associated HIV infection in India.  
Group : III Antenatal Mother (Vertical transmission). 
 A relatively lower antenatal rate for HIV Seropositivity but has been detected 
in our study. 
• Screening should important so urged to have HIV testing. 
• The major advantage for screening, if positive is the counseling for MTP 
(medical termination of pregnancy) in early phase of pregnancy. 
• The other advantage is to relive them from anxiety by giving them the proof, 
if they are uninfected. For those with HIV infection could take precautions 
that they do not spread the disease to other. 
• Identification of seropositive women and follow up of their children is the 
only means available by which children requiring special care in future could 
be identified long before the need arises. 
• The screening also helps the doctor to plan adequate and appropriate 
antenatal intrapartum and postnatal care and intensive neonatal care 
facilities. 
• However, looking towards the magnitude of the problem, health education 
and proper counseling of seropositive mother is a must to prevent the further 
spread of the disease. 
Blood donors : 
 A relatively lower seropositivity rate found among blood donors, but the 
positivity indicates the infectivity in healthy general population.  
• Screening of blood donor is mandatory, but seropositivity may account 
because transfusion of HIV antibody negative blood during the window 
period. 
• A thorough evolution of the transfusion practices and rethinking of single 
bottle transfusion need to be done since HIV testing alone does not eliminate 
the risk of transfusion spreading AIDS. 
• Behavioural risk reduction and education of donors continue to remain the 
only effective tools to limit the progression of this pandemic among the 
blood donors. Measures should be initiated to end the practice of commercial 
paid blood donations and to rehabilitate such donors.  
• HIV testing of donated blood should not culminate in discarding the HIV 
positive blood alone. Proper counseling and education of the effected donors 
should necessarily follow. 
• Efforts should also be infected to prepare HIV test kit and reagents 
indigenously, based on the subtypes prevailing in the region, So that 
detection rates are improved. 
 The study is expected to generate, that will help in evolving timely 
intervention strategies for control of HIV infection, and also provided valuable tools 
for impact assessment of specific intervention programmes. 
 We need to act fact before we are left powerless against AIDS !! 
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